| 1 |
Hemminki K, Försti A, Liska V, Kanerva A, Hemminki O, Hemminki A. Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements. Int J Cancer 2023;152:1837-46. [PMID: 36571455 DOI: 10.1002/ijc.34416] [Reference Citation Analysis]
|
| 2 |
Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol 2023;11:480-9. [PMID: 36643046 DOI: 10.14218/JCTH.2022.00293] [Reference Citation Analysis]
|
| 3 |
Pan J, Zhang M, Dong L, Ji S, Zhang J, Zhang S, Lin Y, Wang X, Ding Z, Qiu S, Gao D, Zhou J, Fan J, Gao Q. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy 2023;19:1184-98. [PMID: 36037300 DOI: 10.1080/15548627.2022.2117893] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Zhang S, Hu Y, Wu Z, Zhou X, Wu T, Li P, Lian Q, Xu S, Gu J, Chen L, Wu G, Zhang T, Tang J, Xue J. Deficiency of Carbamoyl Phosphate Synthetase 1 Engenders Radioresistance in Hepatocellular Carcinoma via Deubiquitinating c-Myc. Int J Radiat Oncol Biol Phys 2023;115:1244-56. [PMID: 36423742 DOI: 10.1016/j.ijrobp.2022.11.022] [Reference Citation Analysis]
|
| 5 |
Bhala N, Ferguson JW, Rajoriya N, Newsome PN. Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally. Hepatology 2023;77:1078-80. [PMID: 36626619 DOI: 10.1097/HEP.0000000000000011] [Reference Citation Analysis]
|
| 6 |
Yao J, Tang S, Shi C, Lin Y, Ge L, Chen Q, Ou B, Liu D, Miao Y, Xie Q, Tang X, Fei J, Yang G, Tian J, Zeng X. Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma. Autophagy 2023;19:1221-38. [PMID: 36048765 DOI: 10.1080/15548627.2022.2119353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Criss C, Nagar AM, Makary MS. Hepatocellular carcinoma: State of the art diagnostic imaging. World J Radiol 2023; 15(3): 56-68 [DOI: 10.4329/wjr.v15.i3.56] [Reference Citation Analysis]
|
| 8 |
Yi C, Wei W, Wan M, Chen Y, Zhang B, Wu W. Expression Patterns of HOX Gene Family Defines Tumor Microenvironment and Immunotherapy in Hepatocellular Carcinoma. Appl Biochem Biotechnol 2023. [PMID: 36976502 DOI: 10.1007/s12010-023-04443-8] [Reference Citation Analysis]
|
| 9 |
Zhang Y, Zhang Y, He P, Ge F, Huo Z, Qiao G. The genetic liability to rheumatoid arthritis may decrease hepatocellular carcinoma risk in East Asian population: a Mendelian randomization study. Arthritis Res Ther 2023;25:49. [PMID: 36973792 DOI: 10.1186/s13075-023-03029-3] [Reference Citation Analysis]
|
| 10 |
Dong A, Zhu M, Zhang Z, Fan W, Wu Z, Chen Y, Tu J, Zhang Y, Zhuang W, He X, Peng Z. Efficacy of Radiation Plus Transarterial Chemoembolization and Lenvatinib in Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.. [DOI: 10.21203/rs.3.rs-2729634/v1] [Reference Citation Analysis]
|
| 11 |
Chen X, Luo F, Zhou H. Sarcomatoid hepatocellular carcinoma in a chronic hepatitis B infection patient without previous antitumor therapy: a case report and literature review.. [DOI: 10.21203/rs.3.rs-2708435/v1] [Reference Citation Analysis]
|
| 12 |
Zhu Y, Feng B, Cai W, Wang B, Meng X, Wang S, Ma X, Zhao X. Prediction of Microvascular Invasion in Solitary AFP-Negative Hepatocellular Carcinoma ≤ 5 cm Using a Combination of Imaging Features and Quantitative Dual-Layer Spectral-Detector CT Parameters. Acad Radiol 2023:S1076-6332(23)00088-0. [PMID: 36958989 DOI: 10.1016/j.acra.2023.02.015] [Reference Citation Analysis]
|
| 13 |
Ippolito D, Maino C, Gatti M, Marra P, Faletti R, Cortese F, Inchingolo R, Sironi S. Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy. World J Gastroenterol 2023; 29(11): 1669-1684 [DOI: 10.3748/wjg.v29.i11.1669] [Reference Citation Analysis]
|
| 14 |
Fan XL, Wang YH, Chen YH, Chen BX, Cai JN, Yang JS, Sun X, Yan FR, He BS. Computed tomography texture analysis combined with preoperative clinical factors serve as a predictor of early efficacy of transcatheter arterial chemoembolization in hepatocellular carcinoma. Abdom Radiol (NY) 2023. [PMID: 36943423 DOI: 10.1007/s00261-023-03868-3] [Reference Citation Analysis]
|
| 15 |
Ye TW, Wang DD, Lu WF, Xie YM, Xu FQ, Fu TW, Zhang KJ, Liu SY, Xie GL, Cheng J, Jiang K, Xiao ZQ, Yao WF, Shen GL, Liu JW, Huang DS, Zhang CW, Liang L. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy. Expert Rev Gastroenterol Hepatol 2023;:1-9. [PMID: 36939280 DOI: 10.1080/17474124.2023.2192479] [Reference Citation Analysis]
|
| 16 |
Zhong X, Hu X, Fan XG. Competing risk model for prognostic comparison between clear cell type and common type hepatocellular carcinoma: A population-based propensity score matching study. Cancer Med 2023. [PMID: 36934433 DOI: 10.1002/cam4.5773] [Reference Citation Analysis]
|
| 17 |
Cheng Z, Li L, Zhang Y, Ren Y, Gu J, Wang X, Zhao H, Lu H. HBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol. Brief Bioinform 2023;24:bbac601. [PMID: 36736372 DOI: 10.1093/bib/bbac601] [Reference Citation Analysis]
|
| 18 |
Wang T, Zhou Y, Zhou Z, Zhang P, Yan R, Sun L, Ma W, Zhang T, Shen S, Liu H, Lu H, Ye L, Feng J, Chen Z, Zhong X, Wu G, Cai Y, Jia W, Gao P, Zhang H. Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps. Nat Commun 2023;14:1513. [PMID: 36934105 DOI: 10.1038/s41467-023-37227-z] [Reference Citation Analysis]
|
| 19 |
Zhang X, Zhuge J, Liu J, Xia Z, Wang H, Gao Q, Jiang H, Qu Y, Fan L, Ma J, Tan C, Luo W, Luo Y. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1153423] [Reference Citation Analysis]
|
| 20 |
Wang H, Liu R, Mo H, Li R, Lian J, Liu Q, Han S. A novel nomogram predicting the early recurrence of hepatocellular carcinoma patients after R0 resection. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1133807] [Reference Citation Analysis]
|
| 21 |
Zhang S, Gong H, Xie H, Huangfu Z, Tang Y, Xiao M, Li M, Li Q, Wang Y. An integrated analysis of Dynamin 1 Like: A new potential prognostic indicator in hepatocellular carcinoma. Mol Carcinog 2023. [PMID: 36929853 DOI: 10.1002/mc.23524] [Reference Citation Analysis]
|
| 22 |
Pang N, Hu Q, Zhou Y, Xiao Y, Li W, Ding Y, Chen Y, Ye M, Pei L, Li Q, Gu Y, Sun Y, Fang EF, Chen M, Zhang Z, Yang L. Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice. Nutrients 2023;15:1447. [DOI: 10.3390/nu15061447] [Reference Citation Analysis]
|
| 23 |
Huang L, Xu R, Li W, Lv L, Lin C, Yang X, Yao Y, Saw PE, Xu X. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. Acta Biomater 2023:S1742-7061(23)00147-2. [PMID: 36931417 DOI: 10.1016/j.actbio.2023.03.014] [Reference Citation Analysis]
|
| 24 |
Lu X, Li Y, Li Y, Zhang X, Shi J, Feng H, Gao Y, Yu Z. Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles. Front Mol Biosci 2023;10. [DOI: 10.3389/fmolb.2023.1114594] [Reference Citation Analysis]
|
| 25 |
Song D, Wang X, Wang Y, Liang W, Luo J, Zheng J, Zhu K. Integrated Analysis of N1-Methyladenosine Methylation Regulators-Related lncRNAs in Hepatocellular Carcinoma. Cancers 2023;15:1800. [DOI: 10.3390/cancers15061800] [Reference Citation Analysis]
|
| 26 |
Li Z, Liao X, Hu Y, Li M, Tang M, Zhang S, Mo S, Li X, Chen S, Qian W, Feng R, Yu R, Xu Y, Yuan S, Xie C, Li J. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma. Free Radic Biol Med 2023;201:41-54. [PMID: 36924851 DOI: 10.1016/j.freeradbiomed.2023.03.013] [Reference Citation Analysis]
|
| 27 |
Chen J, Zhang J, Tian W, Ge C, Su Y, Li J, Tian H. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway. Mol Carcinog 2023. [PMID: 36920042 DOI: 10.1002/mc.23527] [Reference Citation Analysis]
|
| 28 |
Hemminki K, Sundquist K, Sundquist J, Försti A, Liska V, Hemminki A, Li X. Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers. Int J Cancer 2023;152:1107-14. [PMID: 36196489 DOI: 10.1002/ijc.34308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 29 |
Yang J, Li J, Deng Q, Chen Z, He K, Chen Y, Fu Z. Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. BMC Cancer 2023;23:246. [PMID: 36918834 DOI: 10.1186/s12885-023-10712-w] [Reference Citation Analysis]
|
| 30 |
Xiang J, Liu C, He Q, He P, Dong W. Comprehensive analysis of immunogenic cell death associated genes expression, tumor microenvironment, and prognosis in hepatocellular carcinoma. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1122011] [Reference Citation Analysis]
|
| 31 |
Malekshahi A, Alamdary A, Safarzadeh A, Khavandegar A, Nikoo HR, Safavi M, Ajorloo M, Bahavar A, Ajorloo M. Potential roles of core and core+1 proteins during the chronic phase of hepatitis C virus infection. Future Virology 2023. [DOI: 10.2217/fvl-2022-0117] [Reference Citation Analysis]
|
| 32 |
Kao WY, Tan EC, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther 2023. [PMID: 36914943 DOI: 10.1111/apt.17438] [Reference Citation Analysis]
|
| 33 |
Zeng K, Xie W, Wang C, Wang S, Liu W, Su Y, Lin L, Zou R, Sun G, Zhou B, Wang M, Luan R, Bai Y, Huo Y, Kato S, Zhong X, Zhao Y. USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma. Cell Death Dis 2023;14:194. [PMID: 36906615 DOI: 10.1038/s41419-023-05699-y] [Reference Citation Analysis]
|
| 34 |
Wu D, Cai Q, Liu D, Zuo G, Li S, Liu L, Zheng J. Identification of molecular subtypes and prognostic signatures based on transient receptor potential channel-related genes to predict the prognostic risk of hepatocellular carcinoma: A review. Medicine (Baltimore) 2023;102:e33228. [PMID: 36897679 DOI: 10.1097/MD.0000000000033228] [Reference Citation Analysis]
|
| 35 |
Girardi DM, Sousa LP, Miranda TA, Haum FNC, Pereira GCB, Pereira AAL. Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers 2023;15:1680. [DOI: 10.3390/cancers15061680] [Reference Citation Analysis]
|
| 36 |
Sun H, Wang H, Wang Y, Zhong W, Meng Y, Lv Z, Guo W, Han B. Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1129065] [Reference Citation Analysis]
|
| 37 |
Zou L, Liu K, Shi Y, Li G, Li H, Zhao C. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma. Cancer Biomark 2023. [PMID: 36938729 DOI: 10.3233/CBM-220226] [Reference Citation Analysis]
|
| 38 |
D'Artista L, Moschopoulou AA, Barozzi I, Craig AJ, Seehawer M, Herrmann L, Minnich M, Kang TW, Rist E, Henning M, Klotz S, Heinzmann F, Harbig J, Sipos B, Longerich T, Eilers M, Dauch D, Zuber J, Wang XW, Zender L. MYC determines lineage commitment in kras driven primary liver cancer development. J Hepatol 2023:S0168-8278(23)00175-7. [PMID: 36906109 DOI: 10.1016/j.jhep.2023.02.039] [Reference Citation Analysis]
|
| 39 |
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, Kogure T, Yumita S, Ishino T, Ogawa K, Iwanaga T, Nakagawa M, Fujiwara K, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Kato J, Kato N. Exploration of new positions for cabozantinib for advanced hepatocellular carcinoma in the latest real-world practice.. [DOI: 10.21203/rs.3.rs-2655181/v1] [Reference Citation Analysis]
|
| 40 |
Liu B, Wang Q, Mei T, Zheng J, Gao W, Yuan C, Li K, Zhang Y. Effect of HBsAg expression in liver tissue on prognosis of hepatocellular carcinoma after minimally invasive interventional therapy. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1106333] [Reference Citation Analysis]
|
| 41 |
Xiao L, Liao Y, Wang J, Li Q, Zhu H, Hong C, Li R, He J, Cui H, Dong H, Zeng L, Liu L. Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study. Cancer Immunol Immunother 2023. [PMID: 36884079 DOI: 10.1007/s00262-023-03417-3] [Reference Citation Analysis]
|
| 42 |
Wang L, Feng B, Li D, Liang M, Wang S, Wang S, Ma X, Zhao X. Risk stratification of solitary hepatocellular carcinoma ≤ 5 cm without microvascular invasion: prognostic values of MR imaging features based on LI-RADS and clinical parameters. Eur Radiol 2023. [PMID: 36884087 DOI: 10.1007/s00330-023-09484-5] [Reference Citation Analysis]
|
| 43 |
Yuan G, Xu Y, Bai X, Wang W, Wu X, Chen J, Li J, Jia X, Gu Z, Zhang X, Hu W, Wang J, Liu Y, Zhu XM. Autophagy-Targeted Calcium Phosphate Nanoparticles Enable Transarterial Chemoembolization for Enhanced Cancer Therapy. ACS Appl Mater Interfaces 2023;15:11431-43. [PMID: 36848495 DOI: 10.1021/acsami.2c18267] [Reference Citation Analysis]
|
| 44 |
Hou JX, Deng Z, Liu YY, Xu SK, Li ZX, Sun JC, Zhao MY. A Bibliometric Analysis of the Role of 3D Technology in Liver Cancer Resection. World J Surg 2023. [PMID: 36882637 DOI: 10.1007/s00268-023-06950-5] [Reference Citation Analysis]
|
| 45 |
Tsumura S, Shimose S, Niizeki T, Kuboyama E, Iwamoto H, Tanaka M, Moriyama E, Shirono T, Takaki K, Noda Y, Nakano M, Inoue M, Tsustumi K, Kuromatsu R, Koga H, Higuchi K, Kawaguchi T. Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib. J Gastroenterol Hepatol 2023. [PMID: 36880677 DOI: 10.1111/jgh.16168] [Reference Citation Analysis]
|
| 46 |
Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, Wu J, Liu J, Zou F, Wei J, Liu L, Zhang X, Zhuang J, Wang Y, Lin H, Huang X, Chen S, Kuang M, Li J. TREM2(+) macrophages suppress CD8(+) T cell infiltration after transarterial chemoembolization in hepatocellular carcinoma. J Hepatol 2023:S0168-8278(23)00164-2. [PMID: 36889359 DOI: 10.1016/j.jhep.2023.02.032] [Reference Citation Analysis]
|
| 47 |
Gao T, Yang X, Fujisawa M, Ohara T, Wang T, Tomonobu N, Sakaguchi M, Yoshimura T, Matsukawa A. SPRED2: A Novel Regulator of Epithelial-Mesenchymal Transition and Stemness in Hepatocellular Carcinoma Cells. Int J Mol Sci 2023;24. [PMID: 36902429 DOI: 10.3390/ijms24054996] [Reference Citation Analysis]
|
| 48 |
Han X, Huang J, Lu J, He F, Wang F, Li S, Zhong H, Yu H, Pu W. Active compounds and potential targets of Shuganning injection in the treatment of hepatocellular carcinoma by network pharmacology and in vitro validation. Naunyn Schmiedebergs Arch Pharmacol 2023. [PMID: 36869905 DOI: 10.1007/s00210-023-02432-6] [Reference Citation Analysis]
|
| 49 |
Kumar V, Shah M, Gala D, Singh MK, Jeanty H, Thomas R, Forlemu AN, Gayam VR, Etienne D. Hepatic Dystrophic Calcification Secondary to Transarterial Chemoembolization: Case Report and Review of Literature. Cureus 2023. [DOI: 10.7759/cureus.35765] [Reference Citation Analysis]
|
| 50 |
Liao J, Chen Z, Chang R, Yuan T, Li G, Zhu C, Wen J, Wei Y, Huang Z, Ding Z, Liang J, Chu L, Zhang B. CENPA facilitates hepatocellular carcinoma proliferation by cooperating with YY1 to drive transcription of CCND1 and NRP2.. [DOI: 10.21203/rs.3.rs-2630672/v1] [Reference Citation Analysis]
|
| 51 |
Wong JK, Lim HJ, Tam VC, Burak KW, Dawson LA, Chaudhury P, Abraham RJ, Meyers BM, Sapisochin G, Valenti D, Samimi S, Ramjeesingh R, Mujoomdar A, Martins I, Dixon E, Segedi M, Liu DM. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treat Rev 2023;115:102526. [PMID: 36924644 DOI: 10.1016/j.ctrv.2023.102526] [Reference Citation Analysis]
|
| 52 |
Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L. Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2632584/v1] [Reference Citation Analysis]
|
| 53 |
Golkowski M, Lius A, Sapre T, Lau HT, Moreno T, Maly DJ, Ong SE. Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. Mol Cell 2023;83:803-818.e8. [PMID: 36736316 DOI: 10.1016/j.molcel.2023.01.015] [Reference Citation Analysis]
|
| 54 |
Nagami N, Arimura H, Nojiri J, Yunhao C, Ninomiya K, Ogata M, Oishi M, Ohira K, Kitamura S, Irie H. Dual segmentation models for poorly and well-differentiated hepatocellular carcinoma using two-step transfer deep learning on dynamic contrast-enhanced CT images. Phys Eng Sci Med 2023;46:83-97. [PMID: 36469246 DOI: 10.1007/s13246-022-01202-7] [Reference Citation Analysis]
|
| 55 |
Chen YL, Hsieh CC, Chu PM, Chen JY, Huang YC, Chen CY. Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review). Oncol Rep 2023;49:48. [PMID: 36660927 DOI: 10.3892/or.2023.8485] [Reference Citation Analysis]
|
| 56 |
Zhang L, Li XM, Shi XH, Ye K, Fu XL, Wang X, Guo SM, Ma JQ, Xu FF, Sun HM, Li QQ, Zhang WY, Ye LH. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma. Acta Pharmacol Sin 2023;44:622-34. [PMID: 36109580 DOI: 10.1038/s41401-022-00981-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Zhang H, Guo Y, Jiao J, Qiu Y, Miao Y, He Y, Li Z, Xia C, Li L, Cai J, Xu K, Liu X, Zhang C, Bay BH, Song S, Yang Y, Peng M, Wang Y, Fan H. A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging. Nat Biomed Eng 2023;7:221-35. [PMID: 36536254 DOI: 10.1038/s41551-022-00975-2] [Reference Citation Analysis]
|
| 58 |
Elbadrawy E, Mostafa MY. Antioxidant, anti-inflammatory, antimicrobial and anticancer activities of the pods of green broad bean (Vicia faba L.), in vitro.. [DOI: 10.21203/rs.3.rs-2591126/v1] [Reference Citation Analysis]
|
| 59 |
Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X. The application of nanoparticles in immunotherapy for hepatocellular carcinoma. J Control Release 2023;355:85-108. [PMID: 36708880 DOI: 10.1016/j.jconrel.2023.01.051] [Reference Citation Analysis]
|
| 60 |
Deza Z, Caimi GR, Noelia M, Coli L, Ridruejo E, Alvarez L. Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway. Mol Carcinog 2023;62:398-407. [PMID: 36575946 DOI: 10.1002/mc.23494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 61 |
Guo C, Zhang J, Huang X, Chen Y, Sheng J, Huang X, Sun J, Xiao W, Sun K, Gao S, Que R, Shen Y, Zhang M, Wu J, Bai X, Liang T. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatol Commun 2023;7:e0054. [PMID: 36757445 DOI: 10.1097/HC9.0000000000000054] [Reference Citation Analysis]
|
| 62 |
Zhou L, Mao LH, Li X, Wang QL, Chen SY, Chen ZJ, Lei J, Liu HT, Liao SQ, Ran T, Li XQ, Zhou ZH, He S. Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma. Cancer Sci 2023;114:793-805. [PMID: 36369883 DOI: 10.1111/cas.15648] [Reference Citation Analysis]
|
| 63 |
Wu Y, Hao X, Wei H, Sun R, Chen Y, Tian Z. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice. Hepatology 2023;77:965-81. [PMID: 35938354 DOI: 10.1002/hep.32715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 64 |
Zhuo J, Wang Y, Hui H, Li C, Yang J, Zhang P, Fang C, Tian J. Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen. Acta Biomater 2023;158:435-48. [PMID: 36603729 DOI: 10.1016/j.actbio.2022.12.062] [Reference Citation Analysis]
|
| 65 |
Wang Z, Zhang L, Xu J, Song W. Integrated analysis of ferroptosis-related gene signature for overall survival prediction in Asian patients with hepatocellular carcinoma. Clin Transl Oncol 2023;25:721-30. [PMID: 36319928 DOI: 10.1007/s12094-022-02977-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Domini J, Makary MS. Single-center analysis of percutaneous ablation in the treatment of hepatocellular carcinoma: long-term outcomes of a 7-year experience. Abdom Radiol (NY) 2023;48:1173-80. [PMID: 36717404 DOI: 10.1007/s00261-023-03819-y] [Reference Citation Analysis]
|
| 67 |
Gao Q, Sun Z, Fang D. Integrins in human hepatocellular carcinoma tumorigenesis and therapy. Chin Med J (Engl) 2023. [PMID: 36848180 DOI: 10.1097/CM9.0000000000002459] [Reference Citation Analysis]
|
| 68 |
Li J, Chen L, Pang J, Yang C, Xie W, Shen G, Chen H, Li X, Xiao SY, Li Y. Autophagy-Related Gene WD Repeat Domain 45B Promotes Tumor Proliferation and Migration of Hepatocellular Carcinoma through the Akt/mTOR Signaling Pathway. Diagnostics (Basel) 2023;13. [PMID: 36900050 DOI: 10.3390/diagnostics13050906] [Reference Citation Analysis]
|
| 69 |
Yuan G, Liu Z, Wang W, Liu M, Xu Y, Hu W, Fan Y, Zhang X, Liu Y, Si G. Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma. J Nanobiotechnology 2023;21:68. [PMID: 36849981 DOI: 10.1186/s12951-023-01820-7] [Reference Citation Analysis]
|
| 70 |
Jeon SK, Lee DH, Hur BY, Park SJ, Kim SW, Park J, Suh KS, Lee KW, Yi NJ, Han JK. Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment. J Magn Reson Imaging 2023. [PMID: 36825827 DOI: 10.1002/jmri.28665] [Reference Citation Analysis]
|
| 71 |
Chen Z, Zhou X, Zhou X, Tang Y, Lu M, Zhao J, Tian C, Wu M, Liu Y, Prochownik EV, Wang F, Li Y. Phosphomevalonate Kinase Controls β-Catenin Signaling via the Metabolite 5-Diphosphomevalonate. Adv Sci (Weinh) 2023;:e2204909. [PMID: 36808719 DOI: 10.1002/advs.202204909] [Reference Citation Analysis]
|
| 72 |
Hu J, Burrowes DP, Caine BA, Gibson N, Bhayana D, Medellin A, Burak KW, Wilson SR. Nodules Identified on Surveillance Ultrasound for HCC: CEUS or MRI as the Initial Test? J Ultrasound Med 2023. [PMID: 36807925 DOI: 10.1002/jum.16183] [Reference Citation Analysis]
|
| 73 |
Ji D, Feng H, Hou L, Xu Y, Wang X, Zhao W, Pei H, Zhao Q, Chen Q, Tan G. LINC00511, a future star for the diagnosis and therapy of digestive system malignant tumors. Pathol Res Pract 2023;244:154382. [PMID: 36868095 DOI: 10.1016/j.prp.2023.154382] [Reference Citation Analysis]
|
| 74 |
Fu Y, Zeng CH, An C, Liu Y, Shin JH, Li X. How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. Cancers (Basel) 2023;15. [PMID: 36831664 DOI: 10.3390/cancers15041324] [Reference Citation Analysis]
|
| 75 |
Zhang Z, Jiao T, Li J, Hu B, Zhang W, Wang Z, Wan T, Wang Y, Lu S. Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma. World J Surg Oncol 2023;21:53. [PMID: 36803872 DOI: 10.1186/s12957-023-02939-5] [Reference Citation Analysis]
|
| 76 |
Li X, Chen J, Wang X, Bai T, Lu S, Wei T, Tang Z, Huang C, Zhang B, Liu B, Li L, Wu F. Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1110689] [Reference Citation Analysis]
|
| 77 |
Li F, Xue X. Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma. J Oncol 2023;2023:4615297. [PMID: 36844873 DOI: 10.1155/2023/4615297] [Reference Citation Analysis]
|
| 78 |
Mohamed Fteah A, Abdel Rahim A, Ahmed AbdelHady A, Shawky H, A Elrefaiy M, Mamdouh Aly D. Association of PNPLA3 (rs738409) & TM6SF2 (rs58542926) and ATG16L1 (rs2241880) genetic variants with susceptibility to hepatocellular carcinoma in a group of Egyptian patients with HCV-induced liver cirrhosis. Tumour Virus Res 2023;15:200256. [PMID: 36804832 DOI: 10.1016/j.tvr.2023.200256] [Reference Citation Analysis]
|
| 79 |
Fan F, Dong G, Han C, Ding W, Li X, Dong X, Wang Z, Liang P, Yu J. Peripheral immune factors aiding clinical parameter for better early recurrence prediction of hepatocellular carcinoma after thermal ablation. Int J Hyperthermia 2023;40:2172219. [PMID: 36775652 DOI: 10.1080/02656736.2023.2172219] [Reference Citation Analysis]
|
| 80 |
Li C, Xiao J, Wu S, Liu L, Zeng X, Zhao Q, Zhang Z. Clinical application of serum-based proteomics technology in human tumor research. Anal Biochem 2023;663:115031. [PMID: 36580994 DOI: 10.1016/j.ab.2022.115031] [Reference Citation Analysis]
|
| 81 |
Gao X, Jiang P, Wei X, Zhang W, Zheng J, Sun S, Yao H, Liu X, Zhang Q. Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity. BMC Cancer 2023;23:154. [PMID: 36793021 DOI: 10.1186/s12885-023-10608-9] [Reference Citation Analysis]
|
| 82 |
Giacomelli L, Sacco R, Papa S, Carr BI. Understanding the Drawbacks of the Current Tumor Staging Systems: How to Improve? Cancers (Basel) 2023;15. [PMID: 36831584 DOI: 10.3390/cancers15041242] [Reference Citation Analysis]
|
| 83 |
Xu MH, Huang C, Li ML, Zhu XD, Tan CJ, Zhou J, Fan J, Sun HC, Shen YH. Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study. Cancer Med 2023. [PMID: 36790032 DOI: 10.1002/cam4.5661] [Reference Citation Analysis]
|
| 84 |
Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. Cancer 2023;129:590-9. [PMID: 36426410 DOI: 10.1002/cncr.34559] [Reference Citation Analysis]
|
| 85 |
El-Khobar KE, Sukowati CHC. Updates on Organoid Model for the Study of Liver Cancer. Technol Cancer Res Treat 2023;22:15330338231154090. [PMID: 36788421 DOI: 10.1177/15330338231154090] [Reference Citation Analysis]
|
| 86 |
Yang Z, Gao S, Wong CC, Liu W, Chen H, Shang H, Wu ZY, Xu L, Zhang X, Wong N, Kuang M, Yu J. TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Pathol 2023. [PMID: 36787097 DOI: 10.1002/path.6065] [Reference Citation Analysis]
|
| 87 |
Rong D, Wang Y, Liu L, Cao H, Huang T, Liu H, Hao X, Sun G, Sun G, Zheng Z, Kang J, Xia Y, Chen Z, Tang W, Wang X. GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway. J Immunother Cancer 2023;11. [PMID: 36787938 DOI: 10.1136/jitc-2022-005126] [Reference Citation Analysis]
|
| 88 |
Yao CC, Wang JH, Chen CH, Hung CH, Yen YH, Kee KM, Hu TH, Tsai MC, Kuo YH, Lu SN. Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Diagnostics (Basel) 2023;13. [PMID: 36832184 DOI: 10.3390/diagnostics13040696] [Reference Citation Analysis]
|
| 89 |
Zhang W, Yang C, Hu Y, Yi K, Xiao W, Xu X, Chen Z. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer. Sci Rep 2023;13:2409. [PMID: 36765148 DOI: 10.1038/s41598-023-28653-6] [Reference Citation Analysis]
|
| 90 |
Ouyang W, Wang MD, Wang WY, Li C, Yao LQ, Zhu H, Yang T. Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma. J Oncol 2023;2023:5449443. [PMID: 36816356 DOI: 10.1155/2023/5449443] [Reference Citation Analysis]
|
| 91 |
Hu X, Wang Q, Huang G, He X, Sparrelid E, Brismar TB, Fan Y. Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma. Comput Math Methods Med 2023;2023:5424204. [PMID: 36814805 DOI: 10.1155/2023/5424204] [Reference Citation Analysis]
|
| 92 |
Torkian P, Haghshomar M, Farsad K, Wallace S, Golzarian J, Young SJ. Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation. AJR Am J Roentgenol 2023. [PMID: 36752368 DOI: 10.2214/AJR.22.28800] [Reference Citation Analysis]
|
| 93 |
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther 2023;8:58. [PMID: 36750721 DOI: 10.1038/s41392-022-01235-0] [Reference Citation Analysis]
|
| 94 |
Chen Y, Tang L, Huang W, Abisola FH, Zhang Y, Zhang G, Yao L. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma. Biol Direct 2023;18:4. [PMID: 36750831 DOI: 10.1186/s13062-023-00358-w] [Reference Citation Analysis]
|
| 95 |
Jiang D, Ding X, Zhang J, Liu Y, Zhang X, Li J, Shen J, Shi Y, Feng Y, Qiao X, Wei H, Zhuang T, Sun Y, Yang S, Zhou F, Zhao Q, Yang K. LV5plex: Immune-histological phenotypes staged by self-studying for a liver cancer multiplex staining set. Front Cell Dev Biol 2023;11:1058987. [PMID: 36814600 DOI: 10.3389/fcell.2023.1058987] [Reference Citation Analysis]
|
| 96 |
Xue J, Liu H, Li R, Tan S, Yan Y, Dong Z, Hong J, Liu E, Zhang Q, Chen Z, Wang D, Li T. Salvage surgery after combination immunotherapy for initially unresectable hepatocellular carcinoma: A retrospective clinical study.. [DOI: 10.21203/rs.3.rs-2546520/v1] [Reference Citation Analysis]
|
| 97 |
Peng Q, Li J, Wu Q, Wang P, Kang Z, Deng Y, Xiao Y, Zheng P, Ge F, Chen Y. ZNF385A and ZNF346 Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36834567 DOI: 10.3390/ijms24043155] [Reference Citation Analysis]
|
| 98 |
Jeon AJ, Teo YY, Sekar K, Chong SL, Wu L, Chew SC, Chen J, Kendarsari RI, Lai H, Ling WH, Kaya NA, Lim JQ, Ramasamy A, Oguz G, Chung AY, Chan CY, Cheow PC, Kam JH, Madhavan K, Kow A, Ganpathi IS, Lim TKH, Leow WQ, Loong S, Loh TJ, Wan WK, Soon GST, Pang YH, Yoong BK, Ong DB, Lim J, de Villa VH, Cruz RDD, Chanwat R, Thammasiri J, Bonney GK, Goh BKP, Tucker-Kellogg G, Foo RSY, Chow PKH. Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma. BMC Cancer 2023;23:118. [PMID: 36737737 DOI: 10.1186/s12885-022-10444-3] [Reference Citation Analysis]
|
| 99 |
Huang J, Zhong T, Li G, Wang S, Qin R. Epigenetic inhibition of lncRNA GMDS-AS1 by methyltransferase ESET promoted cell viability and metastasis of hepatocellular carcinoma. Clin Transl Oncol 2023. [PMID: 36737533 DOI: 10.1007/s12094-023-03077-w] [Reference Citation Analysis]
|
| 100 |
Zhou H, Zeng C, Liu J, Luo H, Huang W. F-Box Protein 43, Stabilized by N6-Methyladenosine Methylation, Enhances Hepatocellular Carcinoma Cell Growth and Invasion via Promoting p53 Degradation in a Ubiquitin Conjugating Enzyme E2 C-Dependent Manner. Cancers (Basel) 2023;15. [PMID: 36765911 DOI: 10.3390/cancers15030957] [Reference Citation Analysis]
|
| 101 |
Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev 2023. [PMID: 36729264 DOI: 10.1007/s10555-023-10084-4] [Reference Citation Analysis]
|
| 102 |
Chen J, Liu D, Guo Y, Zhang Y, Guo Y, Jiang M, Dai Y, Yao X. Preoperative identification of cytokeratin 19 status of hepatocellular carcinoma based on diffusion kurtosis imaging. Abdom Radiol (NY) 2023;48:579-89. [PMID: 36416905 DOI: 10.1007/s00261-022-03736-6] [Reference Citation Analysis]
|
| 103 |
Jiang C, Sun XD, Qiu W, Chen YG, Sun DW, Lv GY. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy? Hepatobiliary Pancreat Dis Int 2023;22:7-13. [PMID: 36825482 DOI: 10.1016/j.hbpd.2022.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 104 |
Ren Y, Bo L, Shen B, Yang J, Xu S, Shen W, Chen H, Wang X, Chen H, Cai X. Development and validation of a clinical-radiomics model to predict recurrence for patients with hepatocellular carcinoma after curative resection. Med Phys 2023;50:778-90. [PMID: 36269204 DOI: 10.1002/mp.16061] [Reference Citation Analysis]
|
| 105 |
Pinter M, Pinato DJ, Ramadori P, Heikenwalder M. NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. Clin Cancer Res 2023;29:513-20. [PMID: 36166660 DOI: 10.1158/1078-0432.CCR-21-1258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 106 |
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data. Hepatol Res 2023;53:116-26. [PMID: 36316794 DOI: 10.1111/hepr.13852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 107 |
Sebagh M, Desterke C, Feray C, Hamelin J, Habib M, Samuel D, Rosmorduc O, Vibert E, Golse N. Indocyanine green fluorescence patterns of hepatocellular carcinoma correlate with pathological and molecular features. HPB (Oxford) 2023;25:198-209. [PMID: 36411232 DOI: 10.1016/j.hpb.2022.10.008] [Reference Citation Analysis]
|
| 108 |
Mahmoudi S, Bernatz S, Ackermann J, Koch V, Dos Santos DP, Grünewald LD, Yel I, Martin SS, Scholtz JE, Stehle A, Walter D, Zeuzem S, Wild PJ, Vogl TJ, Kinzler MN. Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Clin Oncol (R Coll Radiol) 2023:S0936-6555(23)00023-7. [PMID: 36804153 DOI: 10.1016/j.clon.2023.01.018] [Reference Citation Analysis]
|
| 109 |
Saber S, El-Fattah EEA, Abdelhamid AM, Mourad AAE, Hamouda MAM, Elrabat A, Zakaria S, Haleem AA, Mohamed SZ, Elgharabawy RM, Morsy NE, El Adle Khalaf N, Mohammed OA, El-Bahouty WB, Mostafa SA, Abdelhady R, Galal O, ElSaid ZH, Yahya G, Shata A, Youssef ME. Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling. Biomed Pharmacother 2023;158:114196. [PMID: 36916405 DOI: 10.1016/j.biopha.2022.114196] [Reference Citation Analysis]
|
| 110 |
Kabir T, Goh BK. Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis. Minerva Surg 2023;78:68-75. [PMID: 36519820 DOI: 10.23736/S2724-5691.22.09729-5] [Reference Citation Analysis]
|
| 111 |
Fan GH, Zhang CZ, Gao FQ, Wei XY, Ling SB, Wang K, Wang JG, Zheng SS, Nikfarjam M, Xu X. A mixed blessing for liver transplantation patients - Rapamycin. Hepatobiliary Pancreat Dis Int 2023;22:14-21. [PMID: 36328894 DOI: 10.1016/j.hbpd.2022.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 112 |
Geng Y, Shao WQ, Lin J. Spleen to non-cancerous liver volume ratio predicts liver cirrhosis in hepatocellular carcinoma patients. Abdom Radiol (NY) 2023;48:543-53. [PMID: 36380210 DOI: 10.1007/s00261-022-03727-7] [Reference Citation Analysis]
|
| 113 |
Tan J, Liu T, Fan W, Wei J, Zhu B, Liu Y, Liu L, Zhang X, Chen S, Lin H, Zhang Y, Li J. Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma. Acta Pharm Sin B 2023;13:632-47. [PMID: 36873191 DOI: 10.1016/j.apsb.2022.08.006] [Reference Citation Analysis]
|
| 114 |
Oura K, Morishita A, Hamaya S, Fujita K, Masaki T. The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36769116 DOI: 10.3390/ijms24032805] [Reference Citation Analysis]
|
| 115 |
Luo Q, Qiu L, Zhan K, Zeng L, Liao S, Li C, Mei Z, Lv L. Peroxisomal trans-2-enoyl-CoA inhibits proliferation, migration and invasion of hepatocellular carcinoma cells. Acta Histochem 2023;125:152002. [PMID: 36724637 DOI: 10.1016/j.acthis.2023.152002] [Reference Citation Analysis]
|
| 116 |
Weng MT, Yang SF, Liu SY, Hsu YC, Wu MC, Chou HC, Chiou LL, Liang JD, Wang LF, Lee HS, Sheu JC. In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models. Pharmacol Res 2023;188:106646. [PMID: 36621619 DOI: 10.1016/j.phrs.2023.106646] [Reference Citation Analysis]
|
| 117 |
Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Goh MJ, Kang W, Kim SU. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2023;35:191-7. [PMID: 36574310 DOI: 10.1097/MEG.0000000000002466] [Reference Citation Analysis]
|
| 118 |
Tan CT, Soh NJH, Chang HC, Yu VC. p62/SQSTM1 in liver diseases: the usual suspect with multifarious identities. FEBS J 2023;290:892-912. [PMID: 34882306 DOI: 10.1111/febs.16317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 119 |
Lima HA, Alaimo L, Brown ZJ, Endo Y, Moazzam Z, Tsilimigras DI, Shaikh C, Resende V, Guglielmi A, Ratti F, Aldrighetti L, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Hugh T, Endo I, Shen F, Pawlik TM. Application of hazard functions to investigate recurrence after curative-intent resection for hepatocellular carcinoma. HPB (Oxford) 2023;25:260-8. [PMID: 36470717 DOI: 10.1016/j.hpb.2022.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 120 |
Ding DY, Liu L, Li HL, Gan XJ, Ding WB, Gu FM, Sun DP, Li W, Pan ZY, Yuan SX, Zhou WP. Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients. Hepatobiliary Pancreat Dis Int 2023;22:72-80. [PMID: 35428596 DOI: 10.1016/j.hbpd.2022.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 121 |
Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Kakizaki S, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis. Cancer Med 2023;12:4259-69. [PMID: 36156452 DOI: 10.1002/cam4.5294] [Reference Citation Analysis]
|
| 122 |
Feng X, Cai W, Zheng R, Tang L, Zhou J, Wang H, Liao J, Luo B, Cheng W, Wei A, Zhao W, Jing X, Liang P, Yu J, Huang Q. Diagnosis of hepatocellular carcinoma using deep network with multi-view enhanced patterns mined in contrast-enhanced ultrasound data. Engineering Applications of Artificial Intelligence 2023;118:105635. [DOI: 10.1016/j.engappai.2022.105635] [Reference Citation Analysis]
|
| 123 |
Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D, Li S, Peng H, Liang J, Liu Z, Rao S, Wang J, Zhang R, Zhang L. [(18)F]FAPI PET/CT in the evaluation of focal liver lesions with [(18)F]FDG non-avidity. Eur J Nucl Med Mol Imaging 2023;50:937-50. [PMID: 36346437 DOI: 10.1007/s00259-022-06022-1] [Reference Citation Analysis]
|
| 124 |
Shi Y, Xiao Q, Huang S, Pan Q, Jia H, Zhou Q, Wei J, Kang J, Li Z, Hu Y. Poor Prognostic Biomarker KIAA1522 Is Associated with Immune Infiltrates in Hepatocellular Carcinoma. J Oncol 2023;2023:3538928. [PMID: 36761433 DOI: 10.1155/2023/3538928] [Reference Citation Analysis]
|
| 125 |
Zhan G, Peng H, Zhou L, Jin L, Xie X, He Y, Wang X, Du Z, Cao P. A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort. Front Endocrinol (Lausanne) 2023;14:1070396. [PMID: 36798659 DOI: 10.3389/fendo.2023.1070396] [Reference Citation Analysis]
|
| 126 |
Draškovič T, Zidar N, Hauptman N. Circulating Tumor DNA Methylation Biomarkers for Characterization and Determination of the Cancer Origin in Malignant Liver Tumors. Cancers (Basel) 2023;15. [PMID: 36765815 DOI: 10.3390/cancers15030859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 127 |
Hemminki K, Sundquist K, Sundquist J, Försti A, Liska V, Hemminki A, Li X. Autoimmune diseases as comorbidities for liver, gallbladder, and biliary duct cancers in Sweden. Cancer 2023. [PMID: 36715017 DOI: 10.1002/cncr.34663] [Reference Citation Analysis]
|
| 128 |
Song Y, Lee SY, Kim S, Choi I, Kim N, Park J, Seo HR. HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765811 DOI: 10.3390/cancers15030851] [Reference Citation Analysis]
|
| 129 |
Elbakry MMM, ElBakary NM, Hagag SA, Hemida EHA. Pomegranate Peel Extract Sensitizes Hepatocellular Carcinoma Cells to Ionizing Radiation, Induces Apoptosis and Inhibits MAPK, JAK/STAT3, β-Catenin/NOTCH, and SOCS3 Signaling. Integr Cancer Ther 2023;22:15347354221151021. [PMID: 36710483 DOI: 10.1177/15347354221151021] [Reference Citation Analysis]
|
| 130 |
Eghbali M, Haber ZM, Srinivasa RN, Padia SA. Complications of 90Y Radioembolization Treatment for Liver Tumors. Digestive Disease Interventions 2023. [DOI: 10.1055/s-0043-1760730] [Reference Citation Analysis]
|
| 131 |
Zhu J, Zheng Y, Liu Y, Chen M, Liu Y, Li J. Association between HMGA1 and immunosuppression in hepatocellular carcinoma: A comprehensive bioinformatics analysis. Medicine (Baltimore) 2023;102:e32707. [PMID: 36705364 DOI: 10.1097/MD.0000000000032707] [Reference Citation Analysis]
|
| 132 |
Wu F, Sun H, Zhou C, Huang P, Xiao Y, Yang C, Zeng M. Prognostic factors for long-term outcome in bifocal hepatocellular carcinoma after resection. Eur Radiol 2023. [PMID: 36700957 DOI: 10.1007/s00330-023-09398-2] [Reference Citation Analysis]
|
| 133 |
Durkin C, Schaubel DE, Xu Y, Mahmud N, Kaplan DE, Abt PL, Bittermann T. Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2023. [PMID: 36695564 DOI: 10.1097/TP.0000000000004487] [Reference Citation Analysis]
|
| 134 |
Cannito S, Dianzani U, Parola M, Albano E, Sutti S. Inflammatory processes involved in NASH-related hepatocellular carcinoma. Biosci Rep 2023;43. [PMID: 36691794 DOI: 10.1042/BSR20221271] [Reference Citation Analysis]
|
| 135 |
Hu X, Li C, Wang Q, Wu X, Chen Z, Xia F, Cai P, Zhang L, Fan Y, Ma K. Development and External Validation of a Radiomics Model Derived from Preoperative Gadoxetic Acid-Enhanced MRI for Predicting Histopathologic Grade of Hepatocellular Carcinoma. Diagnostics (Basel) 2023;13. [PMID: 36766518 DOI: 10.3390/diagnostics13030413] [Reference Citation Analysis]
|
| 136 |
Ma J, Bo Z, Zhao Z, Yang J, Yang Y, Li H, Yang Y, Wang J, Su Q, Wang J, Chen K, Yu Z, Wang Y, Chen G. Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765583 DOI: 10.3390/cancers15030625] [Reference Citation Analysis]
|
| 137 |
Brar A, Zhu A, Baciu C, Sharma D, Xu W, Orchanian‐cheff A, Wang B, Reimand J, Grant R, Bhat M. Development of diagnostic and prognostic molecular biomarkers in hepatocellular carcinoma using machine learning: A systematic review. Liver Cancer International 2023. [DOI: 10.1002/lci2.66] [Reference Citation Analysis]
|
| 138 |
Oh S, Jo S, Kim HS, Mai VH, Endaya B, Neuzil J, Jung KH, Hong SS, Kim JM, Park S. Chemical Biopsy for GNMT as Noninvasive and Tumorigenesis-Relevant Diagnosis of Liver Cancer. Anal Chem 2023;95:1184-92. [PMID: 36602057 DOI: 10.1021/acs.analchem.2c03944] [Reference Citation Analysis]
|
| 139 |
Deng J, Liao Z, Gao J. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Curr Oncol 2023;30:1243-54. [PMID: 36661745 DOI: 10.3390/curroncol30010096] [Reference Citation Analysis]
|
| 140 |
Tovo CV, de Mattos AZ, Coral GP, Sartori GDP, Nogueira LV, Both GT, Villela-Nogueira CA, de Mattos AA. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol 2023; 29(2): 343-356 [PMID: 36687125 DOI: 10.3748/wjg.v29.i2.343] [Reference Citation Analysis]
|
| 141 |
Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, Sun B. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma. Immunology 2023. [PMID: 36640111 DOI: 10.1111/imm.13624] [Reference Citation Analysis]
|
| 142 |
Zhao X, Liu C, Wang Z, Zhao Y, Chen X, Tao H, Chen H, Wang X, Duan S. Synergistic Pro-Apoptotic Effect of a Cyclic RGD Peptide-Conjugated Magnetic Mesoporous Therapeutic Nanosystem on Hepatocellular Carcinoma HepG2 Cells. Pharmaceutics 2023;15. [PMID: 36678904 DOI: 10.3390/pharmaceutics15010276] [Reference Citation Analysis]
|
| 143 |
Wong VCK, Yip J, Fragomeli V, Weltman M, Loh H, Le K, Nguyen D, Bui C, Mansberg R. Comparison between PSMA PET/CT and MRI for Characterizing Hepatocellular carcinoma: A Real-World Study. Tomography 2023;9:130-8. [PMID: 36648998 DOI: 10.3390/tomography9010011] [Reference Citation Analysis]
|
| 144 |
Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, Bell ATF, Elisseeff J, Popel AS, Anders RA, Jaffee EM, Yarchoan M, Fertig EJ, Kagohara LT. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. bioRxiv 2023:2023. [PMID: 36712023 DOI: 10.1101/2023.01.10.523481] [Reference Citation Analysis]
|
| 145 |
Xu FL, Wu XH, Chen C, Wang K, Huang LY, Xia J, Liu Y, Shan XF, Tang N. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. Cell Death Dis 2023;14:22. [PMID: 36635256 DOI: 10.1038/s41419-023-05558-w] [Reference Citation Analysis]
|
| 146 |
Huang R, Liu W, Zhang Q, Zhu G, Qu W, Tao C, Gao J, Fang Y, Fu X, Zhou J, Shi Y, Fan J, Tang Z. Laser-Induced Combinatorial Chemotherapeutic, Chemodynamic, and Photothermal Therapy for Hepatocellular Carcinoma Based on Oxaliplatin-Loaded Metal-Organic Frameworks. ACS Appl Mater Interfaces 2023;15:3781-90. [PMID: 36631295 DOI: 10.1021/acsami.2c19305] [Reference Citation Analysis]
|
| 147 |
Wang G, Zhang X, Zhou Z, Song C, Jin W, Zhang H, Wu W, Yi Y, Cui H, Zhang P, Liu X, Xu W, Shen X, Shen W, Wang X. Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway. Discov Oncol 2023;14:4. [PMID: 36631680 DOI: 10.1007/s12672-023-00611-8] [Reference Citation Analysis]
|
| 148 |
Deng J, Ke H. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles. Oncoimmunology 2023;12:2152635. [PMID: 36605619 DOI: 10.1080/2162402X.2022.2152635] [Reference Citation Analysis]
|
| 149 |
Li X, Wang J, Ding X, Xu Y, Yu M, Wu H, Deng N, Li W, Chen J. Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy. Front Pharmacol 2022;13:1032881. [PMID: 36703739 DOI: 10.3389/fphar.2022.1032881] [Reference Citation Analysis]
|
| 150 |
Ben Khaled N, Reiter FP, Geier A, De Toni EN. Systemtherapie des hepatozellulären Karzinoms: mehr als eine „palliative“ Therapie? Gastroenterologie 2023. [DOI: 10.1007/s11377-022-00666-z] [Reference Citation Analysis]
|
| 151 |
Miranda J, Horvat N, Fonseca GM, Araujo-Filho JAB, Fernandes MC, Charbel C, Chakraborty J, Coelho FF, Nomura CH, Herman P. Current status and future perspectives of radiomics in hepatocellular carcinoma. World J Gastroenterol 2023; 29(1): 43-60 [PMID: 36683711 DOI: 10.3748/wjg.v29.i1.43] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 152 |
Wanting H, Jian Z, Chaoxin X, Cheng Y, Chengjian Z, Lin Z, Dan C. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs. J Cancer Res Clin Oncol 2023. [PMID: 36609710 DOI: 10.1007/s00432-022-04560-7] [Reference Citation Analysis]
|
| 153 |
Lin D, Chen Z, Zeng Y, Ding Y, Zhao L, Xu Q, Yu F, Song X, Zhu X. A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma. BMC Med Genomics 2023;16:2. [PMID: 36611208 DOI: 10.1186/s12920-023-01431-z] [Reference Citation Analysis]
|
| 154 |
Dwivedi A, Khabiya R, Shrivastava A, Tyagi S, Nagarajan K, Darwhekar GN. MECHANISM OF ACTION, SYNTHESIS, PROPERTIES AND ANALYTICAL METHODS OF CABOZANTINIB. Int J App Pharm 2023. [DOI: 10.22159/ijap.2023v15i1.46409] [Reference Citation Analysis]
|
| 155 |
Caviglia GP, Abate ML, Troshina G, Carucci P, Rolle E, Risso A, Burlone ME, Albè A, Crevola M, Musso EC, Rosso C, Armandi A, Olivero A, Minisini R, Saracco GM, Bugianesi E, Pirisi M, Ciancio A, Gaia S. Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development. Biology (Basel) 2023;12. [PMID: 36671786 DOI: 10.3390/biology12010094] [Reference Citation Analysis]
|
| 156 |
Liu Q, Liu YY, Chen XM, Tao BY, Chen K, Li WM, Xu CT, Shi Y, Li H, Liu HR. KIF5A upregulation in hepatocellular carcinoma: A novel prognostic biomarker associated with unique tumor microenvironment status. Front Oncol 2022;12:1071722. [PMID: 36686769 DOI: 10.3389/fonc.2022.1071722] [Reference Citation Analysis]
|
| 157 |
López-Cánovas JL, Hermán-Sánchez N, Del Rio-Moreno M, Fuentes-Fayos AC, Lara-López A, Sánchez-Frias ME, Amado V, Ciria R, Briceño J, de la Mata M, Castaño JP, Rodriguez-Perálvarez M, Luque RM, Gahete MD. PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing. Exp Mol Med 2023;55:132-42. [PMID: 36609600 DOI: 10.1038/s12276-022-00917-7] [Reference Citation Analysis]
|
| 158 |
Lei K, Deng ZF, Wang JG, You K, Xu J, Liu ZJ. PNI-Based Nomograms to Predict Tumor Progression and Survival for Patients with Unresectable Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization. J Clin Med 2023;12. [PMID: 36675418 DOI: 10.3390/jcm12020486] [Reference Citation Analysis]
|
| 159 |
Wu T, Fan R, Bai J, Yang Z, Qian YS, Du LT, Wang CY, Wang YC, Jiang GQ, Zheng D, Fan XT, Zheng B, Liu JF, Deng GH, Shen F, Hu HP, Ye YN, Zhang QZ, Zhang J, Gao YH, Xia J, Yan HD, Liang MF, Yu YL, Sun FM, Gao YJ, Sun J, Zhong CX, Wang Y, Wang H, Kong F, Chen JM, Wen H, Wu BM, Wang CX, Wu L, Hou JL, Liu XL, Wang HY, Chen L. The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis. J Hematol Oncol 2023;16:1. [PMID: 36600307 DOI: 10.1186/s13045-022-01396-z] [Reference Citation Analysis]
|
| 160 |
Luo L, Cai Z, Zeng S, Wang L, Kang Z, Yang N, Zhang Y. CT and MRI features of hepatic epithelioid haemangioendothelioma: a multi-institutional retrospective analysis of 15 cases and a literature review. Insights Imaging 2023;14:2. [PMID: 36600110 DOI: 10.1186/s13244-022-01344-y] [Reference Citation Analysis]
|
| 161 |
Li J, Zhai X, Chen C, Zhang R, Huang X, Liu Y. 16S rRNA gene analysis reveals differentially abundant Actinobacteria, Firmicutes, and Proteobacteria in the tumors and adjacent healthy tissues of patients with hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2411606/v1] [Reference Citation Analysis]
|
| 162 |
Ma K, Wu H, Ji L. Construction of HBV gene-related prognostic and diagnostic models for hepatocellular carcinoma. Front Genet 2022;13:1065644. [PMID: 36685852 DOI: 10.3389/fgene.2022.1065644] [Reference Citation Analysis]
|
| 163 |
Hou G, Liu B, Fan ZQ, Li C, Zhang JP, Guo YH, Zhang RY, Zheng Y, Zhu H, Wang NY. Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. Front Oncol 2022;12:1094104. [PMID: 36686731 DOI: 10.3389/fonc.2022.1094104] [Reference Citation Analysis]
|
| 164 |
Chen S, Huang C, Liao G, Sun H, Xie Y, Liao C, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Lin Z, Zhang GP, Xie W, Shen S, Li S, Peng S, Kuang DM, Zhao Q, Duda DG, Kuang M. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences. Gut 2023:gutjnl-2022-328428. [PMID: 36596711 DOI: 10.1136/gutjnl-2022-328428] [Reference Citation Analysis]
|
| 165 |
Li H, Gao L, Kang X, Wang X, Yu Y, Zhang Y, Chen H. RPS24 Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36614249 DOI: 10.3390/ijms24010806] [Reference Citation Analysis]
|
| 166 |
Qiu M, Liu Y, Lin Q, Jiang Y, Zhou Z, Wen Q, Liang X, Zhou X, Yu H. A functional variant in the RAD51 3′ UTR is associated with survival of hepatocellular carcinoma patients. Gene 2023;851:146964. [DOI: 10.1016/j.gene.2022.146964] [Reference Citation Analysis]
|
| 167 |
Dai X, Li X, Du Y, Han M, Wang Z, Wang Y, Yan F, Liu Y. Gold Nanorod–Mesoporous Silica Core Shell Nanocomposites for NIR-II Photothermal Ablation and Dual PD-L1/VEGF Blockade Therapy in Hepatocellular Carcinoma. Chemical Engineering Journal 2023. [DOI: 10.1016/j.cej.2023.141426] [Reference Citation Analysis]
|
| 168 |
Shan T, Ran X, Li H, Feng G, Zhang S, Zhang X, Zhang L, Lu L, An L, Fu R, Sun K, Wang S, Chen R, Li L, Chen W, Wei W, Zeng H, He J. Disparities in stage at diagnosis for liver cancer in China. Journal of the National Cancer Center 2023. [DOI: 10.1016/j.jncc.2022.12.002] [Reference Citation Analysis]
|
| 169 |
White SB, Maddirela DR. Fibrosis and Immunotherapy in Hepatocellular Carcinoma. Interdisciplinary Cancer Research 2023. [DOI: 10.1007/16833_2022_122] [Reference Citation Analysis]
|
| 170 |
Wu S, Yang L, Bi X, Lin Y, Deng W, Jiang T, Li M, Xie Y. Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus. Gastroenterology & Endoscopy 2023. [DOI: 10.1016/j.gande.2022.10.001] [Reference Citation Analysis]
|
| 171 |
Lin C, He Y, Liu M, Wu A, Zhang J, Li S, Li S, Cao Q, Liu F. Vessels That Encapsulate Tumor Clusters (VETC) Predict cTACE Response in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2023;10:383-97. [PMID: 36915392 DOI: 10.2147/JHC.S395903] [Reference Citation Analysis]
|
| 172 |
Qin H, Sheng W, Zhang G, Yang Q, Yao S, Yue Y, Zhang P, Zhu Y, Wang Q, Chen Y, Zeng H, Weng J, Yu F, Yang J. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. Front Genet 2023;14:1094793. [PMID: 36891150 DOI: 10.3389/fgene.2023.1094793] [Reference Citation Analysis]
|
| 173 |
Qiao W, Wang Q, Mei T, Wang Q, Wang W, Zhang Y. External validation and improvement of the scoring system for predicting the prognosis in hepatocellular carcinoma after interventional therapy. Front Surg 2023;10:1045213. [PMID: 36936655 DOI: 10.3389/fsurg.2023.1045213] [Reference Citation Analysis]
|
| 174 |
Chong H, Gong Y, Zhang Y, Dai Y, Sheng R, Zeng M. Radiomics on Gadoxetate Disodium-enhanced MRI: Non-invasively Identifying Glypican 3-Positive Hepatocellular Carcinoma and Postoperative Recurrence. Acad Radiol 2023;30:49-63. [PMID: 35562264 DOI: 10.1016/j.acra.2022.04.006] [Reference Citation Analysis]
|
| 175 |
邹 儒. Advances in the Prediction of Post Hepatectomy Liver Failure. ACM 2023;13:484-491. [DOI: 10.12677/acm.2023.131072] [Reference Citation Analysis]
|
| 176 |
Lindblad KE, Lujambio A. Imaging for better responses to immunotherapy in hepatocellular carcinoma. Hepatology 2023;77:6-9. [PMID: 35727179 DOI: 10.1002/hep.32627] [Reference Citation Analysis]
|
| 177 |
Xu Y, Cai J, Zhong K, Wen Y, Cai L, He G, Liao H, Zhang C, Fu S, Chen T, Cai J, Zhong X, Chen C, Huang M, Cheng Y, Pan M. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection. Front Oncol 2023;13:1119744. [PMID: 36959801 DOI: 10.3389/fonc.2023.1119744] [Reference Citation Analysis]
|
| 178 |
Zheng Z, Hu Y, Ren Y, Mo G, Wan H. Correlation between metastatic patterns and age in patients with metastatic primary liver cancer: A population-based study. PLoS One 2023;18:e0267809. [PMID: 36706100 DOI: 10.1371/journal.pone.0267809] [Reference Citation Analysis]
|
| 179 |
Yu Y, Ding S, Xu X, Yan D, Fan Y, Ruan B, Zhang X, Zheng L, Jie W, Zheng S. Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen (Codonopsis pilosula) Against Hepatocellular Carcinoma: Validation Based on the Active Compound Luteolin. Drug Des Devel Ther 2023;17:659-73. [PMID: 36883114 DOI: 10.2147/DDDT.S386941] [Reference Citation Analysis]
|
| 180 |
Jiang L, Li L, Liu Y, Lu L, Zhan M, Yuan S, Liu Y. Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front Pharmacol 2023;14:1097277. [PMID: 36891274 DOI: 10.3389/fphar.2023.1097277] [Reference Citation Analysis]
|
| 181 |
Ma J, Li J, Jin C, Yang J, Zheng C, Chen K, Xie Y, Yang Y, Bo Z, Wang J, Su Q, Wang J, Chen G, Wang Y. Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case-control study. Liver Int 2023;43:221-33. [PMID: 36300678 DOI: 10.1111/liv.15466] [Reference Citation Analysis]
|
| 182 |
Tian BW, Yan LJ, Ding ZN, Liu H, Meng GX, Xue JS, Han CL, Dong ZR, Hong JG, Chen ZQ, Wang DX, Li T. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis. Expert Rev Gastroenterol Hepatol 2023;17:73-83. [PMID: 36476076 DOI: 10.1080/17474124.2022.2156859] [Reference Citation Analysis]
|
| 183 |
Gupta PP, Sadrani VJ, Gupta PP, Parab MM, Bastikar VA. Hepatitis C virus and hepatocellular carcinoma. Oncogenic Viruses 2023. [DOI: 10.1016/b978-0-12-824152-3.00003-2] [Reference Citation Analysis]
|
| 184 |
Li X, Sun X, Wang B, Li Y, Tong J. Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J Pharm Sci 2023;18:100771. [PMID: 36896445 DOI: 10.1016/j.ajps.2022.100771] [Reference Citation Analysis]
|
| 185 |
Huang ZL, Zhang PB, Zhang JT, Li F, Li TT, Huang XY. Comprehensive Genomic Profiling Identifies FAT1 as a Negative Regulator of EMT, CTCs, and Metastasis of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2023;10:369-82. [PMID: 36915393 DOI: 10.2147/JHC.S398573] [Reference Citation Analysis]
|
| 186 |
Yinzhong W, Miaomiao W, Xiaoxue T, Qian W, Meng Q, Junqiang L. Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Mol Diagn 2023;23:63-9. [PMID: 36633401 DOI: 10.1080/14737159.2023.2167555] [Reference Citation Analysis]
|
| 187 |
He Z, Chen Q, He W, Cao J, Yao S, Huang Q, Zheng Y. Hepatocellular carcinoma subtypes based on metabolic pathways reveals potential therapeutic targets. Front Oncol 2023;13:1086604. [PMID: 36937389 DOI: 10.3389/fonc.2023.1086604] [Reference Citation Analysis]
|
| 188 |
Zeng H, Xu Q, Wang J, Xu X, Luo J, Zhang L, Luo C, Ying J, Li J. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Front Immunol 2023;14:1073133. [PMID: 36756114 DOI: 10.3389/fimmu.2023.1073133] [Reference Citation Analysis]
|
| 189 |
Yoshuantari N, Jeng YM, Liau JY, Lee CH, Tsai JH. Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts. Mod Pathol 2023;36:100042. [PMID: 36788061 DOI: 10.1016/j.modpat.2022.100042] [Reference Citation Analysis]
|
| 190 |
Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2023;72:129-40. [PMID: 35197323 DOI: 10.1136/gutjnl-2021-325918] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 191 |
柴 孟. Effects of Ultrasound-Guided Microwave Ab-lation Therapy on Mental State and Quality of Life in Patients with Hepatocellular Carcinoma. ACM 2023;13:3125-3130. [DOI: 10.12677/acm.2023.133444] [Reference Citation Analysis]
|
| 192 |
Fu J, Jiang J, Liu K. Metabolic syndrome and survival of patients with hepatocellular carcinoma: A meta-analysis. Front Oncol 2023;13:1117846. [PMID: 36910647 DOI: 10.3389/fonc.2023.1117846] [Reference Citation Analysis]
|
| 193 |
Lei X, Hu X, Lu Q, Yao Y, Sun W, Ma Q, Huang D, Xu Q. UBE2K promotes the malignant progression of hepatocellular carcinoma by regulating c-Myc. Biochem Biophys Res Commun 2023;638:210-8. [PMID: 36481361 DOI: 10.1016/j.bbrc.2022.11.046] [Reference Citation Analysis]
|
| 194 |
Chen J, Guo Y, Guo Y, Jiang M, Zhang Y, Dai Y, Yao X. Preoperative assessment of microvascular invasion of hepatocellular carcinoma using non-Gaussian diffusion-weighted imaging with a fractional order calculus model: A pilot study. Magn Reson Imaging 2023;95:110-7. [PMID: 34506910 DOI: 10.1016/j.mri.2021.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 195 |
Yi S, Zhang C, Li M, Wang J. Construction of a Novel Diagnostic Model Based on Ferroptosis-Related Genes for Hepatocellular Carcinoma Using Machine and Deep Learning Methods. J Oncol 2023;2023:1624580. [PMID: 36873737 DOI: 10.1155/2023/1624580] [Reference Citation Analysis]
|
| 196 |
Liu JN, Li JJ, Yan S, Zhang GN, Yi PS. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2023;13:1074793. [PMID: 36910612 DOI: 10.3389/fonc.2023.1074793] [Reference Citation Analysis]
|
| 197 |
Zhang H, Li C, Liao S, Tu Y, Sun S, Yao F, Li Z, Wang Z. PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer. Cancer Biol Ther 2022;23:1-11. [PMID: 36137220 DOI: 10.1080/15384047.2022.2125260] [Reference Citation Analysis]
|
| 198 |
Zhang B, Tao B, Li Y, Yi C, Lin Z, Ma Y, Han J, Shao W, Chen Z, Lin J, Chen J. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. Eur J Intern Med 2022:S0953-6205(22)00454-X. [PMID: 36588054 DOI: 10.1016/j.ejim.2022.12.025] [Reference Citation Analysis]
|
| 199 |
Zhang T, Hu H, Jia Y, Gao Y, Hao F, Wu J, Yang Z, Ren J, Li Z, Liu A, Wu H. Efficacy and safety of radiofrequency ablation and surgery for hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Medicine (Baltimore) 2022;101:e32470. [PMID: 36595979 DOI: 10.1097/MD.0000000000032470] [Reference Citation Analysis]
|
| 200 |
Fan H, Ji Y, Wang Y, Liu D, Wei T, Cao X, Yang M, Bai C, Wang Z. Anthocyanins from Lycium ruthenicum Murray Inhibit HepG2 Cells Growth, Metastasis and Promote Apoptosis and G2/M Phase Cycle Arrest by Activating the AMPK/mTOR Autophagy Pathway. Evid Based Complement Alternat Med 2022;2022:9609596. [PMID: 36619198 DOI: 10.1155/2022/9609596] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 201 |
Zou H, Lei Q, Yan X, Lai Y, Ung COL, Hu H. Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis. Cancers (Basel) 2022;15. [PMID: 36612256 DOI: 10.3390/cancers15010260] [Reference Citation Analysis]
|
| 202 |
He K, Yang Z, Liu X, Yang Y, Song W, Wang S, Chen Y. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. Curr Oncol 2022;30:476-91. [PMID: 36661687 DOI: 10.3390/curroncol30010038] [Reference Citation Analysis]
|
| 203 |
Sun H, Yang W, Zhou W, Zhou C, Liu S, Shi H, Tian W. Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE. Oncol Lett 2023;25:69. [PMID: 36644150 DOI: 10.3892/ol.2022.13655] [Reference Citation Analysis]
|
| 204 |
Cai X, Guillot A, Liu H. Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver? Cells 2022;12. [PMID: 36611926 DOI: 10.3390/cells12010132] [Reference Citation Analysis]
|
| 205 |
Chen B, Zhang L, Cheng J, Wu T, Lei J, Yang X, Zhang R, Safadi R, Li Y, Si T, Lu Y. Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study. Drug Des Devel Ther 2022;16:4429-37. [PMID: 36597443 DOI: 10.2147/DDDT.S386829] [Reference Citation Analysis]
|
| 206 |
Shi CJ, Lv MY, Deng LQ, Zeng WQ, Fu WM, Zhang JF. Linc-ROR drive adriamycin resistance by targeting AP-2α/Wnt/β-catenin axis in hepatocellular carcinoma. Cell Biol Toxicol 2022. [PMID: 36576707 DOI: 10.1007/s10565-022-09777-3] [Reference Citation Analysis]
|
| 207 |
Li SW, Han LF, He Y, Wang XS. Immunological classification of hepatitis B virus-positive hepatocellular carcinoma by transcriptome analysis. World J Hepatol 2022;14:1997-2011. [PMID: 36618328 DOI: 10.4254/wjh.v14.i12.1997] [Reference Citation Analysis]
|
| 208 |
Wang J, Wu R, Sun JY, Lei F, Tan H, Lu X. An overview: Management of patients with advanced hepatocellular carcinoma. Biosci Trends 2022;16:405-25. [PMID: 36476621 DOI: 10.5582/bst.2022.01109] [Reference Citation Analysis]
|
| 209 |
Lu M, Qu Q, Xu L, Zhang J, Liu M, Jiang J, Shen W, Zhang T, Zhang X. Prediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging. Acad Radiol 2022:S1076-6332(22)00659-6. [PMID: 36577606 DOI: 10.1016/j.acra.2022.12.018] [Reference Citation Analysis]
|
| 210 |
Kim JW, Lee CH, Kim KA, Lee J, Park YS. Abbreviated MRI with second shot arterial phase for HCC evaluation: modified version of LI-RADS and recall reduction strategy. Eur Radiol 2022. [PMID: 36562784 DOI: 10.1007/s00330-022-09348-4] [Reference Citation Analysis]
|
| 211 |
Li L, Lu F, Chen P, Song H, Xu W, Guo J, Wang J, Zhou J, Kang X, Jin C, Cai Y, Feng Z, Gao H. Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients. Front Oncol 2022;12:1037742. [PMID: 36620588 DOI: 10.3389/fonc.2022.1037742] [Reference Citation Analysis]
|
| 212 |
Han Y, Zhao W, Wu M, Qian Y. Efficacy and safety of single- and multiple-antenna microwave ablation for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and network meta-analysis. Medicine (Baltimore) 2022;101:e32304. [PMID: 36595779 DOI: 10.1097/MD.0000000000032304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 213 |
Qin X, Zhu J, Tu Z, Ma Q, Tang J, Zhang C. Contrast-Enhanced Ultrasound with Deep Learning with Attention Mechanisms for Predicting Microvascular Invasion in Single Hepatocellular Carcinoma. Acad Radiol 2022:S1076-6332(22)00644-4. [PMID: 36567144 DOI: 10.1016/j.acra.2022.12.005] [Reference Citation Analysis]
|
| 214 |
Elkomos BE, Abdo M, Mamdouh R, Abdelaal A. Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis. Hepatol Int 2023;17:18-37. [PMID: 36564609 DOI: 10.1007/s12072-022-10435-3] [Reference Citation Analysis]
|
| 215 |
Xu K, Ding J, Zhou L, Li D, Luo J, Wang W, Shang M, Lin B, Zhou L, Zheng S. SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis. Cells 2022;12. [PMID: 36611819 DOI: 10.3390/cells12010025] [Reference Citation Analysis]
|
| 216 |
Wang H, Mao Y, Zhang Z, Xu Z, Luo S, Li W, Zou S, Chen B, Wen H, Lin L, Liao W, Huang M. Investigation of a mathematical model describing global cancer growth and treatment: An inhomogeneous model based on the generalized logistic equation.. [DOI: 10.1101/2022.12.18.520960] [Reference Citation Analysis]
|
| 217 |
Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol 2022;13:1070961. [PMID: 36601120 DOI: 10.3389/fimmu.2022.1070961] [Reference Citation Analysis]
|
| 218 |
Casini A, Leone S, Vaccaro R, Vivacqua G, Ceci L, Pannarale L, Franchitto A, Onori P, Gaudio E, Mancinelli R. The Emerging Role of Ferroptosis in Liver Cancers. Life (Basel) 2022;12. [PMID: 36556493 DOI: 10.3390/life12122128] [Reference Citation Analysis]
|
| 219 |
Hassan HM, Onabote O, Isovic M, Passos DT, Dick FA, Torchia J. Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo. Cancers (Basel) 2022;14. [PMID: 36551676 DOI: 10.3390/cancers14246191] [Reference Citation Analysis]
|
| 220 |
Huang Z, Shu Z, Zhu RH, Xin JY, Wu LL, Wang HZ, Chen J, Zhang ZW, Luo HC, Li KY. Deep learning-based radiomics based on contrast-enhanced ultrasound predicts early recurrence and survival outcome in hepatocellular carcinoma. World J Gastrointest Oncol 2022; 14(12): 2380-2392 [DOI: 10.4251/wjgo.v14.i12.2380] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 221 |
Qi R, Huang Z. Novel diagnostic, therapeutic, and prognostic biomarkers for nonalcoholic steatohepatitis-derived hepatocellular carcinoma: Capable to overcome the heterogeneity-specific barrier.. [DOI: 10.21203/rs.3.rs-2367007/v1] [Reference Citation Analysis]
|
| 222 |
Sano A, Inoue J, Kakazu E, Ninomiya M, Iwata T, Tsuruoka M, Sato K, Onuki M, Sawahashi S, Masamune A. Omega-3 polyunsaturated fatty acids are associated with sarcopenia in patients with liver cirrhosis and hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2344312/v1] [Reference Citation Analysis]
|
| 223 |
Jiang C, Wang Y, Fu W, Zhang G, Feng X, Wang X, Wang F, Zhang L, Deng Y. Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis. Front Nutr 2022;9:978110. [PMID: 36590214 DOI: 10.3389/fnut.2022.978110] [Reference Citation Analysis]
|
| 224 |
Zhou Z, Zhou Y, Liu D, Yang Q, Tang M, Liu W. Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma. Front Pharmacol 2022;13:1074123. [PMID: 36588699 DOI: 10.3389/fphar.2022.1074123] [Reference Citation Analysis]
|
| 225 |
Mawatari S, Tamai T, Kumagai K, Saisyoji A, Muromachi K, Toyodome A, Taniyama O, Sakae H, Ijuin S, Tabu K, Oda K, Hiramine Y, Moriuchi A, Sakurai K, Kanmura S, Ido A. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36551623 DOI: 10.3390/cancers14246139] [Reference Citation Analysis]
|
| 226 |
Pang X, Wan W, Wu X, Shen Y. The Novel Action of miR-193b-3p/CDK1 Signaling in HCC Proliferation and Migration: A Study Based on Bioinformatic Analysis and Experimental Investigation. Int J Genomics 2022;2022:8755263. [PMID: 36600989 DOI: 10.1155/2022/8755263] [Reference Citation Analysis]
|
| 227 |
Abd ElAziz ON, Elfiky AM, Yassin MA, Abd El-Hakam FE, Saleh EM, El-Hefnawi M, Mohamed RH. In Silico and In Vivo Evaluation of microRNA-181c-5p's Role in Hepatocellular Carcinoma. Genes (Basel) 2022;13. [PMID: 36553610 DOI: 10.3390/genes13122343] [Reference Citation Analysis]
|
| 228 |
Lu K, Fan Q, Zou X. Antisense oligonucleotide is a promising intervention for liver diseases. Front Pharmacol 2022;13:1061842. [PMID: 36569303 DOI: 10.3389/fphar.2022.1061842] [Reference Citation Analysis]
|
| 229 |
Luo M, Liu X, Yong J, Ou B, Xu X, Zhao X, Liang M, Zhao Z, Ruan J, Luo B. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma based on B-Mode US and CEUS. Eur Radiol 2022. [DOI: 10.1007/s00330-022-09322-0] [Reference Citation Analysis]
|
| 230 |
Giannou AD, Lücke J, Kleinschmidt D, Shiri AM, Steglich B, Nawrocki M, Zhang T, Zazara DE, Kempski J, Zhao L, Giannou O, Agalioti T, Brockmann L, Bertram F, Sabihi M, Böttcher M, Ewald F, Schulze K, von Felden J, Machicote A, Maroulis IC, Arck PC, Graß JK, Mercanoglu B, Reeh M, Wolter S, Tachezy M, Seese H, Theodorakopoulou M, Lykoudis PM, Heumann A, Uzunoglu FG, Ghadban T, Mann O, Izbicki JR, Li J, Duprée A, Melling N, Gagliani N, Huber S. A Critical Role of the IL-22-IL-22 Binding Protein Axis in Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36551508 DOI: 10.3390/cancers14246019] [Reference Citation Analysis]
|
| 231 |
Paslaru L, Bindea G, Nastase A, Sorop A, Zimbru C, Herlea V, Hrehoret D, Brasoveanu V, Zamfir R, Dima S, Popescu I. Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology. Medicina (Kaunas) 2022;58. [PMID: 36557005 DOI: 10.3390/medicina58121803] [Reference Citation Analysis]
|
| 232 |
Lei Wang, Manman Qiu, Lili Wu, Zexing Li, Xinyi Meng, Lu He, Bing Yang. Construction and validation of prognostic signature for hepatocellular carcinoma basing on hepatitis B virus related specific genes. Infect Agent Cancer 2022;17:60. [PMID: 36474267 DOI: 10.1186/s13027-022-00470-y] [Reference Citation Analysis]
|
| 233 |
Zhang S, Xu J, Wang J, Shen B, Jiang J. An Innovative Ferroptosis-related Genes Signature for Prediction of Prognosis and Immune Microenvironment in Patients with Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2315131/v1] [Reference Citation Analysis]
|
| 234 |
Guan J, Pan Y, Li H, Zhu Y, Gao Y, Wang J, Zhou Y, Guan Z, Yang Z. Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma. Mol Pharm 2022;19:4552-64. [PMID: 35508302 DOI: 10.1021/acs.molpharmaceut.2c00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 235 |
Musa AS, Abdul Hadi MFR, Ashour NI, Hashikin NAA. Theranostic Investigation of Gadolinium-159 for Hepatocellular Carcinoma: Monte Carlo Simulation Study. Applied Sciences 2022;12:12396. [DOI: 10.3390/app122312396] [Reference Citation Analysis]
|
| 236 |
Jiayu F, Jiang Y, Zhou X, Zhou M, Pan J, Ke Y, Zhen J, Huang D, Jiang W. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma. Aging (Albany NY) 2022;14:9550-78. [PMID: 36462500 DOI: 10.18632/aging.204312] [Reference Citation Analysis]
|
| 237 |
Peng L, Pan B, Zhang X, Wang Z, Qiu J, Wang X, Tang N. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression. Cell Biol Toxicol 2022;38:1159-73. [PMID: 35438468 DOI: 10.1007/s10565-022-09718-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 238 |
Chi Y, Gong Z, Xin H, Wang Z, Liu Z. microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway. Cell Cycle 2022;21:2651-63. [PMID: 36003063 DOI: 10.1080/15384101.2022.2108275] [Reference Citation Analysis]
|
| 239 |
Fujita N, Kanogawa N, Makishima H, Ogasawara S, Maruta S, Iino Y, Shiko Y, Kanzaki H, Koroki K, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Nakamoto S, Chiba T, Wakatsuki M, Itobayashi E, Obu M, Koma Y, Azemoto R, Kawasaki Y, Kato J, Tsuji H, Kato N. Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma. Hepatol Res 2022;52:1060-71. [PMID: 35951438 DOI: 10.1111/hepr.13827] [Reference Citation Analysis]
|
| 240 |
Dai W, Duan Y, Yuan W, Wang S. circTUBGCP5 promotes liver cancer progression and glycolysis by up-regulating the expression of ACSL4. Appl Biol Chem 2022;65. [DOI: 10.1186/s13765-022-00723-9] [Reference Citation Analysis]
|
| 241 |
Zein N, Elewa YHA, Alruwaili MK, Dewaard M, Alorabi M, Albogami SM, Batiha GE, Zahran MH. Barhi date (Phoenix dactylifera) extract ameliorates hepatocellular carcinoma in male rats. Biomedicine & Pharmacotherapy 2022;156:113976. [DOI: 10.1016/j.biopha.2022.113976] [Reference Citation Analysis]
|
| 242 |
Oda C, Kamimura K, Shibata O, Morita S, Tanaka Y, Setsu T, Abe H, Yokoo T, Sakamaki A, Kamimura H, Kofuji S, Wakai T, Nishina H, Terai S. HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma. Biochemistry and Biophysics Reports 2022;32:101352. [DOI: 10.1016/j.bbrep.2022.101352] [Reference Citation Analysis]
|
| 243 |
Xu X, Chan AKN, Li M, Liu Q, Mattson N, Pangeni Pokharel S, Chang WH, Yuan YC, Wang J, Moore RE, Pirrotte P, Wu J, Su R, Müschen M, Rosen ST, Chen J, Yang L, Chen CW. ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner. Sci Adv 2022;8:eadc8911. [PMID: 36563143 DOI: 10.1126/sciadv.adc8911] [Reference Citation Analysis]
|
| 244 |
Wang H, Mao Y, Zhang C, Hu X, Chen B, Mu L, Wang S, Lin Y, Xiang Z, Huang M. Prediction of effective percutaneous transhepatic biliary drainage in patients with hepatocellular carcinoma: A multi-central retrospective study. Liver Research 2022. [DOI: 10.1016/j.livres.2022.11.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 245 |
Ishtiaq SM, Arshad MI, Khan JA. PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications. Pharmacol Ther 2022;240:108298. [PMID: 36243148 DOI: 10.1016/j.pharmthera.2022.108298] [Reference Citation Analysis]
|
| 246 |
Nicolosi A, Gaia S, Risso A, Rosso C, Rolle E, Abate ML, Olivero A, Armandi A, Ribaldone DG, Carucci P, Fagoonee S, Pellicano R, Saracco GM, Bugianesi E, Caviglia GP. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma. Minerva Gastroenterol (Torino) 2022;68:378-86. [PMID: 36222678 DOI: 10.23736/S2724-5985.21.03006-0] [Reference Citation Analysis]
|
| 247 |
Wong RJ, Jayasekera C, Jones P, Kanwal F, Singal AG, Ahmed A, Taglienti R, Younossi Z, Kulik L, Mehta N. An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma. Gastroenterology Res 2022;15:297-307. [PMID: 36660470 DOI: 10.14740/gr1573] [Reference Citation Analysis]
|
| 248 |
Hong S, Choi WS, Purushothaman B, Koh J, Kim HC, Chung JW, Song JM, Choi JW. Drug delivery in transarterial chemoembolization of hepatocellular carcinoma: Ex vivo evaluation using transparent tissue imaging. Acta Biomater 2022;154:523-35. [PMID: 36374750 DOI: 10.1016/j.actbio.2022.10.044] [Reference Citation Analysis]
|
| 249 |
Yu XC, Liu JB, Tang QH, Diao X, Fan QY, Huang ZY, Tang XM, Li S, Cao YF, Ma YS, Fu D. Recent trends in the incidence and survival of stage I liver cancer: a surveillance, epidemiology, and end results analysis. Ann Med 2022;54:2785-95. [PMID: 36370068 DOI: 10.1080/07853890.2022.2131328] [Reference Citation Analysis]
|
| 250 |
Li X, Sun W, Ding X, Li W, Chen J. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma. Front Immunol 2022;13:1060051. [PMID: 36532029 DOI: 10.3389/fimmu.2022.1060051] [Reference Citation Analysis]
|
| 251 |
Yuan J, Liu Z, Wu Z, Yang J, Yang J. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma. International Immunopharmacology 2022;113:109411. [DOI: 10.1016/j.intimp.2022.109411] [Reference Citation Analysis]
|
| 252 |
Zhong J, Zhang Q, Kuang G, Xia J, Shang L. Multicomponent microspheres with spatiotemporal drug release for post-surgical liver cancer treatment and liver regeneration. Chemical Engineering Journal 2022. [DOI: 10.1016/j.cej.2022.140585] [Reference Citation Analysis]
|
| 253 |
Gan C, Zhou K, Li M, Shang J, Liu L, Zhao Q. NUP153 promotes HCC cells proliferation via c-Myc-mediated downregulation of P15(INK4b). Dig Liver Dis 2022;54:1706-15. [PMID: 35288064 DOI: 10.1016/j.dld.2022.02.008] [Reference Citation Analysis]
|
| 254 |
Li JP, Zhao S, Jiang HJ, Jiang H, Zhang LH, Shi ZX, Fan TT, Wang S. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation. Hepatobiliary Pancreat Dis Int 2022;21:569-76. [PMID: 35729000 DOI: 10.1016/j.hbpd.2022.06.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 255 |
Yue X, Kong Y, Zhang Y, Sun M, Liu S, Wu Z, Gao L, Liang X, Ma C. SREBF2-STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. Cancer Sci 2023;114:477-89. [PMID: 35642354 DOI: 10.1111/cas.15449] [Reference Citation Analysis]
|
| 256 |
Kao WY, Su CW. Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter? Liver Int 2022;42:2597-8. [PMID: 36415175 DOI: 10.1111/liv.15434] [Reference Citation Analysis]
|
| 257 |
Zhu H, Lv S, Yang B, Liu Z, Zhang D. CircGAK inhibits cell growth, migration, invasion, and angiogenesis of hepatocellular carcinoma via miR-1323/HHIP axis. Appl Biol Chem 2022;65. [DOI: 10.1186/s13765-022-00716-8] [Reference Citation Analysis]
|
| 258 |
Kondo T, Fujiwara K, Nakagawa M, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Chiba T, Arai M, Kato J, Kato N. The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma. Sci Rep 2022;12:20726. [PMID: 36456830 DOI: 10.1038/s41598-022-25350-8] [Reference Citation Analysis]
|
| 259 |
Kong X, He Z, Ji Z, Fu T, Yuan X, Zhou H, Shao Z, Zhang W. A Circulating MicroRNA-375 for the Detection of Liver Cancer: A Meta-Analysis. Genet Test Mol Biomarkers 2022;26:564-72. [PMID: 36577123 DOI: 10.1089/gtmb.2022.0128] [Reference Citation Analysis]
|
| 260 |
Kong R, Zhang H, Jia Y, Man Q, Liu S. Integrated analysis revealing the role of TET3-mediated MUC13 promoter hypomethylation in hepatocellular carcinogenesis. Epigenomics 2022;14:1579-91. [PMID: 36916275 DOI: 10.2217/epi-2022-0395] [Reference Citation Analysis]
|
| 261 |
chen Z, Wang W, Tang L, Wei C, Wang B, Xiao H, Tao X, Yang J, Yu T, Guan J, Yuan R, Yu X, Hu Z, Wu H, Wang K. EIF2S3 is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2312592/v1] [Reference Citation Analysis]
|
| 262 |
Wang C, Yao C, Sun Y, Chen J, Ge Y, Wang Y, Wang F, Wang L, Lin Y, Yao S. Identification and verification of a novel epigenetic-related gene signature for predicting the prognosis of hepatocellular carcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.897123] [Reference Citation Analysis]
|
| 263 |
Wang M, Weng S, Li C, Jiang Y, Qian X, Xu P, Ying W. Proteomic overview of hepatocellular carcinoma cell lines and generation of the spectral library. Sci Data 2022;9:732. [PMID: 36446815 DOI: 10.1038/s41597-022-01845-x] [Reference Citation Analysis]
|
| 264 |
Chen H, Shang X, Yuan H, Niu Q, Chen J, Luo S, Li W, Li X. Total flavonoids of Oldenlandia diffusa (Willd.) Roxb. suppresses the growth of hepatocellular carcinoma through endoplasmic reticulum stress-mediated autophagy and apoptosis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019670] [Reference Citation Analysis]
|
| 265 |
Li X, Ding X, Li W, Chen J. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03324-z] [Reference Citation Analysis]
|
| 266 |
Wu YL, Fulgenzi CAM, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ, Ang C. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Cancers (Basel) 2022;14. [PMID: 36497316 DOI: 10.3390/cancers14235834] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 267 |
Ma W, Zhang X, Ma C, Liu P. Highly expressed FAM189B predicts poor prognosis in hepatocellular carcinoma. Pathol Oncol Res 2022;28:1610674. [PMID: 36507118 DOI: 10.3389/pore.2022.1610674] [Reference Citation Analysis]
|
| 268 |
Liu X, Ma H, Wu R, Wang H, Xu H, Li S, Wang G, Lv G, Niu J. Identification of Liver Fibrosis-Related MicroRNAs in Human Primary Hepatic Stellate Cells Using High-Throughput Sequencing. Genes (Basel) 2022;13. [PMID: 36553468 DOI: 10.3390/genes13122201] [Reference Citation Analysis]
|
| 269 |
Sequera C, Grattarola M, Holczbauer A, Dono R, Pizzimenti S, Barrera G, Wangensteen KJ, Maina F. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities. Cell Death Dis 2022;13:994. [PMID: 36433941 DOI: 10.1038/s41419-022-05411-6] [Reference Citation Analysis]
|
| 270 |
López-Cánovas JL, Hermán-Sánchez N, Moreno-Montilla MT, Del Rio-Moreno M, Alors-Perez E, Sánchez-Frias ME, Amado V, Ciria R, Briceño J, de la Mata M, Castaño JP, Rodriguez-Perálvarez M, Luque RM, Gahete MD. Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing. Clin Transl Med 2022;12:e1102. [PMID: 36419260 DOI: 10.1002/ctm2.1102] [Reference Citation Analysis]
|
| 271 |
Wang Q, Qiao W, Zhang H, Liu B, Li J, Zang C, Mei T, Zheng J, Zhang Y. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol 2022;13:1019638. [PMID: 36505501 DOI: 10.3389/fimmu.2022.1019638] [Reference Citation Analysis]
|
| 272 |
Lu T, Han T, Zhao M. miR-3168 promotes hepatocellular carcinoma progression via downregulating p53. Carcinogenesis 2022;43:956-68. [PMID: 35926447 DOI: 10.1093/carcin/bgac062] [Reference Citation Analysis]
|
| 273 |
Wang DD, Zhang JF, Zhang LH, Niu M, Jiang HJ, Jia FC, Feng ST. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00273-9. [PMID: 36456428 DOI: 10.1016/j.hbpd.2022.11.005] [Reference Citation Analysis]
|
| 274 |
Choi JH, Paik WH, Jang DK, Kim MK, Ryu JK, Kim YT, Han K, Lee SH. Acute Pancreatitis Increases the Risk of Gastrointestinal Cancer in Type 2 Diabetic Patients: A Korean Nationwide Cohort Study. Cancers (Basel) 2022;14. [PMID: 36428788 DOI: 10.3390/cancers14225696] [Reference Citation Analysis]
|
| 275 |
Luo F, Yu Y, Li M, Chen Y, Zhang P, Xiao C, Lv G. Polymeric nanomedicines for the treatment of hepatic diseases. J Nanobiotechnol 2022;20:488. [DOI: 10.1186/s12951-022-01708-y] [Reference Citation Analysis]
|
| 276 |
Chen J, Wu Z, He K, Guo L, Rao M, Zhang J, Li H, Su K, Xu K, Gu T, Wang P, Zeng H, Hu L, Han Y. A Potential Predictive Marker for Advanced Hepatocellular Carcinoma PD-1 Inhibitors Combined with Radiation: Expression of PD-L1 on Circulating Tumor Cells.. [DOI: 10.21203/rs.3.rs-2277477/v1] [Reference Citation Analysis]
|
| 277 |
Gazwi HSS, Shoeib NA, Mahmoud ME, Soltan OIA, Hamed MM, Ragab AE. Phytochemical Profile of the Ethanol Extract of Malvaviscus arboreus Red Flower and Investigation of the Antioxidant, Antimicrobial, and Cytotoxic Activities. Antibiotics (Basel) 2022;11. [PMID: 36421296 DOI: 10.3390/antibiotics11111652] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 278 |
Dai X, Sun F, Deng K, Lin G, Yin W, Chen H, Yang D, Liu K, Zhang Y, Huang L. Mallotucin D, a Clerodane Diterpenoid from Croton crassifolius, Suppresses HepG2 Cell Growth via Inducing Autophagic Cell Death and Pyroptosis. Int J Mol Sci 2022;23. [PMID: 36430694 DOI: 10.3390/ijms232214217] [Reference Citation Analysis]
|
| 279 |
Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond) 2023;43:75-86. [PMID: 36397729 DOI: 10.1002/cac2.12393] [Reference Citation Analysis]
|
| 280 |
Li Z, Tan C, Liu X, Feng Z, Li K. Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy. Infect Agents Cancer 2022;17:56. [DOI: 10.1186/s13027-022-00468-6] [Reference Citation Analysis]
|
| 281 |
Qi X, Guo J, Chen G, Fang C, Hu L, Li J, Zhang C. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. J Immunol Res 2022;2022:3393027. [PMID: 36438201 DOI: 10.1155/2022/3393027] [Reference Citation Analysis]
|
| 282 |
Qin Y, Wang S, Chen F, Liu H, Yue K, Wang X, Ning H, Dong P, Yu X, Wang G. Prediction of outcomes by diffusion kurtosis imaging in patients with large (≥5 cm) hepatocellular carcinoma after liver resection: A retrospective study. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.939358] [Reference Citation Analysis]
|
| 283 |
Hess S, Kendall TJ, Pena M, Yamane K, Soong D, Adams L, Truman R, Rambukkana A. In vivo partial reprogramming by bacteria promotes adult liver organ growth without fibrosis and tumorigenesis. Cell Rep Med 2022;3:100820. [PMID: 36384103 DOI: 10.1016/j.xcrm.2022.100820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 284 |
Yoon JS, Lee CW. Protein phosphatases regulate the liver microenvironment in the development of hepatocellular carcinoma. Exp Mol Med 2022;54:1799-813. [PMID: 36380016 DOI: 10.1038/s12276-022-00883-0] [Reference Citation Analysis]
|
| 285 |
Abu-Freha N, Cohen B, Weissmann S, Hizkiya R, Abu-Hammad R, Taha G, Gordon M. Comorbidities and Outcomes among Females with Non-Alcoholic Fatty Liver Disease Compared to Males. Biomedicines 2022;10. [PMID: 36428478 DOI: 10.3390/biomedicines10112908] [Reference Citation Analysis]
|
| 286 |
Ke S, Lu S, Wang C, Xu Y, Bai M, Yu H, Feng Z, Yin B, Li Z, Huang J, Li X, Qian B, Hua Y, Pan S, Wu Y, Ma Y. Comprehensive analysis of the prognostic value and functions of prefoldins in hepatocellular carcinoma. Front Mol Biosci 2022;9. [DOI: 10.3389/fmolb.2022.957001] [Reference Citation Analysis]
|
| 287 |
Si Y, Zhang J, Bao S, Wise SG, Wang Y, Zhang Y, Tang Y. IL-32 and IL-34 in hepatocellular carcinoma. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1051113] [Reference Citation Analysis]
|
| 288 |
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [PMID: 36369487 DOI: 10.1038/s41575-022-00704-9] [Reference Citation Analysis]
|
| 289 |
Wang S, Wang Y, Yu J, Wu H, Zhou Y. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14. [PMID: 36428618 DOI: 10.3390/cancers14225525] [Reference Citation Analysis]
|
| 290 |
Wu Z, Hu H, Zhang Q, Wang T, Li H, Qin Y, Ai X, Yi W, Wei X, Gao W, Ouyang C. Four circadian rhythm-related genes predict incidence and prognosis in hepatocellular carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.937403] [Reference Citation Analysis]
|
| 291 |
Zhang X, Wang C, Zheng D, Liao Y, Wang X, Huang Z, Zhong Q. Radiomics nomogram based on multi-parametric magnetic resonance imaging for predicting early recurrence in small hepatocellular carcinoma after radiofrequency ablation. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1013770] [Reference Citation Analysis]
|
| 292 |
Liu Y, Yang S, Zhou Q, Zhou J, Li J, Ma Y, Hu B, Liu C, Zhao Y. Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy. Nanoscale Adv 2022;4:4847-62. [PMID: 36545394 DOI: 10.1039/d2na00322h] [Reference Citation Analysis]
|
| 293 |
He L, Qiu L, Chen F, Chen T, Peng F, Li Z, Dong X, Cai Z, Fang Y, Chen H, Chen G, Liu X. Dysregulation of global circular RNA abundance regulated by spliceosomes predicts prognosis in hepatocellular carcinoma. Hepatol Commun 2022;6:3578-91. [PMID: 36349484 DOI: 10.1002/hep4.2074] [Reference Citation Analysis]
|
| 294 |
He B, Guo L, Hu Y, Huang H, Wan L, Xu K, Wang F, Wen Z. Desmocollin-2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma via the ERK/c-MYC signaling pathway. Aging 2022. [DOI: 10.18632/aging.204370] [Reference Citation Analysis]
|
| 295 |
Cao L, Zhu L, Cheng L. ncRNA-Regulated LAYN Serves as a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Hepatocellular Carcinoma: A Bioinformatics Analysis. BioMed Research International 2022;2022:1-23. [DOI: 10.1155/2022/5357114] [Reference Citation Analysis]
|
| 296 |
Duan J, Deng M, Xiang Z, Hu J, Qu C, Zhu T, Xu M, Chen J, Xie J, Xie D, Cai M, Li M, Liang H. Impact of WTAP in small HCC and paired adjacent non-neoplastic liver tissue on recurrence: A cohort study with external extension analysis. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.973548] [Reference Citation Analysis]
|
| 297 |
Wang H, Wang Y, Lai S, Zhao L, Liu W, Liu S, Chen H, Wang J, Du G, Tang B. LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2. Cell Death Discov 2022;8:449. [DOI: 10.1038/s41420-022-01234-8] [Reference Citation Analysis]
|
| 298 |
Fang Y, Xu Y, Liao W, Ji T, Yu L, Li L, Pan M, Yang D. Multiomics analyses and machine learning of nuclear receptor coactivator 6 reveal its essential role in hepatocellular carcinoma. Cancer Sci 2023;114:75-90. [PMID: 36086920 DOI: 10.1111/cas.15577] [Reference Citation Analysis]
|
| 299 |
Zheng S, Pan B. Multilevel data integration and molecular docking approach to systematically elucidate the underlying pharmacological mechanisms of Er-Zhi-Wan against hepatocellular carcinoma. Aging 2022. [DOI: 10.18632/aging.204369] [Reference Citation Analysis]
|
| 300 |
Tang Y, Zhang H, Chen L, Zhang T, Xu N, Huang Z. Identification of Hypoxia-Related Prognostic Signature and Competing Endogenous RNA Regulatory Axes in Hepatocellular Carcinoma. IJMS 2022;23:13590. [DOI: 10.3390/ijms232113590] [Reference Citation Analysis]
|
| 301 |
Bai S, Zhao Y, Chen W, Peng W, Wang Y, Xiong S, - A, Li Y, Yang Y, Chen S, Cheng B, Wang R. The stromal-tumor amplifying STC1-Notch1 feedforward signal promotes the stemness of hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2175987/v1] [Reference Citation Analysis]
|
| 302 |
Li Z, Zhou Y, Jia K, Yang Y, Zhang L, Wang S, Dong Y, Wang M, Li Y, Lu S, Zhang W, Zhang L, Fan Y, Zhang D, Li N, Yu Y, Cao X, Hou J. JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis. J Hematol Oncol 2022;15:161. [DOI: 10.1186/s13045-022-01381-6] [Reference Citation Analysis]
|
| 303 |
Zhou J, Zhang Z, Wu B. Correlation between immune-related adverse events and long-terms outcome in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: a retrospective study.. [DOI: 10.21203/rs.3.rs-2222674/v1] [Reference Citation Analysis]
|
| 304 |
Machairas N, Papaconstantinou D, Dorovinis P, Tsilimigras DI, Keramida MD, Kykalos S, Schizas D, Pawlik TM. Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36358817 DOI: 10.3390/cancers14215398] [Reference Citation Analysis]
|
| 305 |
da Silva Freire AK, Furtado de Mendonça Belmont T, Pinto Santiago EJ, Cristina Cordeiro Farias I, Palmeira do Ó K, Soares da Silva A, Richardson Silva Vasconcelos L. Potential role of circulating miR-21 in the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Mol Diagn 2022;22:1037-52. [PMID: 36348568 DOI: 10.1080/14737159.2022.2145189] [Reference Citation Analysis]
|
| 306 |
Matsushima-nishiwaki R, Toyoda H, Atsuyuki M, Kaneoka Y, Kumada T, Kozawa O. Correlation between the complex of small heat shock proteins (HSPBs) and the progression in patients with hepatocellular carcinoma. Archives of Biochemistry and Biophysics 2022. [DOI: 10.1016/j.abb.2022.109461] [Reference Citation Analysis]
|
| 307 |
Fu C, Wei C, Chu C, Lee P, Huo T, Huang Y, Chao Y, Hou M, Wu J, Su C. The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.11.006] [Reference Citation Analysis]
|
| 308 |
Mahmoudi S, Bernatz S, Althoff FC, Koch V, Grünewald LD, Scholtz J, Walter D, Zeuzem S, Wild PJ, Vogl TJ, Kinzler MN. Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma. European Journal of Radiology 2022;156:110556. [DOI: 10.1016/j.ejrad.2022.110556] [Reference Citation Analysis]
|
| 309 |
Chen B, Lei J, Zhao H, Dong J, Zeng Z, Li Y, Yu L, Zhou L, Jia A, Lu Y, Cheng J. Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. JHC 2022;Volume 9:1171-1185. [DOI: 10.2147/jhc.s387254] [Reference Citation Analysis]
|
| 310 |
Prince DS, Schlaphoff G, Davison SA, Huo YR, Xiang H, Chan MV, Lee AU, Thailakanathan C, Jebeili H, Rogan C, Al-Omary A, Gupta S, Lockart I, Tiwari N, Clark-Dickson M, Hillhouse JW, Laube R, Chang J, Nguyen V, Danta M, Cheng R, Strasser SI, Zekry A, Levy MT, Chan C, Liu K. Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study. J Gastroenterol Hepatol 2022;37:2173-81. [PMID: 36031345 DOI: 10.1111/jgh.15986] [Reference Citation Analysis]
|
| 311 |
Huang WY, Liao ZB, Zhang JC, Zhang X, Zhang HW, Liang HF, Zhang ZY, Yang T, Yu J, Dong KS. USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling. Cell Death Dis 2022;13:917. [PMID: 36319631 DOI: 10.1038/s41419-022-05363-x] [Reference Citation Analysis]
|
| 312 |
Zhang C, Dai D, Zhang W, Yang W, Guo Y, Wei Q. Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol 2022;37:2039-50. [PMID: 36066844 DOI: 10.1111/jgh.15999] [Reference Citation Analysis]
|
| 313 |
Hemminki J, Försti A, Hemminki A, Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer 2022;175:77-85. [PMID: 36096040 DOI: 10.1016/j.ejca.2022.08.015] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 314 |
Gofton C, Agar M, George J. Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma. Semin Liver Dis 2022;42:514-30. [PMID: 36193677 DOI: 10.1055/a-1946-5592] [Reference Citation Analysis]
|
| 315 |
Lee TH, Hirshman N, Cardona DM, Berg CL, Fowler KJ, Bashir MR, Ronald J. LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions. Dig Dis Sci 2022;67:5345-52. [PMID: 35257246 DOI: 10.1007/s10620-022-07428-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 316 |
Charonpongsuntorn C, Tanasanvimon S, Korphaisarn K, Payapwattanawong S, Siripoon T, Pakvisal N, Juengsamarn J, Phaibulvatanapong E, Chindaprasirt J, Prasongsook N, Udomdamrongkul K, Ngamphaiboon N, Sirachainan E. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study. JCO Glob Oncol 2022;8:e2200205. [PMID: 36455172 DOI: 10.1200/GO.22.00205] [Reference Citation Analysis]
|
| 317 |
Xia C, Chen W. The NCC mathematical modeling framework for decision-making of six major cancers. Journal of the National Cancer Center 2022. [DOI: 10.1016/j.jncc.2022.11.002] [Reference Citation Analysis]
|
| 318 |
Yang J, Li J, Deng Q, Chen Z, He K, Chen Y, Fu Z. Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short- term clinical outcome of locally advanced gastric cancer.. [DOI: 10.21203/rs.3.rs-2187367/v1] [Reference Citation Analysis]
|
| 319 |
Lin N, Wang L, Huang Q, Zhou W, Liu X, Liu J. A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma. PLoS One 2022;17:e0276627. [PMID: 36315553 DOI: 10.1371/journal.pone.0276627] [Reference Citation Analysis]
|
| 320 |
Wang L, Hu X, Liu X, Feng Y, Zhang Y, Han J, Liu X, Meng F. m7G regulator-mediated methylation modification patterns define immune cell infiltration and patient survival. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1022720] [Reference Citation Analysis]
|
| 321 |
Mokhria RK, Singh J. Role of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma. Artif Intell Gastroenterol 2022; 3(4): 96-104 [DOI: 10.35712/aig.v3.i4.96] [Reference Citation Analysis]
|
| 322 |
Chen Z, Wu H, Jiang S, Liu X, Luo M, Yuan Y. Serum SALL4 as a predictive biomarker for the prognosis of patients with hepatocellular carcinoma who underwent nonsurgical treatment. Medicine (Baltimore) 2022;101:e31200. [PMID: 36316931 DOI: 10.1097/MD.0000000000031200] [Reference Citation Analysis]
|
| 323 |
Li X, Zhang Q, Lu Q, Cheng Z, Liu F, Han Z, Yu X, Yu J, Liang P. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1023983] [Reference Citation Analysis]
|
| 324 |
Bispo IMC, Granger HP, Almeida PP, Nishiyama PB, de Freitas LM. Systems biology and OMIC data integration to understand gastrointestinal cancers. World J Clin Oncol 2022; 13(10): 762-778 [DOI: 10.5306/wjco.v13.i10.762] [Reference Citation Analysis]
|
| 325 |
Yuan LT, Yang YC, Lee HL, Shih PC, Chen LH, Tang CH, Chang LC, Wang HL, Yang SF, Chien MH. Genetic Polymorphisms of lncRNA LINC00673 as Predictors of Hepatocellular Carcinoma Progression in an Elderly Population. Int J Mol Sci 2022;23. [PMID: 36361527 DOI: 10.3390/ijms232112737] [Reference Citation Analysis]
|
| 326 |
Xiudan Han, Wei Long, Ying Liu, Jixiong Xu. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis. Front Surg 2022;9:985034. [PMID: 36338652 DOI: 10.3389/fsurg.2022.985034] [Reference Citation Analysis]
|
| 327 |
Qi Y, Hu J, Liang J, Hu X, Ma N, Xiang B. Clonorchis sinensis infection contributes to hepatocellular carcinoma progression in rat. Parasitol Res 2022. [PMID: 36266591 DOI: 10.1007/s00436-022-07699-x] [Reference Citation Analysis]
|
| 328 |
Yan W, Wang DD, Zhang HD, Huang J, Hou JC, Yang SJ, Zhang J, Lu L, Zhang Q. Expression profile and prognostic values of SMC family members in HCC. Medicine (Baltimore) 2022;101:e31336. [PMID: 36281130 DOI: 10.1097/MD.0000000000031336] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 329 |
Shen Q, He Y, Qian J, Wang X. Identifying tumor immunity-associated molecular features in liver hepatocellular carcinoma by multi-omics analysis. Front Mol Biosci 2022;9:960457. [DOI: 10.3389/fmolb.2022.960457] [Reference Citation Analysis]
|
| 330 |
Wang N, Pei B, Yuan X, Yi C, Wiredu Ocansey DK, Qian H, Mao F. Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers. Front Bioeng Biotechnol 2022;10:1019459. [DOI: 10.3389/fbioe.2022.1019459] [Reference Citation Analysis]
|
| 331 |
Thormann M, Surov A, Pech M, March C, Hass P, Damm R, Omari J. Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging. Acta Radiol 2022;:2841851221129714. [PMID: 36262039 DOI: 10.1177/02841851221129714] [Reference Citation Analysis]
|
| 332 |
Tang B, wang H, Wang Y, Lai S, Zhao L, Liu W, Liu S, Chen H, Wang J, Du G. LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2.. [DOI: 10.21203/rs.3.rs-2051343/v1] [Reference Citation Analysis]
|
| 333 |
Fan FS. Coffee reduces the risk of hepatocellular carcinoma probably through inhibition of NLRP3 inflammasome activation by caffeine. Front Oncol 2022;12:1029491. [DOI: 10.3389/fonc.2022.1029491] [Reference Citation Analysis]
|
| 334 |
Giuffrè M, Zuliani E, Visintin A, Tarchi P, Martingano P, Pizzolato R, Bonazza D, Masutti F, Moretti R, Crocè LS; Liver Multidisciplinary Group of Trieste. Predictors of Hepatocellular Carcinoma Early Recurrence in Patients Treated with Surgical Resection or Ablation Treatment: A Single-Center Experience. Diagnostics (Basel) 2022;12. [PMID: 36292205 DOI: 10.3390/diagnostics12102517] [Reference Citation Analysis]
|
| 335 |
Rusu I, Pirlog R, Chiroi P, Nutu A, Puia VR, Fetti AC, Rusu DR, Berindan-Neagoe I, Al Hajjar N. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC. Int J Mol Sci 2022;23:12370. [PMID: 36293225 DOI: 10.3390/ijms232012370] [Reference Citation Analysis]
|
| 336 |
Fang X, Yan Q, Liu S, Guan XY. Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation. Int J Mol Sci 2022;23:12327. [PMID: 36293184 DOI: 10.3390/ijms232012327] [Reference Citation Analysis]
|
| 337 |
Yu Y, Lu X, Yan Y, Wang Y, Meng J, Tian S, Mu J, Zheng D. The lncRNA KIF9-AS1 Accelerates Hepatocellular Carcinoma Growth by Recruiting DNMT1 to Promote RAI2 DNA Methylation. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/3888798] [Reference Citation Analysis]
|
| 338 |
Wang S, Chen L, Liu W. Matrix stiffness-dependent STEAP3 coordinated with PD-L2 identify tumor responding to sorafenib treatment in hepatocellular carcinoma. Cancer Cell Int 2022;22:318. [PMID: 36229881 DOI: 10.1186/s12935-022-02634-7] [Reference Citation Analysis]
|
| 339 |
Gao C, Zhou G, Cheng M, Feng L, Cao P, Zhou G. Identification of senescence-associated long non-coding RNAs to predict prognosis and immune microenvironment in patients with hepatocellular carcinoma. Front Genet 2022;13:956094. [DOI: 10.3389/fgene.2022.956094] [Reference Citation Analysis]
|
| 340 |
Liu C, Wu Z, Wang L, Yang Q, Huang J, Huang J. A Mitophagy-Related Gene Signature for Subtype Identification and Prognosis Prediction of Hepatocellular Carcinoma. IJMS 2022;23:12123. [DOI: 10.3390/ijms232012123] [Reference Citation Analysis]
|
| 341 |
Wang M, Ma X, Wang G, Song Y, Zhang M, Mai Z, Zhou B, Ye Y, Xia W. Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery. Cell Mol Biol Lett 2022;27:92. [PMID: 36224534 DOI: 10.1186/s11658-022-00394-w] [Reference Citation Analysis]
|
| 342 |
Mo Z, Liu D, Chen Y, Luo J, Li W, Liu J, Yu L, Huang B, Zhang S. Single-cell transcriptomics reveals the role of Macrophage-Naïve CD4 + T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. J Transl Med 2022;20:466. [PMID: 36221095 DOI: 10.1186/s12967-022-03675-2] [Reference Citation Analysis]
|
| 343 |
Armakolas A, Dimopoulou V, Nezos A, Stamatakis G, Samiotaki M, Panayotou G, Tampaki M, Stathaki M, Dourakis S, Koskinas J. Cellular, Molecular and Proteomic Characteristics of Early Hepatocellular Carcinoma. Curr Issues Mol Biol 2022;44:4714-34. [PMID: 36286037 DOI: 10.3390/cimb44100322] [Reference Citation Analysis]
|
| 344 |
Huang D, Huang D. Relationship between M6A methylation regulator and prognosis in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Heliyon 2022;8:e10931. [PMID: 36262291 DOI: 10.1016/j.heliyon.2022.e10931] [Reference Citation Analysis]
|
| 345 |
Wang Q, Feng J, Tang L. Non-Coding RNA Related to MAPK Signaling Pathway in Liver Cancer. IJMS 2022;23:11908. [DOI: 10.3390/ijms231911908] [Reference Citation Analysis]
|
| 346 |
Yu X, Chen P, Yi W, Ruan W, Xiong X. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma. Front Immunol 2022;13:1029872. [DOI: 10.3389/fimmu.2022.1029872] [Reference Citation Analysis]
|
| 347 |
Liu J, Liu T, Zhang C, He J, Zhou D, Wang Z, Wang R. EIF2S2 is a novel independent prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Front Genet 2022;13:992343. [DOI: 10.3389/fgene.2022.992343] [Reference Citation Analysis]
|
| 348 |
Cong T, Luo Y, Liu Y, Yang C, Yang H, Li Y, Li J, Li X. Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. Front Genet 2022;13:1000997. [DOI: 10.3389/fgene.2022.1000997] [Reference Citation Analysis]
|
| 349 |
Wu G, Yang Y, Ye R, Yue H, Zhang H, Huang T, Liu M, Zheng Y, Wang Y, Zhou Y, Guo Q. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma. BMC Cancer 2022;22:1036. [PMID: 36195857 DOI: 10.1186/s12885-022-10049-w] [Reference Citation Analysis]
|
| 350 |
Chang Z, Zhang Q, Hu Q, Liu Y, Zhang L, Liu R. Tannins in Terminalia bellirica inhibits hepatocellular carcinoma growth via re-educating tumor-associated macrophages and restoring CD8+T cell function. Biomedicine & Pharmacotherapy 2022;154:113543. [DOI: 10.1016/j.biopha.2022.113543] [Reference Citation Analysis]
|
| 351 |
He Y, Luo J, Zhang G, Jin Y, Wang N, Lu J, Li C, Guo X, Qin N, Dai J, Chen Y. Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma. Hepatology 2022;76:1013-29. [PMID: 35243668 DOI: 10.1002/hep.32444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 352 |
Lee HW, Kim E, Cho KJ, Park HJ, Seo J, Lee H, Baek E, Choi JR, Han KH, Lee ST, Park JY. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma. Liver Int 2022;42:2317-26. [PMID: 35776657 DOI: 10.1111/liv.15356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 353 |
Chen Z, Qiu Z, Wang G, Wang G, Jiang W, Gao F. Safety and effectiveness of transjugular intrahepatic portosystemic shunt in hepatocellular carcinoma patients with portal hypertension: a systematic review and meta-analysis. Clinical Radiology 2022. [DOI: 10.1016/j.crad.2022.09.126] [Reference Citation Analysis]
|
| 354 |
Park MK, Lee YB, Moon H, Choi NR, Kim MA, Jang H, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation. Dig Dis Sci 2022;67:4939-49. [PMID: 35048224 DOI: 10.1007/s10620-021-07365-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 355 |
Zhu Y, Qin LX. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2022;21:420-9. [PMID: 35977874 DOI: 10.1016/j.hbpd.2022.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 356 |
Sohn W, Kang D, Kang M, Guallar E, Cho J, Paik YH. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. Clin Mol Hepatol 2022;28:851-63. [PMID: 36263667 DOI: 10.3350/cmh.2022.0037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 357 |
Tian D, Yu Y, Zhang L, Sun J, Jiang W. 23-hydroxybetulinic acid reduces tumorigenesis, metastasis and immunosuppression in a mouse model of hepatocellular carcinoma via disruption of the MAPK signaling pathway. Anticancer Drugs 2022;33:815-25. [PMID: 36136986 DOI: 10.1097/CAD.0000000000001325] [Reference Citation Analysis]
|
| 358 |
Filliol A, Saito Y, Nair A, Dapito DH, Yu LX, Ravichandra A, Bhattacharjee S, Affo S, Fujiwara N, Su H, Sun Q, Savage TM, Wilson-Kanamori JR, Caviglia JM, Chin L, Chen D, Wang X, Caruso S, Kang JK, Amin AD, Wallace S, Dobie R, Yin D, Rodriguez-Fiallos OM, Yin C, Mehal A, Izar B, Friedman RA, Wells RG, Pajvani UB, Hoshida Y, Remotti HE, Arpaia N, Zucman-Rossi J, Karin M, Henderson NC, Tabas I, Schwabe RF. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature 2022;610:356-65. [PMID: 36198802 DOI: 10.1038/s41586-022-05289-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 359 |
Akutsu N, Kawakami Y, Numata Y, Hirano T, Wagatsuma K, Ishigami K, Sasaki S, Nakase H. A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases. Clin J Gastroenterol 2022;15:960-967. [DOI: 10.1007/s12328-022-01669-7] [Reference Citation Analysis]
|
| 360 |
Hu X, Pan H, Zhou S, Pang Q, Wang Y, Zhu C, Liu H, Jin H, Xu A. HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression. Biochemical and Biophysical Research Communications 2022;623:111-9. [DOI: 10.1016/j.bbrc.2022.07.047] [Reference Citation Analysis]
|
| 361 |
Wei H, Yang T, Chen J, Duan T, Jiang H, Song B. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions. Liver Int 2022;42:2131-44. [PMID: 35808845 DOI: 10.1111/liv.15362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 362 |
Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022;21:450-4. [PMID: 36100543 DOI: 10.1016/j.hbpd.2022.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 363 |
Zhang K, Li WC, Xie SS, Lin LY, Shen ZW, Ye ZX, Shen W. Preoperative determination of pathological grades of primary single HCC: development and validation of a scoring model. Abdom Radiol (NY) 2022;47:3468-77. [PMID: 35842888 DOI: 10.1007/s00261-022-03606-1] [Reference Citation Analysis]
|
| 364 |
Xiong Y, Cao P, Lei X, Tang W, Ding C, Qi S, Chen G. Accurate prediction of microvascular invasion occurrence and effective prognostic estimation for patients with hepatocellular carcinoma after radical surgical treatment. World J Surg Oncol 2022;20:328. [PMID: 36180867 DOI: 10.1186/s12957-022-02792-y] [Reference Citation Analysis]
|
| 365 |
Chang SH, Kim TS, Jeon YH, Jung NH, Choi DH. Novel management of expected post-radiotherapy complications in hepatocellular carcinoma patients: a case report. J Liver Cancer 2022;22:183-187. [DOI: 10.17998/jlc.2022.08.03] [Reference Citation Analysis]
|
| 366 |
Xia W, Zhao X, Guo Y, Cao G, Wu G, Fan W, Yao Q, Xu S, Guo C, Hu H, Li H. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study. Front Oncol 2022;12:961394. [DOI: 10.3389/fonc.2022.961394] [Reference Citation Analysis]
|
| 367 |
Hu R, Liang X, Li Q, Liu Y, Shi Z. Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/4869732] [Reference Citation Analysis]
|
| 368 |
Hu X, Zhu H, Feng S, Wang C, Ye Y, Xiong X. Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma. Front Genet 2022;13:1006357. [PMID: 36246598 DOI: 10.3389/fgene.2022.1006357] [Reference Citation Analysis]
|
| 369 |
Gao Q, Fan L, Chen Y, Cai J. Identification of the hub and prognostic genes in liver hepatocellular carcinoma via bioinformatics analysis. Front Mol Biosci 2022;9:1000847. [DOI: 10.3389/fmolb.2022.1000847] [Reference Citation Analysis]
|
| 370 |
Xu M, Yang L, Lin Y, Lu Y, Bi X, Jiang T, Deng W, Zhang L, Yi W, Xie Y, Li M. Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma. J Nanobiotechnology 2022;20:427. [PMID: 36175957 DOI: 10.1186/s12951-022-01615-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 371 |
Eshkiki ZS, Agah S, Tabaeian SP, Sedaghat M, Dana F, Talebi A, Akbari A. Neoantigens and their clinical applications in human gastrointestinal cancers. World J Surg Oncol 2022;20:321. [PMID: 36171610 DOI: 10.1186/s12957-022-02776-y] [Reference Citation Analysis]
|
| 372 |
Li W, Shen H, Han L, Liu J, Xiao B, Li X, Ye Z, Kolla J. A Multiparametric Fusion Radiomics Signature Based on Contrast-Enhanced MRI for Predicting Early Recurrence of Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/3704987] [Reference Citation Analysis]
|
| 373 |
Lin Y, He Z, Gao X, Lu L, Lu C, Huang J, Luo M, Ye J, Liang R, Yuan Q. Integrative Analysis Reveals the Potential Role and Prognostic Value of GOLM1 in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-24. [DOI: 10.1155/2022/8284500] [Reference Citation Analysis]
|
| 374 |
Yoon JH, Choi SK, Cho SB, Kim HJ, Ko YS, Jun CH. Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study. World J Gastroenterol 2022; 28(36): 5351-5363 [DOI: 10.3748/wjg.v28.i36.5351] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 375 |
Chen M, Wu G, Xie Z, Shi D, Luo M. A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening. Front Genet 2022;13:942166. [DOI: 10.3389/fgene.2022.942166] [Reference Citation Analysis]
|
| 376 |
Xiaochun H, Feixiong P, Shengsong O, Xiaojiao W, Yuju X, Yanhua L, Schmalz G. Identification and Validation of an Inflammatory Response-Related Polygenic Risk Score as a Prognostic Marker in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/1739995] [Reference Citation Analysis]
|
| 377 |
Chen G, Liu Z. Inferring causal gene regulatory network via GreyNet: From dynamic grey association to causation. Front Bioeng Biotechnol 2022;10:954610. [DOI: 10.3389/fbioe.2022.954610] [Reference Citation Analysis]
|
| 378 |
Kuang Y, Shen W, Zhu H, Huang H, Zhou Q, Yin W, Zhou Y, Cao Y, Wang L, Li X, Ren C, Jiang X. The role of lncRNA just proximal to XIST (JPX) in human disease phenotypes and RNA methylation: The novel biomarker and therapeutic target potential. Biomed Pharmacother 2022;155:113753. [PMID: 36179492 DOI: 10.1016/j.biopha.2022.113753] [Reference Citation Analysis]
|
| 379 |
Cheng X, Li J, Feng L, Feng S, Wu X, Li Y. The role of hypoxia-related genes in TACE-refractory hepatocellular carcinoma: Exploration of prognosis, immunological characteristics and drug resistance based on onco-multi-OMICS approach. Front Pharmacol 2022;13:1011033. [DOI: 10.3389/fphar.2022.1011033] [Reference Citation Analysis]
|
| 380 |
Seo EB, Jang HJ, Kwon SH, Kwon YJ, Kim SK, Lee SH, Jeong AJ, Shin HM, Kim YN, Ma S, Kim H, Lee YH, Suh PG, Ye SK. Loss of phospholipase Cγ1 suppresses hepatocellular carcinogenesis through blockade of STAT3-mediated cancer development. Hepatol Commun 2022;6:3234-46. [PMID: 36153805 DOI: 10.1002/hep4.2077] [Reference Citation Analysis]
|
| 381 |
Cerrito L, Ainora ME, Mosoni C, Borriello R, Gasbarrini A, Zocco MA. Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. Cancers 2022;14:4647. [DOI: 10.3390/cancers14194647] [Reference Citation Analysis]
|
| 382 |
Wang Z, Zhang Y, Zhang Q, Ao Q, Luo C, Wang B, Bai C, Ge X, Wang Y, Wang J, Qian Y, Yu H, Gu X, Kolla J. On the Core Prescriptions and Their Mechanisms of Traditional Chinese Medicine in Hepatitis B, Liver Cirrhosis, and Liver Cancer Treatment. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/5300523] [Reference Citation Analysis]
|
| 383 |
Xie D, Qian B, Li X. Nucleic acids and proteins carried by exosomes from various sources: Potential role in liver diseases. Front Physiol 2022;13:957036. [DOI: 10.3389/fphys.2022.957036] [Reference Citation Analysis]
|
| 384 |
Wu J, Wu J, Li Y, Qiu F, Zhou S, Yin Z, Chen Y, Li B, Zhou J, Yan M. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study. Front Oncol 2022;12:985380. [DOI: 10.3389/fonc.2022.985380] [Reference Citation Analysis]
|
| 385 |
Cheng R, Xu X. Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis. J Hepatocell Carcinoma 2022;9:987-97. [PMID: 36117526 DOI: 10.2147/JHC.S377435] [Reference Citation Analysis]
|
| 386 |
Xia W, Xu S, Guo Y, Zhao X, Hu H, Zhao Y, Yao Q, Zheng L, Zhang D, Guo C, Fan W, Li H. Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma. Front Oncol 2022;12:1014653. [DOI: 10.3389/fonc.2022.1014653] [Reference Citation Analysis]
|
| 387 |
Huang Y, Wang T, Chen M, Lin C, Chang C, Tai H, Hsu S, Chen Y. Radiomics-based nomogram as predictive model for prognosis of hepatocellular carcinoma with portal vein tumor thrombosis receiving radiotherapy. Front Oncol 2022;12:906498. [DOI: 10.3389/fonc.2022.906498] [Reference Citation Analysis]
|
| 388 |
Zhang W, Wan Y, Zhang Y, Liu Q, Zhu X. CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma. Cancer Manag Res 2022;14:2691-709. [PMID: 36117731 DOI: 10.2147/CMAR.S359545] [Reference Citation Analysis]
|
| 389 |
Dai XM, Xiang ZQ, Wang Q, Li HJ, Zhu Z. Oncological outcomes of anatomic versus non-anatomic resections for small hepatocellular carcinoma: systematic review and meta-analysis of propensity-score matched studies. World J Surg Oncol 2022;20:299. [PMID: 36117165 DOI: 10.1186/s12957-022-02770-4] [Reference Citation Analysis]
|
| 390 |
Han P, Lei Y, Liu J, Liu J, Huang H, Tian D, Yan W. Cell adhesion molecule BVES functions as a suppressor of tumor cells extrusion in hepatocellular carcinoma metastasis. Cell Commun Signal 2022;20:149. [PMID: 36123685 DOI: 10.1186/s12964-022-00962-9] [Reference Citation Analysis]
|
| 391 |
Zhang B, Yue J, Shi X, Cui K, Li L, Zhang C, Sun P, Zhong J, Li Z, Zhao L. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma. BMJ Open 2022;12:e060955. [PMID: 36115673 DOI: 10.1136/bmjopen-2022-060955] [Reference Citation Analysis]
|
| 392 |
Li Y, Yan L, Jiang L, Xu Q, Wang B, Sun Y. Predicting Prognosis of Hepatocellular Carcinoma Patients Based on the Expression Signatures of Mitophagy Genes. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/4835826] [Reference Citation Analysis]
|
| 393 |
Cheng W, Gao A, Lin H, Zhang W. Novel roles of METTL1/WDR4 in tumor via m7G methylation. Mol Ther Oncolytics 2022;26:27-34. [PMID: 35784404 DOI: 10.1016/j.omto.2022.05.009] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 394 |
Wei X, Yao J, Shen W, Xie Q, Li Y, Ge L, Zeng X, Tang X. Capillarisenol C, a novel bisphenol from Artemisia capillaris, induces autophagic death in hepatocellular carcinoma through endoplasmic reticulum stress.. [DOI: 10.21203/rs.3.rs-2043984/v1] [Reference Citation Analysis]
|
| 395 |
Wang Q, Tan Y, Yang H, Zhang J, Lei X, Liu M, He L. Using radiomics to predict microvascular invasion in hepatocellular carcinoma based on multi-sequence gadoxetate disodium–enhanced MRI combined with clinical parameters.. [DOI: 10.21203/rs.3.rs-2055181/v1] [Reference Citation Analysis]
|
| 396 |
Hao F, Li H, Li N, Li J, Wu H. Laparoscopic repeat hepatectomy versus conventional open repeat hepatectomy for recurrent hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:960204. [DOI: 10.3389/fonc.2022.960204] [Reference Citation Analysis]
|
| 397 |
Wang G, Chen Z. HBV Genomic Integration and Hepatocellular Carcinoma. Advanced Gut & Microbiome Research 2022;2022:1-7. [DOI: 10.1155/2022/2140886] [Reference Citation Analysis]
|
| 398 |
Huang A, Du J, Liu Z, Zhang G, Abuduwaili W, Yan J, Sun J, Xu R, Liu T, Shen X, Dong L, Zhu J, Li Y. Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma. Nanomaterials 2022;12:3191. [DOI: 10.3390/nano12183191] [Reference Citation Analysis]
|
| 399 |
Sposito C, Citterio D, Virdis M, Battiston C, Droz Dit Busset M, Flores M, Mazzaferro V. Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World J Gastroenterol 2022; 28(34): 4929-4942 [DOI: 10.3748/wjg.v28.i34.4929] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 400 |
Lu K, Pan Y, Huang Z, Liang H, Ding ZY, Zhang B. TRIM proteins in hepatocellular carcinoma. J Biomed Sci 2022;29:69. [PMID: 36100865 DOI: 10.1186/s12929-022-00854-7] [Reference Citation Analysis]
|
| 401 |
Zheng Z, Guan R, Zou Y, Jian Z, Lin Y, Guo R, Jin H. Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma-A Multicentre Experience. J Inflamm Res 2022;15:5089-102. [PMID: 36091335 DOI: 10.2147/JIR.S378099] [Reference Citation Analysis]
|
| 402 |
Orimo T, Kamiyama T, Kakisaka T, Nagatsu A, Asahi Y, Aiyama T, Kamachi H, Taketomi A. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas. Ann Surg Oncol. [DOI: 10.1245/s10434-022-12495-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 403 |
Huang S, Wu H, Luo F, Zhang B, Li T, Yang Z, Ren B, Yin W, Wu D, Tai S. Exploring the role of mast cells in the progression of liver disease. Front Physiol 2022;13:964887. [DOI: 10.3389/fphys.2022.964887] [Reference Citation Analysis]
|
| 404 |
Wang H, Shi F, Zheng S, Zhao M, Pan Z, Xiong L, Zheng L. Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Front Oncol 2022;12:896662. [DOI: 10.3389/fonc.2022.896662] [Reference Citation Analysis]
|
| 405 |
Kim M, Hui KM, Shi M, Reau N, Aloman C. Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma. Hepatol Commun 2022;6:3247-59. [PMID: 36097402 DOI: 10.1002/hep4.2079] [Reference Citation Analysis]
|
| 406 |
Xu J, Wu X, Wang X. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma. Biochem Genet. [DOI: 10.1007/s10528-022-10279-4] [Reference Citation Analysis]
|
| 407 |
Epremyan KK, Goleva TN, Rogov AG, Lavrushkina SV, Zinovkin RA, Zvyagilskaya RA. The First Yarrowia lipolytica Yeast Models Expressing Hepatitis B Virus X Protein: Changes in Mitochondrial Morphology and Functions. Microorganisms 2022;10:1817. [PMID: 36144419 DOI: 10.3390/microorganisms10091817] [Reference Citation Analysis]
|
| 408 |
Liu P, Zhu Z, Ma J, Wei L, Han Y, Shen E, Tan X, Chen Y, Cai C, Guo C, Peng Y, Gao Y, Liu Y, Huang Q, Gao L, Li Y, Jiang Z, Wu W, Liu Y, Zeng S, Li W, Feng Z, Shen H. Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma. Front Immunol 2022;13:951529. [DOI: 10.3389/fimmu.2022.951529] [Reference Citation Analysis]
|
| 409 |
Oranratnachai S, Rattanasiri S, Sirachainan E, Tansawet A, Raunroadroong N, McKay GJ, Attia J, Thakkinstian A. Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors. Cancer Med 2023;12:3046-53. [PMID: 36082831 DOI: 10.1002/cam4.5224] [Reference Citation Analysis]
|
| 410 |
Tu B, Duan S, Wu M, Wei B, Huang P. Prognostic model for older patients with hepatocellular carcinoma after surgery: a SEER population-based analysis.. [DOI: 10.21203/rs.3.rs-2031871/v1] [Reference Citation Analysis]
|
| 411 |
Wei H, Li W, Yang M, Fang Q, Nian J, Huang Y, Wei Q, Huang Z, Liu G, Xu Z, Hu A, Pu J. ZNNT1/osteopontin/S100A9 feedback loop promote hepatocellular carcinoma progression via mediating crosstalk between hepatocellular carcinoma cells and macrophages.. [DOI: 10.21203/rs.3.rs-2034019/v1] [Reference Citation Analysis]
|
| 412 |
zeng X, Liu C, He Q, Zou Z, Liao Q, Wu C, Li G, Zhang Z, Tian Y, Zhu S, Yang X, Cui S, Zeng L. A novel lncRNA BF368575 promotes cell proliferation in hepatocellular carcinoma via PI3K/AKT/mTOR signaling pathway.. [DOI: 10.21203/rs.3.rs-2027515/v1] [Reference Citation Analysis]
|
| 413 |
Gu E, Liu Y, Pan L, Hu Y, Ye X, Luo P. A high throughput method for Monitoring of Sorafenib, regorafenib, cabozantinib and their metabolites with UPLC-MS/MS in rat plasma. Front Pharmacol 2022;13:955263. [DOI: 10.3389/fphar.2022.955263] [Reference Citation Analysis]
|
| 414 |
Tuszynski JA, Costa F. Low-energy amplitude-modulated radiofrequency electromagnetic fields as a systemic treatment for cancer: Review and proposed mechanisms of action. Front Med Technol 2022;4. [DOI: 10.3389/fmedt.2022.869155] [Reference Citation Analysis]
|
| 415 |
Kahraman DC, Bilget Guven E, Aytac PS, Aykut G, Tozkoparan B, Cetin Atalay R. A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation. Sci Rep 2022;12:15139. [PMID: 36071119 DOI: 10.1038/s41598-022-17444-0] [Reference Citation Analysis]
|
| 416 |
Chen P, Qi D, Sun K, Song S, Li T. Identification of novel enhancer RNA biomarkers and corresponding prognostic signatures of hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-1703926/v2] [Reference Citation Analysis]
|
| 417 |
Wang J, Miao Y, Li L, Wu Y, Ren Y, Cui Y, Cao H. Multi-omics data integration for hepatocellular carcinoma subtyping with multi-kernel learning. Front Genet 2022;13:962870. [DOI: 10.3389/fgene.2022.962870] [Reference Citation Analysis]
|
| 418 |
Chen W, Yang Z, Chen Y, Trivanovic D. A Novel Oxidative Phosphorylation-Associated Gene Signature for Prognosis Prediction in Patients with Hepatocellular Carcinoma. Disease Markers 2022;2022:1-20. [DOI: 10.1155/2022/3594901] [Reference Citation Analysis]
|
| 419 |
Liu C, Chen K, Zhao F, Xuan L, Wang Y, Xu C, Wu Z, Wang D, Qu C. Occult infection with hepatitis B virus PreS variants synergistically promotes hepatocellular carcinoma development in a high-fat diet context by generating abnormal ceramides. BMC Med 2022;20:279. [PMID: 36058909 DOI: 10.1186/s12916-022-02481-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 420 |
Fu X, Yang Y, Zhang X. A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma. Front Genet 2022;13:919599. [DOI: 10.3389/fgene.2022.919599] [Reference Citation Analysis]
|
| 421 |
Mossenta M, Busato D, Dal Bo M, Macor P, Toffoli G. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Int J Mol Sci 2022;23:10038. [PMID: 36077433 DOI: 10.3390/ijms231710038] [Reference Citation Analysis]
|
| 422 |
Hashimoto R, Himoto T, Yamada M, Mimura S, Fujita K, Tani J, Morishita A, Masaki T. Antitumor Effect of Zinc Acetate in Hepatocellular Carcinoma Cell Lines via the Induction of Apoptosis. J Nutr Sci Vitaminol (Tokyo) 2022;68:303-11. [PMID: 36047102 DOI: 10.3177/jnsv.68.303] [Reference Citation Analysis]
|
| 423 |
Zhang L, Qi Q, Li Q, Ren S, Liu S, Mao B, Li X, Wu Y, Yang L, Liu L, Li Y, Duan S, Zhang L. Ultrasomics prediction for cytokeratin 19 expression in hepatocellular carcinoma: A multicenter study. Front Oncol 2022;12:994456. [DOI: 10.3389/fonc.2022.994456] [Reference Citation Analysis]
|
| 424 |
Lu F, Zhao X, Zhang Z, Xiong M, Wang Y, Sun Y, He B, Zhu J. The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis. Front Genet 2022;13:927079. [DOI: 10.3389/fgene.2022.927079] [Reference Citation Analysis]
|
| 425 |
Du J, Qian M, Yuan T, Zhang B, Chen X, An N, He Q, Yang B, Ye S, Zhu H. Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression. Acta Pharm 2022;72:427-36. [PMID: 36651547 DOI: 10.2478/acph-2022-0029] [Reference Citation Analysis]
|
| 426 |
Tabrizian P, Holzner ML, Mehta N, Halazun K, Agopian VG, Yao F, Busuttil RW, Roberts J, Emond JC, Samstein B, Brown RS Jr, Najjar M, Chapman WC, Doyle MM, Florman SS, Schwartz ME, Llovet JM. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma. JAMA Surg 2022;157:779-88. [PMID: 35857294 DOI: 10.1001/jamasurg.2022.2800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 427 |
Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
|
| 428 |
Xia H, Huang Z, Xu Y, Yam JWP, Cui Y. Reprogramming of central carbon metabolism in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2022;153:113485. [DOI: 10.1016/j.biopha.2022.113485] [Reference Citation Analysis]
|
| 429 |
Hemminki K, Försti A, Hemminki O, Liska V, Hemminki A. Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100602] [Reference Citation Analysis]
|
| 430 |
Havas A, Yin S, Adams PD. The role of aging in cancer. Mol Oncol 2022;16:3213-9. [PMID: 36128609 DOI: 10.1002/1878-0261.13302] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 431 |
Moon AM, Ioannou GN. Moving Away From a One-Size-Fits-All Approach to Hepatocellular Carcinoma Surveillance. Am J Gastroenterol 2022;117:1409-11. [PMID: 35973179 DOI: 10.14309/ajg.0000000000001897] [Reference Citation Analysis]
|
| 432 |
Yang J, Ye J, Ma T, Tang F, Huang L, Liu Z, Tian S, Cheng X, Zhang L, Guo Z, Tu F, He M, Xu X, Lu X, Wu Y, Zeng X, Zou J, Wang X, Peng W, Zhang P. Tripartite motif-containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome-mediated degradation of pleckstrin homology domain leucine-rich repeats protein phosphatase 1. Hepatology 2022;76:612-29. [PMID: 34767673 DOI: 10.1002/hep.32234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 433 |
Wilson A, Lim A. Microvascular imaging: new Doppler technology for assessing focal liver lesions. Is it useful? Clinical Radiology 2022. [DOI: 10.1016/j.crad.2022.05.032] [Reference Citation Analysis]
|
| 434 |
Zhang JX, Chen YX, Zhou CG, Liu J, Liu S, Shi HB, Zu QQ. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study. Hepatol Res 2022;52:794-803. [PMID: 35698267 DOI: 10.1111/hepr.13801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 435 |
Ren G, Guo J, Feng C, Ding Y, Dong B, Han Y, Li Y, Wang L, Jiang J. Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model. Molecular Therapy - Oncolytics 2022;26:372-86. [DOI: 10.1016/j.omto.2022.08.001] [Reference Citation Analysis]
|
| 436 |
Xie Y, Yan F, Wang X, Yu L, Yan H, Pu Q, Li W, Yang Z. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma. Cancer Med 2023;12:3237-59. [PMID: 36043445 DOI: 10.1002/cam4.5064] [Reference Citation Analysis]
|
| 437 |
Caligiuri A, Gitto S, Lori G, Marra F, Parola M, Cannito S, Gentilini A. Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer. Cancers 2022;14:4211. [DOI: 10.3390/cancers14174211] [Reference Citation Analysis]
|
| 438 |
Xiao M, Wang D, Lin GL, Lin X, Tao LY, Li QY. Safely Modified Laparoscopic Liver Resection for Segment VI and/or VII Hepatic Lesions Using the Left Lateral Decubitus Position. Int J Gen Med 2022;15:6691-9. [PMID: 36034184 DOI: 10.2147/IJGM.S376919] [Reference Citation Analysis]
|
| 439 |
Chen L, Zhang D, Zheng S, Li X, Gao P. Stemness analysis in hepatocellular carcinoma identifies an extracellular matrix gene–related signature associated with prognosis and therapy response. Front Genet 2022;13:959834. [DOI: 10.3389/fgene.2022.959834] [Reference Citation Analysis]
|
| 440 |
Che Y, Wang G, Xia Q. CDK2AP1 influences immune infiltrates and serves as a prognostic indicator for hepatocellular carcinoma. Front Genet 2022;13:937310. [DOI: 10.3389/fgene.2022.937310] [Reference Citation Analysis]
|
| 441 |
Tao Q, Zhu K, Zhan Y, Zhang R, Lang Z, Yu Z, Wang M. Construction of a novel exosomes-related gene signature in hepatocellular carcinoma. Front Cell Dev Biol 2022;10:997734. [DOI: 10.3389/fcell.2022.997734] [Reference Citation Analysis]
|
| 442 |
Liava C, Sinakos E, Papadopoulou E, Giannakopoulou L, Potsi S, Moumtzouoglou A, Chatziioannou A, Stergioulas L, Kalogeropoulou L, Dedes I, Akriviadis E, Chourmouzi D. Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview. World J Gastroenterol 2022; 28(32): 4540-4556 [DOI: 10.3748/wjg.v28.i32.4540] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 443 |
Liu YY, Lin CL, Weng CH, Chang PH, Chien CH, Huang KC, Hua MC, Hu CC. Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy. Diagnostics (Basel) 2022;12. [PMID: 36140487 DOI: 10.3390/diagnostics12092085] [Reference Citation Analysis]
|
| 444 |
Li H, Liu B, Xu X, Li S, Zhang D, Liu Q. Circ_SNX27 regulates hepatocellular carcinoma development via miR-637/FGFR1 axis. Environ Toxicol 2022. [PMID: 36029209 DOI: 10.1002/tox.23640] [Reference Citation Analysis]
|
| 445 |
Loneker AE, Alisafaei F, Kant A, Janmey PA, Shenoy VB, Wells RG. Lipid droplets are intracellular mechanical stressors in fatty hepatocyte.. [DOI: 10.1101/2022.08.27.505524] [Reference Citation Analysis]
|
| 446 |
Li A, Ye B, Lin F, Zhou P, Wang Y, Miao X, Jiang Y. Dissecting Novel Tumor Antigens and Immune Subtypes Guided mRNA Vaccine Development for HBV Related-Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-1962830/v1] [Reference Citation Analysis]
|
| 447 |
Lv GZ, Li GC, Tang WT, Zhou D, Yang Y. Spontaneous acute epidural hematoma secondary to skull and dural metastasis of hepatocellular carcinoma: A case report. World J Clin Cases 2022; 10(24): 8728-8734 [DOI: 10.12998/wjcc.v10.i24.8728] [Reference Citation Analysis]
|
| 448 |
Yuan M, Chen TY, Chen XR, Lu YF, Shi J, Zhang WS, Ye C, Tang BZ, Yang ZG. Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study. World J Clin Cases 2022; 10(24): 8535-8546 [DOI: 10.12998/wjcc.v10.i24.8535] [Reference Citation Analysis]
|
| 449 |
Jia X, Zhang G. Characterization of chromatin regulators in hepatocellular carcinoma to guide clinical therapy. Front Genet 2022;13:961018. [DOI: 10.3389/fgene.2022.961018] [Reference Citation Analysis]
|
| 450 |
Tsujimoto G, Ito R, Yoshikawa K, Ueki C, Okada N. NFYA promotes the anti-tumor effects of gluconeogenesis in hepatocellular carcinoma through the regulation of PCK1 expression. Front Cell Dev Biol 2022;10:983599. [DOI: 10.3389/fcell.2022.983599] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 451 |
Yang C, Guan Z, Pang X, Tan Z, Yang X, Li X, Guan F. Desialylated Mesenchymal Stem Cells-Derived Extracellular Vesicles Loaded with Doxorubicin for Targeted Inhibition of Hepatocellular Carcinoma. Cells 2022;11:2642. [DOI: 10.3390/cells11172642] [Reference Citation Analysis]
|
| 452 |
Wang T, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Smith DA, Salih H, Campbell C, Freeman O, Harris S, Várnai KA, Roadknight G, Little S, Noble T, Woods K, Matthews PC, Davies J, Cooke GS, Barnes E, NIHR Health Informatics Collaborative Viral Hepatitis Theme Consortium. Identifying Hepatocellular Carcinoma from imaging reports using natural language processing to facilitate data extraction from electronic patient records.. [DOI: 10.1101/2022.08.23.22279119] [Reference Citation Analysis]
|
| 453 |
Zhu Y, Huang G, Li S, Xiong H, Chen R, Zuo L, Liu H. CircSMARCA5: A key circular RNA in various human diseases. Front Genet 2022;13:921306. [DOI: 10.3389/fgene.2022.921306] [Reference Citation Analysis]
|
| 454 |
Liang J, Wang J, Zeng J, Bai Z, Zheng Z, Zheng Y, Jiang F, Wu D. The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility. Dis Markers 2022;2022:3144742. [PMID: 36046377 DOI: 10.1155/2022/3144742] [Reference Citation Analysis]
|
| 455 |
Androutsakos T, Bakasis AD, Pouliakis A, Gazouli M, Vallilas C, Hatzis G. Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinoma-A Single-Center Study. Int J Mol Sci 2022;23. [PMID: 36012696 DOI: 10.3390/ijms23169430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 456 |
Khan A, Zhang X. Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials. Bioengineering 2022;9:406. [DOI: 10.3390/bioengineering9080406] [Reference Citation Analysis]
|
| 457 |
Moein S, Tenen DG, Amabile G, Chai L. SALL4: An Intriguing Therapeutic Target in Cancer Treatment. Cells 2022;11:2601. [PMID: 36010677 DOI: 10.3390/cells11162601] [Reference Citation Analysis]
|
| 458 |
Beyoğlu D, Idle JR. The gut microbiota - a vehicle for the prevention and treatment of hepatocellular carcinoma. Biochem Pharmacol 2022;:115225. [PMID: 35998677 DOI: 10.1016/j.bcp.2022.115225] [Reference Citation Analysis]
|
| 459 |
Lu Z, Yang H, Shao Y, Sun W, Jiang Y, Li J. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma. Biochem Biophys Res Commun 2022;627:103-10. [PMID: 36030651 DOI: 10.1016/j.bbrc.2022.08.040] [Reference Citation Analysis]
|
| 460 |
Wang X, Xing Z, Chen H, Yang H, Wang Q, Xing T. High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma. Front Oncol 2022;12:953529. [DOI: 10.3389/fonc.2022.953529] [Reference Citation Analysis]
|
| 461 |
Liu J, Zhang L, Zhao D, Yue S, Sun H, Ni C, Zhong Z. Polymersome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy. J Control Release 2022;350:122-31. [PMID: 35973474 DOI: 10.1016/j.jconrel.2022.08.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 462 |
Kuo Y, Huang T, Wang J, Chen Y, Tsai M, Chen Y, Lu S, Hu T, Chen C, Hung C. Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers 2022;14:3971. [DOI: 10.3390/cancers14163971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 463 |
Jin C, Zhao JS, Huang XQ, Yang XZ, Niu FY, Lin JR, Ma L, Shi YX, Li XS, Jiang P, Gao S, Li F, Song Y. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35947245 DOI: 10.1007/s12072-022-10375-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 464 |
Liu L, Liao R, Wu Z, Du C, You Y, Que K, Duan Y, Yin K, Ye W. Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma via the miRNA-4474-3P-ALOX-15 and EMT axes. Biosci Trends 2022. [PMID: 35934785 DOI: 10.5582/bst.2022.01281] [Reference Citation Analysis]
|
| 465 |
Li H, Xu L, Yi P, Li L, Yan T, Xie L, Zhu Z. High-throughput circular RNA sequencing reveals the profiles of circular RNA in non-cirrhotic hepatocellular carcinoma. BMC Cancer 2022;22:857. [PMID: 35931993 DOI: 10.1186/s12885-022-09909-2] [Reference Citation Analysis]
|
| 466 |
Blankenburg M, Elhamamy M, Zhang D, Corbin A, Jin G, Harris J, Knobloch G. Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA. J Med Econ 2022;:1-65. [PMID: 35930705 DOI: 10.1080/13696998.2022.2110353] [Reference Citation Analysis]
|
| 467 |
Wang Y, Setiawan MF, Liu H, Dakal TC, Liu H, Ge F, Rudan O, Chen P, Zhao C, Gonzalez-Carmona MA, Kornek MT, Strassburg CP, Schmid M, Maciaczyk J, Sharma A, Schmidt-Wolf IGH. Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs) Harboring Oncogenic Potential and Is Markedly Upregulated in Hepatocellular Carcinoma. Biology (Basel) 2022;11. [PMID: 36009801 DOI: 10.3390/biology11081174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 468 |
Liu W, Song K, Zheng W, Huo L, Zhang S, Xu X, Wang P, Jia N. Hepatobiliary Phase Features of Preoperative Gadobenate-Enhanced MR can Predict Early Recurrence of Hepatocellular Carcinoma in Patients Who Underwent Anatomical Hepatectomy. Front Oncol 2022;12:862967. [DOI: 10.3389/fonc.2022.862967] [Reference Citation Analysis]
|
| 469 |
Wang W, Zheng H, Jiang J, Li Z, Jiang D, Shi X, Wang H, Jiang J, Xie Q, Gao M, Chu J, Cai X, Xia T, Li R. Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments. Nat Commun 2022;13:4495. [PMID: 35918337 DOI: 10.1038/s41467-022-32066-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 470 |
Kim N, Kim S, Song Y, Choi I, Lee SY, Kim KM, Rhu HC, Lee JY, Seo HR. Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl cyclase-associated protein 1) expression in hepatocellular carcinoma. Chem Biol Interact 2022;:110066. [PMID: 35931200 DOI: 10.1016/j.cbi.2022.110066] [Reference Citation Analysis]
|
| 471 |
Yin Y, Xu Z, Liu Y, Huang W, Zhang Q, Li J, Zou X. . JHC 2022;Volume 9:885-900. [DOI: 10.2147/jhc.s378175] [Reference Citation Analysis]
|
| 472 |
Li H, Mu H, Xiao Y, Zhao Z, Cui X, Wu D, Zhang Z. Comprehensive Analysis of Histone Modifications in Hepatocellular Carcinoma Reveals Different Subtypes and Key Prognostic Models. Journal of Oncology 2022;2022:1-20. [DOI: 10.1155/2022/5961603] [Reference Citation Analysis]
|
| 473 |
Wang F, Zhang N, Wu X, Zhang W, Lu Q, Wu R, Zhang X, Guo H, Lv Y. Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.07.003] [Reference Citation Analysis]
|
| 474 |
Prateepchaiboon T, Chang A, Pungpipattrakul N, Akarapatima K, Rattanasupar A, Songjamrat A, Pakdeejit S, Piratvisuth T. Factors affecting prognosis in hepatocellular carcinoma patients post-transarterial chemoembolization. Indian J Gastroenterol 2022;41:352-61. [PMID: 36029371 DOI: 10.1007/s12664-021-01227-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 475 |
Li N, Zheng H, Yu Q, Chen F, Su X, Qiu X. Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma. J Int Med Res 2022;50:030006052211152. [DOI: 10.1177/03000605221115251] [Reference Citation Analysis]
|
| 476 |
Chen J, Chen X, Li T, Wang L, Lin G. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response. Int Immunopharmacol 2022;109:108866. [PMID: 35691273 DOI: 10.1016/j.intimp.2022.108866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 477 |
Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int 2022;42:2042-54. [PMID: 34894051 DOI: 10.1111/liv.15130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 478 |
Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2022;42:2055-66. [PMID: 34780081 DOI: 10.1111/liv.15101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 479 |
Sheng J, Wu J, Yin X, Sun Z, Wang X, Zhang J, Tang J, Ji Y, Song J, Wei X, Wang L, Zhao Y, Zhang H, Li T, Zhang Q, Bai X, Chen L, Chen D, Liang T. Synergetic treatment of oxygen microcapsules and lenvatinib for enhanced therapy of HCC by alleviating hypoxia condition and activating anti-tumor immunity. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.08.018] [Reference Citation Analysis]
|
| 480 |
Nagaraj M, Höring M, Ahonen MA, Nguyen VD, Zhou Y, Vihinen H, Jokitalo E, Liebisch G, Nidhina Haridas P, Olkkonen VM. GOLM1 depletion modifies cellular sphingolipid metabolism and adversely affects cell growth. Journal of Lipid Research 2022. [DOI: 10.1016/j.jlr.2022.100259] [Reference Citation Analysis]
|
| 481 |
Hassan EA, Hathout RM, Gad HA, Sammour OA. Multi-purpose zein nanoparticles for battling hepatocellular carcinoma: A Green approach. European Polymer Journal 2022;176:111396. [DOI: 10.1016/j.eurpolymj.2022.111396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 482 |
Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, Ribaldone DG, Fermer C, Saracco GM, Gaia S, Bugianesi E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Curr Oncol 2022;29:5457-65. [PMID: 36005169 DOI: 10.3390/curroncol29080431] [Reference Citation Analysis]
|
| 483 |
Lim DH, Casadei-Gardini A, Lee MA, Lonardi S, Kim JW, Masi G, Chon HJ, Rimini M, Kim I, Cheon J, Hwang JE, Kang JH, Lim HY, Yoo C. Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib. Future Oncol 2022. [PMID: 35903991 DOI: 10.2217/fon-2022-0524] [Reference Citation Analysis]
|
| 484 |
Dou Z, Lu F, Ren L, Song X, Li B, Li X. Efficacy and safety of microwave ablation and radiofrequency ablation in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e29321. [PMID: 35905207 DOI: 10.1097/MD.0000000000029321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 485 |
Xu F, Ye T, Wang D, Xie Y, Zhang K, Cheng J, Xiao Z, Liu S, Jiang K, Yao W, Shen G, Liu J, Zhang C, Huang D, Liang L. Association of preoperative albumin–bilirubin with surgical textbook outcomes following laparoscopic hepatectomy for hepatocellular carcinoma. Front Oncol 2022;12:964614. [DOI: 10.3389/fonc.2022.964614] [Reference Citation Analysis]
|
| 486 |
Zhang Q, Li H, Liu Y, Li J, Wu C, Tang H. Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma. Curr Oncol 2022;29:5383-406. [PMID: 36005165 DOI: 10.3390/curroncol29080427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 487 |
Hu H, Zhong T, Jiang S. H2AFX might be a prognostic biomarker for hepatocellular carcinoma. Cancer Rep (Hoboken) 2023;6:e1684. [PMID: 35903980 DOI: 10.1002/cnr2.1684] [Reference Citation Analysis]
|
| 488 |
Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607 [DOI: 10.3748/wjg.v28.i28.3595] [Reference Citation Analysis]
|
| 489 |
Hytiroglou P, Bioulac-sage P, Theise ND, Sempoux C. Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms. Cancers 2022;14:3670. [DOI: 10.3390/cancers14153670] [Reference Citation Analysis]
|
| 490 |
Pu Z, Ren Z, Xu Q, Wang X, Chen J, Chen J. Editorial: The role of tumor microenvironment in primary liver cancer therapeutic resistance. Front Oncol 2022;12:938557. [DOI: 10.3389/fonc.2022.938557] [Reference Citation Analysis]
|
| 491 |
Bai H, Meng S, Xiong C, Liu Z, Shi W, Ren Q, Xia W, Zhao X, Jian J, Song Y, Ni C, Gao X, Li Z. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2022. [PMID: 35896687 DOI: 10.1007/s00270-022-03221-z] [Reference Citation Analysis]
|
| 492 |
Ma P, Zou C, Xia S. Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma. Immunogenetics 2022. [PMID: 35895154 DOI: 10.1007/s00251-022-01273-6] [Reference Citation Analysis]
|
| 493 |
Liakina V, Strainiene S, Stundiene I, Maksimaityte V, Kazenaite E. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis. World J Hepatol 2022;14:1277-90. [PMID: 36158907 DOI: 10.4254/wjh.v14.i7.1277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 494 |
Li R, Okada H, Yamashita T, Nio K, Chen H, Li Y, Shimakami T, Takatori H, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition. IJMS 2022;23:8305. [DOI: 10.3390/ijms23158305] [Reference Citation Analysis]
|
| 495 |
Qin Y, Wang CJ, Ye HL, Ye GX, Wang S, Pan DB, Wang J, Shen HJ, Xu SQ. WWP2 overexpression inhibits the antitumor effects of doxorubicin in hepatocellular carcinoma. Cell Biol Int 2022. [PMID: 35880837 DOI: 10.1002/cbin.11856] [Reference Citation Analysis]
|
| 496 |
Wang H, Wang X, Ye X, Ju Y, Cao N, Wang S, Cai J. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. BMC Cancer 2022;22:814. [PMID: 35879685 DOI: 10.1186/s12885-022-09861-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 497 |
Liu X, Jin Y, Wan X, Liang X, Wang K, Liu J, Jiang J, Meng B, Han S, Zhou L, Cai S, Zou F. SALIS transcriptionally represses IGFBP3/Caspase-7-mediated apoptosis by associating with STAT5A to promote hepatocellular carcinoma. Cell Death Dis 2022;13:642. [PMID: 35871161 DOI: 10.1038/s41419-022-05094-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 498 |
Liu Y, Wang X, Zeng X, Wu Y, Liu X, Tan J, Li X. Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation. Open Med (Wars) 2022;17:1183-202. [PMID: 35859792 DOI: 10.1515/med-2022-0510] [Reference Citation Analysis]
|
| 499 |
Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R, Petronini PG. CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. Front Oncol 2022;12:942341. [DOI: 10.3389/fonc.2022.942341] [Reference Citation Analysis]
|
| 500 |
Wang S, Wu J, Wang Z, Gong Z, Liu Y, Wang Z. Emerging Roles of Circ-ZNF609 in Multiple Human Diseases. Front Genet 2022;13:837343. [DOI: 10.3389/fgene.2022.837343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 501 |
Chen J, Zhao Y, Zhang F, Li J, Boland JA, Cheng NC, Liu K, Tiffen JC, Bertolino P, Bowen DG, Krueger A, Lisowski L, Alexander IE, Vadas MA, El-Omar E, Gamble JR, McCaughan GW. Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7. Cell Mol Life Sci 2022;79:443. [PMID: 35867177 DOI: 10.1007/s00018-022-04452-6] [Reference Citation Analysis]
|
| 502 |
Fan C, Zhu X, Zhou Q, Wang W, Shi Z. CircFMN2 Boosts Sorafenib Resistance in Hepatocellular Carcinoma Cells via Upregulating CNBP by Restraining Ubiquitination. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/2674163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 503 |
Ueno M, Takeda H, Takai A, Seno H. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World J Gastroenterol 2022; 28(27): 3410-3421 [DOI: 10.3748/wjg.v28.i27.3410] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 504 |
Zhang M, Lai W, Zhang J, Hu B, Huang L, Chu C. Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma. Dis Markers 2022;2022:6957580. [PMID: 35845129 DOI: 10.1155/2022/6957580] [Reference Citation Analysis]
|
| 505 |
Banini BA, Mehta R, Santhekadur PK. Editorial: Recent advances in the understanding of hepatocellular carcinogenesis. Front Oncol 2022;12:963998. [DOI: 10.3389/fonc.2022.963998] [Reference Citation Analysis]
|
| 506 |
Zheng Y, Jia R, Li J, Tian X, Qian Y. Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma. J Nanobiotechnology 2022;20:339. [PMID: 35858935 DOI: 10.1186/s12951-022-01554-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 507 |
Hu Y, Tang C, Zhu W, Ye H, Lin Y, Wang R, Zhou T, Wen S, Yang J, Fang C. Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy. Comput Biol Med 2022;148:105896. [PMID: 35868048 DOI: 10.1016/j.compbiomed.2022.105896] [Reference Citation Analysis]
|
| 508 |
Cheng C, Cai J, Teng W, Zheng Y, Huang Y, Wang Y, Peng C, Tang Y, Lee W, Yeh T, Xiao J, Lu L, Liao C, Harrison AP. A flexible three‐dimensional heterophase computed tomography hepatocellular carcinoma detection algorithm for generalizable and practical screening. Hepatology Communications. [DOI: 10.1002/hep4.2029] [Reference Citation Analysis]
|
| 509 |
Park HM, Won YJ, Kang MJ, Park SJ, Kim SW, Jung KW, Han SS. Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. J Korean Med Sci 2022;37:e216. [PMID: 35851861 DOI: 10.3346/jkms.2022.37.e216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 510 |
He Q, Yang J, Jin Y. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma. Brief Bioinform 2022;23:bbac291. [PMID: 35849048 DOI: 10.1093/bib/bbac291] [Reference Citation Analysis]
|
| 511 |
Qin H, Yuan B, Huang W, Wang Y. Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances. Front Oncol 2022;12:924696. [DOI: 10.3389/fonc.2022.924696] [Reference Citation Analysis]
|
| 512 |
Xia H, Huang Z, Wang Z, Liu S, Zhao X, You J, Xu Y, Yam JWP, Cui Y. Glucometabolic reprogramming: From trigger to therapeutic target in hepatocellular carcinoma. Front Oncol 2022;12:953668. [DOI: 10.3389/fonc.2022.953668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 513 |
Menshikov KV, Sultanbaev AV, Musin SI, Rakhmatullina IR, Menshikova IA, Abdeev RR, Sultanbaeva NI, Popova EV, Serebrennikov GA. Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. Kreativnaâ hirurgiâ i onkologiâ 2022;12:139-150. [DOI: 10.24060/2076-3093-2022-12-2-139-150] [Reference Citation Analysis]
|
| 514 |
Cheng M, Yang Q, Liu Y, Zhao M, Du X, Sun J, Shu W, Huang Z, Bi J, Xu X, Du H. SETD3 Methyltransferase Regulates PLK1 Expression to Promote In Situ Hepatic Carcinogenesis. Front Oncol 2022;12:882202. [DOI: 10.3389/fonc.2022.882202] [Reference Citation Analysis]
|
| 515 |
Xiu Z, Zhu Y, Han J, Li Y, Yang X, Yang G, Song G, Li S, Li Y, Cheng C, Li Y, Fang J, Li X, Jin N. Caryophyllene Oxide Induces Ferritinophagy by Regulating the NCOA4/FTH1/LC3 Pathway in Hepatocellular Carcinoma. Front Pharmacol 2022;13:930958. [DOI: 10.3389/fphar.2022.930958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 516 |
Bertuzzi C, Germinario G, Righi S, Ravaioli M, Agostinelli C, Pession A, D'Errico A, Sabattini E, Vasuri F. The role of peritumoral CD8 + /TIA1 + lymphocytes in hepatocellular carcinoma aggressiveness and recurrence after surgical resection. Pathol Res Pract 2022;237:154016. [PMID: 35872367 DOI: 10.1016/j.prp.2022.154016] [Reference Citation Analysis]
|
| 517 |
Zhang B, Tang B, Lv J, Gao J, Qin L. Systematic analyses to explore immune gene sets-based signature in hepatocellular carcinoma, in which IGF2BP3 contributes to tumor progression. Clin Immunol 2022;241:109073. [PMID: 35817291 DOI: 10.1016/j.clim.2022.109073] [Reference Citation Analysis]
|
| 518 |
Li L, Li X, Li W, Ding X, Zhang Y, Chen J, Li W. Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal. BMC Cancer 2022;22:750. [PMID: 35810271 DOI: 10.1186/s12885-022-09841-5] [Reference Citation Analysis]
|
| 519 |
Crouchet E, Li S, Sojoodi M, Bandiera S, Fujiwara N, El Saghire H, Zhu S, Qian T, Rasha FA, Del Zompo F, Barrett SC, Schaeffer E, Oudot MA, Ponsolles C, Durand SC, Ghoshal S, Arora G, Giannone F, Chung RT, Slovic N, Van Renne N, Felli E, Pessaux P, Lupberger J, Pochet N, Schuster C, Tanabe KK, Hoshida Y, Fuchs BC, Baumert TF. Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight 2022;7:e159254. [PMID: 35801591 DOI: 10.1172/jci.insight.159254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 520 |
Chen Z, Hao W, Tang J, Gao W, Xu H. CSTF2 Promotes Hepatocarcinogenesis and Hepatocellular Carcinoma Progression via Aerobic Glycolysis. Front Oncol 2022;12:897804. [DOI: 10.3389/fonc.2022.897804] [Reference Citation Analysis]
|
| 521 |
Wang H, Wu D, Gao C, Teng H, Zhao Y, He Z, Chen W, Zong Y, Du R. Seco-Lupane Triterpene Derivatives Induce Ferroptosis through GPX4/ACSL4 Axis and Target Cyclin D1 to Block the Cell Cycle. J Med Chem 2022. [PMID: 35801495 DOI: 10.1021/acs.jmedchem.2c00664] [Reference Citation Analysis]
|
| 522 |
Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol 2022;15:87. [PMID: 35799264 DOI: 10.1186/s13045-022-01307-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 523 |
Wu C, Yu S, Zhang Y, Zhu L, Chen S, Liu Y. CT-Based Radiomics Nomogram Improves Risk Stratification and Prediction of Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2022;12:896002. [DOI: 10.3389/fonc.2022.896002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 524 |
de Ataide EC, Perales SR, Teramoto FD, Garcia A, Cunha-Silva M, Sevá-Pereira T, Foratto A, Fernandes DP, Marcondes DC, Meneses CJ, da Costa LBE, Neto FC, de Fatima Santana Ferreira Boin IS. Validation of New York/California Score in the Preoperative Period of Liver Transplant for Hepatocellular Carcinoma at University of Campinas's Hospital. Transplant Proc 2022:S0041-1345(22)00314-1. [PMID: 35810016 DOI: 10.1016/j.transproceed.2022.03.039] [Reference Citation Analysis]
|
| 525 |
Zhang Y, Wang X, Wang H, Jiang Y, Xu Z, Luo L. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:893107. [DOI: 10.3389/fonc.2022.893107] [Reference Citation Analysis]
|
| 526 |
Tsujimoto G, Ito R, Yoshikawa K, Ueki C, Okada N. NFYA promotes the anti-tumor effects of gluconeogenesis in hepatocellular carcinoma through the regulation of PCK1 expression.. [DOI: 10.1101/2022.06.30.498215] [Reference Citation Analysis]
|
| 527 |
Nasereldin DS, White LJ, Hodge DO, Roberts LR, Patel T, Antwi SO. Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. Dig Liver Dis 2022;54:964-72. [PMID: 34953761 DOI: 10.1016/j.dld.2021.12.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 528 |
Ghamari SH, Yoosefi M, Abbasi-Kangevari M, Malekpour MR, Saeedi Moghaddam S, Shahin S, Esfahani Z, Koolaji S, Shobeiri P, Ghaffari A, Sohrabi H, Kazemi A, Rezaei N, Larijani B, Farzadfar F. Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990-2019. Hepatol Commun 2022;6:1764-75. [PMID: 35134275 DOI: 10.1002/hep4.1910] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 529 |
Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5:e2222721. [PMID: 35849393 DOI: 10.1001/jamanetworkopen.2022.22721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 530 |
Yang X, Shao G, Zhang Y, Wang W, Qi Y, Han S, Li H. Applications of Magnetic Particle Imaging in Biomedicine: Advancements and Prospects. Front Physiol 2022;13:898426. [PMID: 35846005 DOI: 10.3389/fphys.2022.898426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 531 |
Katabathina VS, Khanna L, Surabhi VR, Minervini M, Shanbhogue K, Dasyam AK, Prasad SR. Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma. Radiographics 2022;:210106. [PMID: 35776676 DOI: 10.1148/rg.210206] [Reference Citation Analysis]
|
| 532 |
Wang W, Ma L, Xing Z, Yuan T, Bao J, Zhu Y, Zhao X, Zhao Y, Zong Y, Zhang Y, Shen S, Qiu X, Yang S, Wang H, Gao D, Wang P, Chen L. Tumor-specific circRNA-derived antigen peptide identification for hepatobiliary tumors. Engineering 2022. [DOI: 10.1016/j.eng.2022.06.008] [Reference Citation Analysis]
|
| 533 |
Tabrizian P, Saberi B, Holzner ML, Rocha C, Kyung Jung Y, Myers B, Florman SS, Schwartz ME. Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >20,000 patients. HPB (Oxford) 2022;24:1082-90. [PMID: 34955348 DOI: 10.1016/j.hpb.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 534 |
Goya T, Horisawa K, Udono M, Ohkawa Y, Ogawa Y, Sekiya S, Suzuki A. Direct Conversion of Human Endothelial Cells Into Liver Cancer-Forming Cells Using Nonintegrative Episomal Vectors. Hepatol Commun 2022;6:1725-40. [PMID: 35220676 DOI: 10.1002/hep4.1911] [Reference Citation Analysis]
|
| 535 |
Gallard C, Lebsir N, Khursheed H, Reungoat E, Plissonnier ML, Bré J, Michelet M, Chouik Y, Zoulim F, Pécheur EI, Bartosch B, Grigorov B. Heparanase-1 is upregulated by hepatitis C virus and favors its replication. J Hepatol 2022;77:29-41. [PMID: 35085593 DOI: 10.1016/j.jhep.2022.01.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 536 |
Chen M, Wang H, Shi S, Zhang H, Xu S, Jiang Y. miR-6071 inhibits hepatocellular carcinoma progression via targeting PTPN11. Archives of Biochemistry and Biophysics 2022. [DOI: 10.1016/j.abb.2022.109345] [Reference Citation Analysis]
|
| 537 |
Hou W, Bridgeman B, Malnassy G, Ding X, Cotler SJ, Dhanarajan A, Qiu W. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. Hepatol Commun 2022;6:1786-802. [PMID: 35238496 DOI: 10.1002/hep4.1928] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 538 |
Sun H, Yang H, Xu H. A commentary on “Laparoscopic Anatomical Versus Non-anatomical hepatectomy in the Treatment of Hepatocellular Carcinoma: A randomised controlled trial” (Int J Surg 2022;102:106652). International Journal of Surgery 2022. [DOI: 10.1016/j.ijsu.2022.106783] [Reference Citation Analysis]
|
| 539 |
Zhu L, Zhou KX, Ma MZ, Yao LL, Zhang YL, Li H, Du C, Yang XM. Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation. J Immunol Res 2022;2022:1590717. [PMID: 35769513 DOI: 10.1155/2022/1590717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 540 |
Wang Y, Li X, Yu J, Cheng Z, Hou Q, Liang P. Prognostic Nutritional Index in Hepatocellular Carcinoma Patients With Hepatitis B Following US-Guided Percutaneous Microwave Ablation: A Retrospective Study With 1,047 Patients. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.878737] [Reference Citation Analysis]
|
| 541 |
Jia JA, Zhang S, Bai X, Fang M, Chen S, Liang X, Zhu S, Wong DK, Zhang A, Feng J, Sun F, Gao C. Sparse logistic regression revealed the associations between HBV PreS quasispecies and hepatocellular carcinoma. Virol J 2022;19:114. [PMID: 35765099 DOI: 10.1186/s12985-022-01836-9] [Reference Citation Analysis]
|
| 542 |
Ding LH, Fallgren CM, Yu Y, McCarthy M, Edmondson EF, Ullrich RL, Weil MM, Story MD. Orthologs of human circulating miRNAs associated with hepatocellular carcinoma are elevated in mouse plasma months before tumour detection. Sci Rep 2022;12:10927. [PMID: 35764780 DOI: 10.1038/s41598-022-15061-5] [Reference Citation Analysis]
|
| 543 |
McLaughlin KL, Nelson MAM, Coalson HS, Hagen JT, Montgomery MM, Wooten AR, Zeczycki TN, Vohra NA, Fisher-Wellman KH. Bioenergetic Phenotyping of DEN-Induced Hepatocellular Carcinoma Reveals a Link Between Adenylate Kinase Isoform Expression and Reduced Complex I-Supported Respiration. Front Oncol 2022;12:919880. [PMID: 35756609 DOI: 10.3389/fonc.2022.919880] [Reference Citation Analysis]
|
| 544 |
Adetutu Adisa R, Adegboyega Sulaimon L. Hepatocellular Carcinoma. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.105473] [Reference Citation Analysis]
|
| 545 |
Wang L, Ma X, Feng B, Wang S, Liang M, Li D, Wang S, Zhao X. Multi-Sequence MR-Based Radiomics Signature for Predicting Early Recurrence in Solitary Hepatocellular Carcinoma ≤5 cm. Front Oncol 2022;12:899404. [PMID: 35756618 DOI: 10.3389/fonc.2022.899404] [Reference Citation Analysis]
|
| 546 |
Heinrich B, Ruf B, Subramanyam V, Myojin Y, Lai CW, Craig AJ, Fu J, Xie C, Kroemer A, Greten TF, Korangy F. Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Front Immunol 2022;13:849958. [DOI: 10.3389/fimmu.2022.849958] [Reference Citation Analysis]
|
| 547 |
Kim HW, Joo YS, Kang SC, Koh HB, Han SH, Yoo TH, Kang SW, Park JT. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep 2022;12:10807. [PMID: 35752695 DOI: 10.1038/s41598-022-14713-w] [Reference Citation Analysis]
|
| 548 |
Wang L, Hensley CR, Howell ME, Ning S. Bioinformatics-Driven Identification of p62 as A Crucial Oncogene in Liver Cancer. Front Oncol 2022;12:923009. [DOI: 10.3389/fonc.2022.923009] [Reference Citation Analysis]
|
| 549 |
Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 550 |
Pan S, Yu Y, Wang S, Tu B, Shen Y, Qiu Q, Liu X, Su N, Zuo Y, Luan J, Zhang JY, Shi M, Meng F, Wang FS. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Front Immunol 2022;13:892618. [PMID: 35711409 DOI: 10.3389/fimmu.2022.892618] [Reference Citation Analysis]
|
| 551 |
Hou L, Zeng X, Li X, Zhao C, Zou J, Li Y, Liu G. MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights. Comput Math Methods Med 2022;2022:3116303. [PMID: 35720029 DOI: 10.1155/2022/3116303] [Reference Citation Analysis]
|
| 552 |
Chen J, Ji K, Gu L, Fang Y, Pan M, Tian S, Zhang ZG. HMGA1 Promotes Macrophage Recruitment via Activation of NF-κB-CCL2 Signaling in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/4727198] [Reference Citation Analysis]
|
| 553 |
Wang Y, Zhang Y, Mi J, Jiang C, Wang Q, Li X, Zhao M, Geng Z, Song X, Li J, Zuo L, Ge S, Zhang Z, Wen H, Wang Z, Su F. ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma. Oncogene 2022. [PMID: 35725908 DOI: 10.1038/s41388-022-02380-0] [Reference Citation Analysis]
|
| 554 |
Wang G, Zhang W, Chen J, Luan X, Wang Z, Wang Y, Xu X, Yao S, Guan Z, Tian J, Lu S, Xu B, Ma G. Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Front Oncol 2022;12:884372. [PMID: 35719917 DOI: 10.3389/fonc.2022.884372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 555 |
Perramón M, Jiménez W. Pituitary Tumor-Transforming Gene 1/Delta like Non-Canonical Notch Ligand 1 Signaling in Chronic Liver Diseases. IJMS 2022;23:6897. [DOI: 10.3390/ijms23136897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 556 |
Chen R, Hou B, Qiu S, Shao S, Yu Z, Zhou F, Guo B, Li Y, Zhang Y, Han T. Development and Validation of Nomogram for Predicting Survival of Primary Liver Cancers Using Machine Learning. Front Oncol 2022;12:926359. [DOI: 10.3389/fonc.2022.926359] [Reference Citation Analysis]
|
| 557 |
Bahcivanci B, Shafiha R, Gkoutos GV, Acharjee A. Associating transcriptomics data with inflammatory markers to understand tumour microenvironment in hepatocellular carcinoma. Cancer Med 2023;12:696-711. [PMID: 35715992 DOI: 10.1002/cam4.4941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 558 |
Liu B, Zeng Q, Huang J, Zhang J, Zheng Z, Liao Y, Deng K, Zhou W, Xu Y. IVIM using convolutional neural networks predicts microvascular invasion in HCC. Eur Radiol 2022. [PMID: 35713662 DOI: 10.1007/s00330-022-08927-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 559 |
Núñez KG, Sandow T, Lakey MA, Fort D, Cohen AJ, Thevenot PT. Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy. Front Oncol 2022;12:809860. [DOI: 10.3389/fonc.2022.809860] [Reference Citation Analysis]
|
| 560 |
Li N, Wan X, Zhang H, Zhang Z, Guo Y, Hong D. Tumor and peritumor radiomics analysis based on contrast-enhanced CT for predicting early and late recurrence of hepatocellular carcinoma after liver resection. BMC Cancer 2022;22:664. [PMID: 35715783 DOI: 10.1186/s12885-022-09743-6] [Reference Citation Analysis]
|
| 561 |
Xu MH, Xu B, Zhou CH, Xue Z, Chen ZS, Xu WX, Huang C, Zhu XD, Zhou J, Fan J, Sun HC, Shen YH. An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study. World J Surg Oncol 2022;20:206. [PMID: 35710377 DOI: 10.1186/s12957-022-02672-5] [Reference Citation Analysis]
|
| 562 |
Van Tong H, Van Dung P, Thi Mong Diep N, Linh Toan N. Circulating Biomarkers for Early Diagnosis of Hepatocellular Carcinoma. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.98483] [Reference Citation Analysis]
|
| 563 |
Zhang P, Chen L, Wu S, Ye B, Chen C, Shi L. Construction of a Metabolism-Related Long Non-Coding RNAs-Based Risk Score Model of Hepatocellular Carcinoma for Prognosis and Personalized Treatment Prediction. Pathol Oncol Res 2022;28:1610066. [PMID: 35685867 DOI: 10.3389/pore.2022.1610066] [Reference Citation Analysis]
|
| 564 |
Gao H, Zhang Y, Mo X, Huo L, Luo Y, Zhang T, Ma X, Hu W, Jing T. Antitumor Effect of Pseudolaric Acid B Involving Regulation of Notch1/Akt Signaling Response in Human Hepatoma Cell In Vitro. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-11. [DOI: 10.1155/2022/5353686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 565 |
Wu MY, Wang CC, Chang YC, Yu CY, Sung WW, Chen CJ, Tsai MC. The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-κB Signaling. Medicina (Kaunas) 2022;58:798. [PMID: 35744061 DOI: 10.3390/medicina58060798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 566 |
Zhou Y, Li X, Luo W, Zhu J, Zhao J, Wang M, Sang L, Chang B, Wang B. Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment. Front Pharmacol 2022;13:903259. [DOI: 10.3389/fphar.2022.903259] [Reference Citation Analysis]
|
| 567 |
Yang X, Xiao J, Jiang L, Ran L, Fan Y, Zhang M, Xu Y, Yao C, An B, Yang Y, Yang C, Tian G, Zhang G, Zhang Y. A Multifunctional Vanadium-Iron-Oxide Nanoparticle Eradicates Hepatocellular Carcinoma via Targeting Tumor and Endothelial Cells. ACS Appl Mater Interfaces 2022. [PMID: 35698257 DOI: 10.1021/acsami.2c03474] [Reference Citation Analysis]
|
| 568 |
Zhang Y, Chen W, Cheng X, Wang F, Gao C, Song F, Song F, Liang X, Fang W, Chen Z. Sphingomyelin Phodiesterase Acid-Like 3A Promotes Hepatocellular Carcinoma Growth Through the Enhancer of Rudimentary Homolog. Front Oncol 2022;12:852765. [PMID: 35686107 DOI: 10.3389/fonc.2022.852765] [Reference Citation Analysis]
|
| 569 |
Ye T, Lin L, Cao L, Huang W, Wei S, Shan Y, Zhang Z. Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes. Front Oncol 2022;12:863266. [PMID: 35677150 DOI: 10.3389/fonc.2022.863266] [Reference Citation Analysis]
|
| 570 |
Li Y, Li J, Chen H, Wang J, Jiang L, Tan X. The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma. J Biochem Mol Toxicol 2022;:e23119. [PMID: 35678308 DOI: 10.1002/jbt.23119] [Reference Citation Analysis]
|
| 571 |
Ni Z, Wu B, Li M, Han X, Hao X, Zhang Y, Cheng W, Guo C. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis. Ultrasound Med Biol 2022:S0301-5629(22)00365-9. [PMID: 35690523 DOI: 10.1016/j.ultrasmedbio.2022.04.217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 572 |
Sun BY, Gu PY, Guan RY, Zhou C, Lu JW, Yang ZF, Pan C, Zhou PY, Zhu YP, Li JR, Wang ZT, Gao SS, Gan W, Yi Y, Luo Y, Qiu SJ. Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma. World J Surg Oncol 2022;20:189. [PMID: 35676669 DOI: 10.1186/s12957-022-02645-8] [Reference Citation Analysis]
|
| 573 |
Liu Y, Fu B, Yu Z, Song G, Zeng H, Gong Y, Ding Y, Huang D. Identification of KRBA1 as a Potential Prognostic Biomarker Associated with Immune Infiltration and m6A Modification in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:497-516. [PMID: 35669909 DOI: 10.2147/JHC.S363862] [Reference Citation Analysis]
|
| 574 |
Guang Y. Ligand-modified Nanomaterials for Specific Targeting of Hepatocellular Carcinoma. Journal of Modern Nanotechnology 2022;2. [DOI: 10.53964/jmn.2022004] [Reference Citation Analysis]
|
| 575 |
Dong W, Xie Y, Huang H. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma. Front Endocrinol 2022;13:884777. [DOI: 10.3389/fendo.2022.884777] [Reference Citation Analysis]
|
| 576 |
Wang W, Yuan T, Ma L, Zhu Y, Bao J, Zhao X, Zhao Y, Zong Y, Zhang Y, Yang S, Qiu X, Shen S, Wu R, Wu T, Wang H, Gao D, Wang P, Chen L. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors. Adv Sci (Weinh) 2022;:e2105810. [PMID: 35665491 DOI: 10.1002/advs.202105810] [Reference Citation Analysis]
|
| 577 |
Chen S, Huang C, Liao G, Sun H, Xie Y, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Zeng Q, Zhang G, Liao C, Xie W, Shen S, Li S, Peng S, Kuang D, Zhao Q, Duda DG, Kuang M. Distinct Single-cell Immune Ecosystems Distinguish True and De Novo HBV-related Hepatocellular Carcinoma Recurrences.. [DOI: 10.1101/2022.06.02.494526] [Reference Citation Analysis]
|
| 578 |
Yang Y, Qu Y, Li Z, Tan Z, Lei Y, Bai S. Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics. Front Genet 2022;13:874805. [PMID: 35651938 DOI: 10.3389/fgene.2022.874805] [Reference Citation Analysis]
|
| 579 |
Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res 2022;41:189. [PMID: 35655320 DOI: 10.1186/s13046-022-02383-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 580 |
Zhuang H, Chen B, Tang C, Chen X, Tan W, Yang L, Xie Z, Ma X, Wang Q, Zhang C, Shang C, Chen Y. Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma. Front Oncol 2022;12:871771. [PMID: 35646684 DOI: 10.3389/fonc.2022.871771] [Reference Citation Analysis]
|
| 581 |
Huang J, Kang W, Pan S, Yu C, Jie Z, Chen C, Ciccarone F. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/6891155] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 582 |
Yang Y, Lu Y, Pei T, Guo B, Li J, Wang H, Ba Q. Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. Pharmacological Research - Modern Chinese Medicine 2022;3:100108. [DOI: 10.1016/j.prmcm.2022.100108] [Reference Citation Analysis]
|
| 583 |
Zhu Y, Chen M, Xu D, Li TE, Zhang Z, Li JH, Wang XY, Yang X, Lu L, Jia HL, Dong QZ, Qin LX. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma. Cell Mol Immunol 2022;19:726-37. [PMID: 35459855 DOI: 10.1038/s41423-022-00848-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 584 |
Cheng N, Ren Y, Zhou J, Zhang Y, Wang D, Zhang X, Chen B, Liu F, Lv J, Cao Q, Chen S, Du H, Hui D, Weng Z, Liang Q, Su B, Tang L, Han L, Chen J, Shao C. Deep Learning-Based Classification of Hepatocellular Nodular Lesions on Whole-Slide Histopathologic Images. Gastroenterology 2022;162:1948-1961.e7. [PMID: 35202643 DOI: 10.1053/j.gastro.2022.02.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 585 |
Wei X, Su R, Yang M, Pan B, Lu J, Lin H, Shu W, Wang R, Xu X. Quantitative proteomic profiling of hepatocellular carcinoma at different serum alpha-fetoprotein level. Translational Oncology 2022;20:101422. [DOI: 10.1016/j.tranon.2022.101422] [Reference Citation Analysis]
|
| 586 |
Rizzo A, Brandi G. Radiofrequency ablation, radiation therapy, transarterial chemoembolization, and yttrium 90: no differences for local treatment of liver cancer? Acta Oncol 2022;61:730. [PMID: 35253595 DOI: 10.1080/0284186X.2022.2046849] [Reference Citation Analysis]
|
| 587 |
Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 2022;80:104069. [PMID: 35605429 DOI: 10.1016/j.ebiom.2022.104069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 588 |
Wang L, Li B, Bo X, Yi X, Xiao X, Zheng Q. Hypoxia-induced LncRNA DACT3-AS1 upregulates PKM2 to promote metastasis in hepatocellular carcinoma through the HDAC2/FOXA3 pathway. Exp Mol Med 2022;54:848-60. [PMID: 35764883 DOI: 10.1038/s12276-022-00767-3] [Reference Citation Analysis]
|
| 589 |
Yu S, Cen C, Zhang X, Cheng L, Xia W, Jia J, Ye Y, Yu J, Zhang M, Shen Y, Zheng S. Utilization of hepatitis B virus surface antigen positive grafts in liver transplantation: A matched study based on a national registry cohort. J Gastroenterol Hepatol 2022;37:1052-9. [PMID: 35249229 DOI: 10.1111/jgh.15821] [Reference Citation Analysis]
|
| 590 |
Nie L, Liao Y, Zhou R, Liang X, Wan X, Li X, Su M. Anti-hepatic carcinoma mechanisms of calycosin through targeting of ferroptosis. Intelligent Medicine 2022. [DOI: 10.1016/j.imed.2022.06.001] [Reference Citation Analysis]
|
| 591 |
shan L, xiaotong D, Qiyi W, Jingxian L, Tianmu H, Jianyong Z, Xiaofei L. Mechanisms underlying the activity of paederus in hepatocellular carcinoma: A network pharmacology and in vitro validation approach. Pharmacological Research - Modern Chinese Medicine 2022;3:100089. [DOI: 10.1016/j.prmcm.2022.100089] [Reference Citation Analysis]
|
| 592 |
Zhuravleva E, O'Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol 2022;19:367-82. [PMID: 35273358 DOI: 10.1038/s41575-022-00587-w] [Reference Citation Analysis]
|
| 593 |
Wang W, Sun H, Gong Y, Liu X, Liu X, Wang M, Li S, Li J, Zhu L, Meng H. Ratiometric co-delivery of hydroxychloroquine and calculated low-dose paclitaxel efficiently suppresses tumor growth in hepatocellular carcinoma mouse models in vivo. Nano Today 2022;44:101446. [DOI: 10.1016/j.nantod.2022.101446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 594 |
Reinoso-pereira GL, Paranaguá-vezozzo DC, Mazo DF, França JID, Ono SK, Carrilho FJ. HIGH VALUES OF LIVER STIFFNESS PLAY AN IMPORTANT ROLE IN STRATIFYING THE RISK OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC HEPATITIS C PATIENTS. Arq Gastroenterol 2022;59:204-211. [DOI: 10.1590/s0004-2803.202202000-38] [Reference Citation Analysis]
|
| 595 |
Funato K, Otsuka M, Sekiba K, Miyakawa Y, Seimiya T, Shibata C, Kishikawa T, Fujishiro M. Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors. Biochemical and Biophysical Research Communications 2022;607:89-95. [DOI: 10.1016/j.bbrc.2022.03.137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 596 |
Zhang S, Jiang M, Cao H, Xiong J, Xu J. CTB-193M12.5 Promotes Hepatocellular Carcinoma Progression via Enhancing NSD1-Mediated WNT10B/Wnt/β-Catenin Signaling Activation. JHC 2022;Volume 9:553-69. [DOI: 10.2147/jhc.s365302] [Reference Citation Analysis]
|
| 597 |
Fukumoto T, Minami T, Moriyama M, Yamada T, Wake T, Kinoshita MN, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Enooku K, Nakagawa H, Fujishiro M, Shiina S, Koike K, Tateishi R. Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals. Hepatol Commun 2022. [PMID: 35641233 DOI: 10.1002/hep4.2010] [Reference Citation Analysis]
|
| 598 |
Mercan-stanciu A, Isac T, Rababoc R, Rusie D, Toma L, Vacaroiu IA, Tulin R, Iliescu EL. Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals. Cureus. [DOI: 10.7759/cureus.25487] [Reference Citation Analysis]
|
| 599 |
Qiu Z, Wang X, Yang Z, Liao S, Dong W, Sun T, Wu H, Zhang Q, Pan Z, Lam SM, Shui G, Jin J. GBA1-dependent membrane glucosylceramide reprogramming promotes liver cancer metastasis via activation of the Wnt/β-catenin signalling pathway. Cell Death Dis 2022;13:508. [PMID: 35637196 DOI: 10.1038/s41419-022-04968-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 600 |
Wen M, Xu H, Peng H, Sheng Y, Yang W, Yan J. MiR-27a-3p targets USP46 to inhibit the cell proliferation of hepatocellular carcinoma. Chem Biol Drug Des 2022. [PMID: 35637630 DOI: 10.1111/cbdd.14063] [Reference Citation Analysis]
|
| 601 |
Liu H, Tang T, Hu X, Tan W, Zhou P, Zhang H, Liu Y, Chen C, Yang M, Zhou M, Xuan S, Cheng B, Yin W, Lin J, Wang F. miR-138-5p Inhibits Vascular Mimicry by Targeting the HIF-1α/VEGFA Pathway in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/7318950] [Reference Citation Analysis]
|
| 602 |
Lachiondo-ortega S, Delgado TC, Baños-jaime B, Velázquez-cruz A, Díaz-moreno I, Martínez-chantar ML. Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors. Cancers 2022;14:2666. [DOI: 10.3390/cancers14112666] [Reference Citation Analysis]
|
| 603 |
Zhang Q, Yu X, Zhang S, Guo W, He Y. Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders. Sci Rep 2022;12:8905. [PMID: 35618810 DOI: 10.1038/s41598-022-13013-7] [Reference Citation Analysis]
|
| 604 |
Huang S, Li D, Zhuang L, Zhang J, Wu J. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients. Front Med 2022;9:850343. [DOI: 10.3389/fmed.2022.850343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 605 |
Hu X, Zhou J, Li Y, Wang Y, Guo J, Sack I, Chen W, Yan F, Li R, Wang C. Added Value of Viscoelasticity for MRI-Based Prediction of Ki-67 Expression of Hepatocellular Carcinoma Using a Deep Learning Combined Radiomics (DLCR) Model. Cancers (Basel) 2022;14:2575. [PMID: 35681558 DOI: 10.3390/cancers14112575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 606 |
Li H, Song J, He Y, Liu Y, Liu Z, Sun W, Hu W, Lei QY, Hu X, Chen Z, He X. CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4-Fatty Acid β-Oxidation Pathway. Adv Sci (Weinh) 2022;:e2105126. [PMID: 35603967 DOI: 10.1002/advs.202105126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 607 |
Pan C, Luo N, Guo K, Wang W, Li L, Fan N, Tian Y. Members of the Chromobox Family Have Prognostic Value in Hepatocellular Carcinoma. Front Genet 2022;13:887925. [DOI: 10.3389/fgene.2022.887925] [Reference Citation Analysis]
|
| 608 |
Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
|
| 609 |
Ma S, Adzavon YM, Wen X, Zhao P, Xie F, Liu M, Ma X. Novel Insights in the Regulatory Mechanisms of Ferroptosis in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:873029. [DOI: 10.3389/fcell.2022.873029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 610 |
Qu C, Wang Q, Li C, Xie Q, Cai P, Yan X, Sparrelid E, Zhang L, Ma K, Brismar TB. A Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 cm. Front Oncol 2022;12:831795. [DOI: 10.3389/fonc.2022.831795] [Reference Citation Analysis]
|
| 611 |
Lee CY, Chau GY, Wei CY, Chao Y, Huang YH, Huo TI, Hou MC, Su YH, Wu JC, Su CW. Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. Sci Rep 2022;12:8343. [PMID: 35585167 DOI: 10.1038/s41598-022-12350-x] [Reference Citation Analysis]
|
| 612 |
Yu J, Liu Z, Liang D, Li J, Ma S, Wang G, Chen W. Meat Intake and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Nutr Cancer 2022;:1-11. [PMID: 35583453 DOI: 10.1080/01635581.2022.2077386] [Reference Citation Analysis]
|
| 613 |
Liu P, Han B, Zhang Y, Wang X, Ahmad S. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. Computational Intelligence and Neuroscience 2022;2022:1-14. [DOI: 10.1155/2022/7102500] [Reference Citation Analysis]
|
| 614 |
Hong WF, Liu MY, Liang L, Zhang Y, Li ZJ, Han K, Du SS, Chen YJ, Ma LH. Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma. Front Immunol 2022;13:868480. [PMID: 35572523 DOI: 10.3389/fimmu.2022.868480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 615 |
Mangla A, Cioffi G, Barnholtz-Sloan JS, Lee RT. Treatment Outcomes for Primary Hepatic Angiosarcoma: National Cancer Database Analysis 2004-2014. Curr Oncol 2022;29:3637-46. [PMID: 35621682 DOI: 10.3390/curroncol29050292] [Reference Citation Analysis]
|
| 616 |
Alvarez M, Benhammou JN, Darci-Maher N, French SW, Han SB, Sinsheimer JS, Agopian VG, Pisegna JR, Pajukanta P. Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. Genome Med 2022;14:50. [PMID: 35581624 DOI: 10.1186/s13073-022-01055-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 617 |
Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]
|
| 618 |
Wu Y, Xu X, Liu M, Qin X, Wu Q, Ding H, Zhao Q. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis. Biochem Pharmacol 2022;:115093. [PMID: 35580648 DOI: 10.1016/j.bcp.2022.115093] [Reference Citation Analysis]
|
| 619 |
Zhu X, Hou Y, Ye X, Zou Y, Xia X, Yang S, Huang P, Yu R. Identifying and Exploring the Candidate Susceptibility Genes of Cirrhosis Using the Multi-Tissue Transcriptome-Wide Association Study. Front Genet 2022;13:878607. [DOI: 10.3389/fgene.2022.878607] [Reference Citation Analysis]
|
| 620 |
Mi H, Ho WJ, Yarchoan M, Popel AS. Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma. Front Immunol 2022;13:892250. [DOI: 10.3389/fimmu.2022.892250] [Reference Citation Analysis]
|
| 621 |
Yu S, Wang H, Gao J, Liu L, Sun X, Wang Z, Wen P, Shi X, Shi J, Guo W, Zhang S. Identification of Context-Specific Fitness Genes Associated With Metabolic Rearrangements for Prognosis and Potential Treatment Targets for Liver Cancer. Front Genet 2022;13:863536. [DOI: 10.3389/fgene.2022.863536] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 622 |
Jethwa KR, Hallemeier CL. Hepatobiliary Cancers. Principles and Practice of Particle Therapy 2022. [DOI: 10.1002/9781119707530.ch19] [Reference Citation Analysis]
|
| 623 |
Blanco JR, Verdugo-Sivianes EM, Amiama A, Muñoz-Galván S. The circadian rhythm of viruses and its implications on susceptibility to infection. Expert Rev Anti Infect Ther 2022;:1-9. [PMID: 35546444 DOI: 10.1080/14787210.2022.2072296] [Reference Citation Analysis]
|
| 624 |
Yi L, He S, Cheng Z, Chen X, Ren X, Bai Y, Santhekadur PK. DNAJA1 Stabilizes EF1A1 to Promote Cell Proliferation and Metastasis of Liver Cancer Mediated by miR-205-5p. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/2292481] [Reference Citation Analysis]
|
| 625 |
Cui Y, Yun T, Zhao GG. Bioinformatics analysis of clinical significance of STMN1 gene in prognosis and immune infiltration in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2022; 30(9): 411-419 [DOI: 10.11569/wcjd.v30.i9.411] [Reference Citation Analysis]
|
| 626 |
Yu J, Zhang H, Zhang Y, Zhang X. Integrated Analysis of the Altered lncRNA, microRNA, and mRNA Expression in HBV-Positive Hepatocellular Carcinoma. Life 2022;12:701. [DOI: 10.3390/life12050701] [Reference Citation Analysis]
|
| 627 |
Lin X, Xiao M, Gu YJ, Zhu HK, Li MX, Zhuang L, Zheng SS, Li QY. The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00120-5. [PMID: 35568681 DOI: 10.1016/j.hbpd.2022.05.002] [Reference Citation Analysis]
|
| 628 |
Shen L, Gu P, Qiu C, Ding WT, Zhang L, Cao WY, Li ZY, Yan B, Sun X. Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway. Ann Hepatol 2022;27:100680. [PMID: 35108614 DOI: 10.1016/j.aohep.2022.100680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 629 |
Bourayou E, Golub R. Signaling Pathways Tuning Innate Lymphoid Cell Response to Hepatocellular Carcinoma. Front Immunol 2022;13:846923. [PMID: 35281021 DOI: 10.3389/fimmu.2022.846923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 630 |
Li S, Zhang S, Huang M, Hu H, Xie Y. U1RNP/lncRNA/Transcription Cycle Axis Promotes Tumorigenesis of Hepatocellular Carcinoma. Diagnostics 2022;12:1133. [DOI: 10.3390/diagnostics12051133] [Reference Citation Analysis]
|
| 631 |
Chen Y, Huang M, Zhu J, Xu L, Cheng W, Lu X, Yan F. Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma. Front Pharmacol 2022;13:857060. [PMID: 35496321 DOI: 10.3389/fphar.2022.857060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 632 |
Liang J, Li G, Liao J, Huang Z, Wen J, Wang Y, Chen Z, Cai G, Xu W, Ding Z, Liang H, Datta PK, Chu L, Chen X, Zhang B. Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation. Cell Death Differ 2022;29:988-1003. [PMID: 35034103 DOI: 10.1038/s41418-022-00929-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 633 |
Shen GL, Lu Y, Liang L, Lu WF, Diao YK, Xiao ZQ, Zhang KJ, Zhang JG, Zhang CW, Liu J. Impact of diabetes mellitus on the long-term prognosis of patients with hepatocellular carcinoma after hepatectomy. Expert Rev Gastroenterol Hepatol 2022;16:473-8. [PMID: 35387530 DOI: 10.1080/17474124.2022.2063837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 634 |
Ma A, Biersack B, Goehringer N, Nitzsche B, Höpfner M. Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. JPM 2022;12:738. [DOI: 10.3390/jpm12050738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 635 |
Lu L, Shen L, Wu Z, Shi Y, Hou P, Xue Z, Lin C, Chen X; Fujian HCC-biomarker Study Group. Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study. EClinicalMedicine 2022;47:101391. [PMID: 35480077 DOI: 10.1016/j.eclinm.2022.101391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 636 |
Chen S, Dong Y, Qi X, Cao Q, Luo T, Bai Z, He H, Fan Z, Xu L, Xing G, Wang C, Jin Z, Li Z, Chen L, Zhong Y, Wang J, Ge J, Xiao X, Bian X, Wen W, Ren J, Wang H. Aristolochic acids exposure was not the main cause of liver tumorigenesis in adulthood. Acta Pharm Sin B 2022;12:2252-67. [PMID: 35646530 DOI: 10.1016/j.apsb.2021.11.011] [Reference Citation Analysis]
|
| 637 |
Zhang L, Chen J, Jiang H, Rong D, Guo N, Yang H, Zhu J, Hu B, He B, Yin M, Venkatesh SK, Ehman RL, Wang J. MR Elastography as a biomarker for Prediction of Early and Late Recurrence in HBV-related Hepatocellular Carcinoma Patients before Hepatectomy. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110340] [Reference Citation Analysis]
|
| 638 |
Tey SK, Wong SWK, Yeung CLS, Li JYK, Mao X, Chung CYS, Yam JWP. Liver cancer cells with nuclear MET overexpression release translation regulatory protein‐enriched extracellular vesicles exhibit metastasis promoting activity. J of Extracellular Bio 2022;1. [DOI: 10.1002/jex2.39] [Reference Citation Analysis]
|
| 639 |
Giardino Torchia ML, Letizia M, Gilbreth R, Merlino A, Sult E, Monks N, Chesebrough J, Tammali R, Chu N, Tong J, Meekin J, Schifferli K, Vashisht K, Dacosta K, Clarke L, Gesse C, Yao X, Bridges C, Moody G. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2022.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 640 |
Tong W, Yang L, Liu L, Liu X, Luo N. SPINDOC is Highly Expressed in Pan-Cancer Samples and Can Promote the Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating Wnt/β-Catenin Signaling Pathway. OTT 2022;Volume 15:555-70. [DOI: 10.2147/ott.s348843] [Reference Citation Analysis]
|
| 641 |
Claxton L, Walton M, Sharif-Hurst S, Wade R, Eastwood A, Hodgson R. The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom. Value Health 2022;25:787-95. [PMID: 35500948 DOI: 10.1016/j.jval.2021.10.009] [Reference Citation Analysis]
|
| 642 |
Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, Yang C, Chen Y, Xiong B. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis. Clin Res Hepatol Gastroenterol 2022;46:101893. [PMID: 35247625 DOI: 10.1016/j.clinre.2022.101893] [Reference Citation Analysis]
|
| 643 |
Bévant K, Desoteux M, Angenard G, Pineau R, Caruso S, Louis C, Papoutsoglou P, Sulpice L, Gilot D, Zucman-Rossi J, Coulouarn C. TGFβ-induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer. Hepatol Commun 2022;6:1157-71. [PMID: 34825776 DOI: 10.1002/hep4.1866] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 644 |
Li X, Yao Q, Liu C, Wang J, Zhang H, Li S, Cai P. Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know? JHC 2022;Volume 9:379-87. [DOI: 10.2147/jhc.s364742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 645 |
Tsai JH, Jeng YM, Lee CH, Liau JY. Molecular features of primary hepatic undifferentiated carcinoma. Mod Pathol 2022;35:680-7. [PMID: 34949765 DOI: 10.1038/s41379-021-00970-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 646 |
Wang F, Chen Q, Zhang Y, Chen Y, Zhu Y, Zhou W, Liang X, Yang Y, Hu H. CT-Based Radiomics for the Recurrence Prediction of Hepatocellular Carcinoma After Surgical Resection. JHC 2022;Volume 9:453-65. [DOI: 10.2147/jhc.s362772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 647 |
Grinspan LT, Villanueva A. Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Semin Liver Dis 2022;42:188-201. [PMID: 35738257 DOI: 10.1055/s-0042-1748924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 648 |
Xu X, Sun S, Liu Q, Liu X, Wu F, Shen C. Preoperative application of systemic inflammatory biomarkers combined with MR imaging features in predicting microvascular invasion of hepatocellular carcinoma. Abdom Radiol (NY) 2022;47:1806-16. [PMID: 35267069 DOI: 10.1007/s00261-022-03473-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 649 |
Xie Y, Sun R, Gao L, Guan J, Wang J, Bell A, Zhu J, Zhang M, Xu M, Lu P, Cai X, Ren S, Xu P, Monga SP, Ma X, Yang D, Liu Y, Lu B, Xie W. Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma. Hepatol Commun 2022;6:1123-39. [PMID: 34981658 DOI: 10.1002/hep4.1880] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 650 |
Furuke H, Konishi H, Arita T, Kataoka S, Shibamoto J, Takabatake K, Takaki W, Shimizu H, Yamamoto Y, Morimura R, Komatsu S, Shiozaki A, Ikoma H, Otsuji E. miR‑4730 suppresses the progression of liver cancer by targeting the high mobility group A1 pathway. Int J Mol Med 2022;49:83. [PMID: 35485281 DOI: 10.3892/ijmm.2022.5139] [Reference Citation Analysis]
|
| 651 |
Raissa R, Riawan W, Safitri A, Masruri M, Beltran MAG, Aulanniam A. In vitro and in vivo study: Ethanolic extract leaves of Azadirachta indica Juss. variant of Indonesia and Philippines suppresses tumor growth of hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling. F1000Res 2022;11:477. [DOI: 10.12688/f1000research.109557.1] [Reference Citation Analysis]
|
| 652 |
Fang W, Gan Y, Zhang L, Xiong J. COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma. Front Oncol 2022;12:853026. [DOI: 10.3389/fonc.2022.853026] [Reference Citation Analysis]
|
| 653 |
Baek M, Chai JC, Choi HI, Yoo E, Binas B, Lee YS, Jung KH, Chai YG. Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS ONE 2022;17:e0266966. [DOI: 10.1371/journal.pone.0266966] [Reference Citation Analysis]
|
| 654 |
He W, Chen M, Li C, Wang X, Chen W, Pan L, Cui Y, Yu Z, Wu G, Yang Y, Tang Q, Wang J, He Z. Metformin decreases Cyp26a1 to prevent hepatocarcinogenesis through down- regulating CD8+ T cells.. [DOI: 10.1101/2022.04.27.489721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 655 |
Eltelbany A, Khoudari G, Al-khadra Y, Mccullough A, Alkhouri N. Lower Rates of Hepatocellular Carcinoma Observed Among Cannabis Users: A Population-Based Study. Cureus 2022. [DOI: 10.7759/cureus.24576] [Reference Citation Analysis]
|
| 656 |
Di Stasio D, Lucchese A, Romano A, Elio Adinolfi L, Serpico R, Marrone A. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. Clin Oral Investig 2022. [PMID: 35477818 DOI: 10.1007/s00784-022-04507-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 657 |
Rusie D, Mercan Stanciu A, Toma L, Iliescu EL. Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals. Cureus 2022. [DOI: 10.7759/cureus.24506] [Reference Citation Analysis]
|
| 658 |
Li W, Han L, Xiao B, Li X, Ye Z. A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection. Diagnostics (Basel) 2022;12. [PMID: 35626229 DOI: 10.3390/diagnostics12051073] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 659 |
Sun J, Chen Q, Ma J. Notch–Sox9 Axis Mediates Hepatocyte Dedifferentiation in KrasG12V-Induced Zebrafish Hepatocellular Carcinoma. IJMS 2022;23:4705. [DOI: 10.3390/ijms23094705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 660 |
Zhao M, Duan X, Mi L, Shi J, Li N, Yin X, Han X, Wang J, Han G, Hou J, Yin F. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncol 2022;18:2269-88. [PMID: 35440159 DOI: 10.2217/fon-2021-1087] [Reference Citation Analysis]
|
| 661 |
Lee C, Han J, Jung Y. Pathological Contribution of Extracellular Vesicles and Their MicroRNAs to Progression of Chronic Liver Disease. Biology 2022;11:637. [DOI: 10.3390/biology11050637] [Reference Citation Analysis]
|
| 662 |
Lee T, Rawding PA, Bu J, Hyun S, Rou W, Jeon H, Kim S, Lee B, Kubiatowicz LJ, Kim D, Hong S, Eun H. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14:2061. [PMID: 35565192 DOI: 10.3390/cancers14092061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 663 |
Elmas A, Lujambio A, Huang KL. Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. Front Oncol 2022;12:814120. [PMID: 35433463 DOI: 10.3389/fonc.2022.814120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 664 |
Moon H, Park H, Chae MJ, Choi HJ, Kim DY, Ro SW. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer 2022;22:423. [PMID: 35439973 DOI: 10.1186/s12885-022-09516-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 665 |
Kang SM, Khalil L, El-Rayes BF, Akce M. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Front Oncol 2022;12:821903. [PMID: 35433430 DOI: 10.3389/fonc.2022.821903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 666 |
Liu Y, Xia H, Li M, Chen Y, Zhou W, Chen Y, Wu Y, Ali L. Overexpressed RING Finger 44 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Journal of Healthcare Engineering 2022;2022:1-18. [DOI: 10.1155/2022/3522866] [Reference Citation Analysis]
|
| 667 |
Wu J, Ding W, Wang Y, Liu S, Zhang X, Yang Q, Cai W, Yu X, Liu F, Kong D, Zhong H, Yu J, Liang P. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. International Journal of Hyperthermia 2022;39:595-604. [DOI: 10.1080/02656736.2022.2062463] [Reference Citation Analysis]
|
| 668 |
Deng J, Wen F. Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do? Front Oncol 2022;12:824799. [PMID: 35425716 DOI: 10.3389/fonc.2022.824799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 669 |
Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 670 |
Gou Y, Zheng X, Li W, Deng H, Qin S. Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis. Integr Cancer Ther 2022;21:153473542210902. [DOI: 10.1177/15347354221090221] [Reference Citation Analysis]
|
| 671 |
Tan C, Xia P, Zhang H, Xu K, Liu P, Guo D, Liu Z. YY1-Targeted RBM15B Promotes Hepatocellular Carcinoma Cell Proliferation and Sorafenib Resistance by Promoting TRAM2 Expression in an m6A-Dependent Manner. Front Oncol 2022;12:873020. [DOI: 10.3389/fonc.2022.873020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 672 |
Da Fonseca LG, Leonardi PC, Hashizume PH, Sansone F, Saud LR, Carrilho FJ, Herman P. A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes. Clin Exp Hepatol 2022;8:42-8. [PMID: 35415264 DOI: 10.5114/ceh.2022.114297] [Reference Citation Analysis]
|
| 673 |
Liu ZP, Yao LQ, Diao YK, Chen ZX, Feng ZH, Gu WM, Chen ZL, Chen TH, Zhou YH, Wang H, Xu XF, Wang MD, Li C, Liang L, Zhang CW, Pawlik TM, Lau WY, Shen F, Chen ZY, Yang T. Association of Preoperative Body Mass Index with Surgical Textbook Outcomes Following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Study of 1206 Patients. Ann Surg Oncol 2022. [PMID: 35419755 DOI: 10.1245/s10434-022-11721-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 674 |
Park H, Park H, Baek J, Moon H, Ro SW. Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Biology 2022;11:585. [DOI: 10.3390/biology11040585] [Reference Citation Analysis]
|
| 675 |
Hemminki K, Sundquist K, Sundquist J, Försti A, Liska V, Hemminki A, Li X. Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country. Cancers (Basel) 2022;14:1938. [PMID: 35454845 DOI: 10.3390/cancers14081938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 676 |
Kuo C, Wu H, Li C, Cata JP, Liu H, Hou M, Cherng Y, Tai Y. Long-Term Survival Impact of High-Grade Complications after Liver Resection for Hepatocellular Carcinoma: A Retrospective Single-Centre Cohort Study. Medicina 2022;58:534. [DOI: 10.3390/medicina58040534] [Reference Citation Analysis]
|
| 677 |
Yang XG, Huang YC, Wang CH, Sun YY, Huang Z, Xu GH. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined with Radiofrequency Ablation. Cancer Invest 2022;:1-31. [PMID: 35404178 DOI: 10.1080/07357907.2022.2065508] [Reference Citation Analysis]
|
| 678 |
Yuan Q, Ma Y, Wu L, Song Y, He C, Huang X, Yang C, Liu B, Han H, Zhang K, Wang J. Clinical Outcome of CT-Guided Iodine-125 Radioactive Seed Implantation for Intrahepatic Recurrent Hepatocellular Carcinoma: A Retrospective, Multicenter Study. Front Oncol 2022;12:819934. [DOI: 10.3389/fonc.2022.819934] [Reference Citation Analysis]
|
| 679 |
Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Yumita S, Nakagawa M, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Ozawa Y, Kawasaki Y, Kurokawa T, Hanaoka H, Tsuji H, Kato N. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open 2022;12:e059779. [PMID: 35396315 DOI: 10.1136/bmjopen-2021-059779] [Reference Citation Analysis]
|
| 680 |
Millian DE, Saldarriaga OA, Wanninger T, Burks JK, Rafati YN, Gosnell J, Stevenson HL. Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment-Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 35454766 DOI: 10.3390/cancers14081861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 681 |
Wo L, Zhang X, Ma C, Zhou C, Li J, Hu Z, Gong X, Zhan M, He M, Zhao Q. LncRNA HABON promoted liver cancer cells survival under hypoxia by inhibiting mPTP opening. Cell Death Discov 2022;8:171. [PMID: 35387966 DOI: 10.1038/s41420-022-00917-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 682 |
El-Mahdy HA, Sallam AM, Ismail A, Elkhawaga SY, Elrebehy MA, Doghish AS. miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. Pathol Res Pract 2022;233:153886. [PMID: 35405621 DOI: 10.1016/j.prp.2022.153886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 683 |
Duan J, Chen W, Xie J, Zhang M, Nie R, Liang H, Mei J, Han K, Xiang Z, Wang F, Teng K, Chen R, Deng M, Yin Y, Zhang N, Xie D, Cai M. A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01537-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 684 |
Hassan-Kadle MA, Osman MM, Keles E, Eker HH, Baydili KN, Ahmed HM, Osman AA. Clinical Characteristics of Patients with Hepatocellular Carcinoma: A Single-Center 3-Year Experience from Somalia. Int J Hepatol 2022;2022:3370992. [PMID: 35411218 DOI: 10.1155/2022/3370992] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 685 |
Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
|
| 686 |
Zhou HZ, Li F, Cheng ST, Xu Y, Deng HJ, Gu DY, Wang J, Chen WX, Zhou YJ, Yang ML, Ren JH, Zheng L, Huang AL, Chen J. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis. Hepatology 2022;75:847-65. [PMID: 34626132 DOI: 10.1002/hep.32195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 687 |
Luo J, Dong Z, Xie H, Zhang W, An L, Yu Z, Chang X, Chen Y, Yang W, Hu K, Liu F, Yang Y. Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study. Liver Int 2022;42:918-29. [PMID: 35065003 DOI: 10.1111/liv.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 688 |
Patil OB, Manjappa AS, Kumbhar PS, Bhosale SP, Disouza JI, Salawi A, Sambamoorthy U. Development of stable self-nanoemulsifying composition and its nanoemulsions for improved oral delivery of non-oncology drugs against hepatic cancer. OpenNano 2022. [DOI: 10.1016/j.onano.2022.100044] [Reference Citation Analysis]
|
| 689 |
Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2022;57:473-80. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 690 |
Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiología y diagnóstico. Revista de Gastroenterología de México 2022;87:216-234. [DOI: 10.1016/j.rgmx.2021.10.002] [Reference Citation Analysis]
|
| 691 |
Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, Kudo M; JSUM A. I. investigators. Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. J Gastroenterol 2022;57:309-21. [PMID: 35220490 DOI: 10.1007/s00535-022-01849-9] [Reference Citation Analysis]
|
| 692 |
Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022;19:257-73. [PMID: 35022608 DOI: 10.1038/s41575-021-00568-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 693 |
Deng L, Liang P, Cui H. Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy? Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.03.007] [Reference Citation Analysis]
|
| 694 |
Pan Y, Tan WF, Yang MQ, Li JY, Geller DA. The therapeutic potential of exosomes derived from different cell sources in liver diseases. Am J Physiol Gastrointest Liver Physiol 2022;322:G397-404. [PMID: 35107032 DOI: 10.1152/ajpgi.00054.2021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 695 |
Tawfik NG, Mohamed WR, Mahmoud HS, Alqarni MA, Naguib IA, Fahmy AM, Ahmed OM. Isatin Counteracts Diethylnitrosamine/2-Acetylaminofluorene-Induced Hepatocarcinogenesis in Male Wistar Rats by Upregulating Anti-Inflammatory, Antioxidant, and Detoxification Pathways. Antioxidants 2022;11:699. [DOI: 10.3390/antiox11040699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 696 |
Tang Y, Wang Y, Xu X, Sun H, Tang W. STEAP4 promoter methylation correlates with tumorigenesis of hepatocellular carcinoma. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153870] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 697 |
Zhou J, Chen L, Chen L, Zeng X, Zhang Y, Yuan Y. Emerging role of nanoparticles in the diagnostic imaging of gastrointestinal cancer. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 698 |
Vilmanis J, Strēle I, Ozoliņš A, Miklaševičs E, Gardovskis J. Epidemiology of Hepatocellular Carcinoma in Latvia from 1997 to 2017. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2022;76:246-253. [DOI: 10.2478/prolas-2022-0037] [Reference Citation Analysis]
|
| 699 |
Guo Y, Yang J, Ren K, Tian X, Gao H, Tian X, Zhang X, Kan Q. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma. Front Immunol 2022;13:861525. [PMID: 35355983 DOI: 10.3389/fimmu.2022.861525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 700 |
Ho C, Lin K, Shen R, Gu D, Lee S, Su W, Jou Y. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.04.008] [Reference Citation Analysis]
|
| 701 |
Tey SK, Wong SWK, Chan JYT, Mao X, Ng TH, Yeung CLS, Leung Z, Fung HL, Tang AHN, Wong DKH, Mak LY, Yuen MF, Sin CF, Ng IO, Ma SKY, Lee TKW, Cao P, Zhong K, Gao Y, Yun JP, Yam JWP. Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. J Hepatol 2022;76:883-95. [PMID: 34922977 DOI: 10.1016/j.jhep.2021.12.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 702 |
Nguyen N, Rode A, Trillaud H, Aubé C, Manichon AF, Hocquelet A, Paisant A, Dao T, Nahon P, Ganne-Carrié N, Blaise L, Cauchy F, Sutter O, Séror O, Nault JC. Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. Liver Int 2022;42:905-17. [PMID: 34894060 DOI: 10.1111/liv.15129] [Reference Citation Analysis]
|
| 703 |
Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3:386-401. [PMID: 35484418 DOI: 10.1038/s43018-022-00357-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 704 |
Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Expert Rev Gastroenterol Hepatol 2022;16:333-9. [PMID: 35403533 DOI: 10.1080/17474124.2022.2064273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 705 |
Chen Q, Lu X, Xie J, Ma N, Xu W, Zhang Z, Huang X, Liu H, Hou J, Zhang X, Zhu W. Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:813275. [DOI: 10.3389/fonc.2022.813275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 706 |
Su CH, Chung PC, Lin SF, Tsai HW, Yang TL, Su YC. Multi-Scale Attention Convolutional Network for Masson Stained Bile Duct Segmentation from Liver Pathology Images. Sensors (Basel) 2022;22:2679. [PMID: 35408293 DOI: 10.3390/s22072679] [Reference Citation Analysis]
|
| 707 |
Melis M, Tang X, Trasino SE, Gudas LJ. Retinoids in the Pathogenesis and Treatment of Liver Diseases. Nutrients 2022;14:1456. [DOI: 10.3390/nu14071456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 708 |
Barmoudeh Z, Ardakani MT, Doustimotlagh AH, Bardania H, Ali MY. Evaluation of the Antioxidant and Anticancer Activities of Hydroalcoholic Extracts of Thymus daenensis Čelak and Stachys pilifera Benth. Journal of Toxicology 2022;2022:1-8. [DOI: 10.1155/2022/1924265] [Reference Citation Analysis]
|
| 709 |
Xia F, Zhu P, Chen XP, Zhang BX, Zhang MY. Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis. J Oncol 2022;2022:7531452. [PMID: 35342424 DOI: 10.1155/2022/7531452] [Reference Citation Analysis]
|
| 710 |
Garbarine IC, Gerber DA. Risk of intra-abdominal seeding after laparoscopic-assisted thermal ablation of exophytic hepatocellular carcinoma tumors. Surg Endosc 2022. [PMID: 35348874 DOI: 10.1007/s00464-022-09192-z] [Reference Citation Analysis]
|
| 711 |
Zhao X, Yang J, Zhang J, Wang X, Chen L, Zhang C, Shen Z. Inhibitory Effect of Aptamer-Carbon Dot Nanomaterial-siRNA Complex on the Metastasis of Hepatocellular Carcinoma Cells by Interfering with FMRP. Eur J Pharm Biopharm 2022:S0939-6411(22)00061-3. [PMID: 35364257 DOI: 10.1016/j.ejpb.2022.03.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 712 |
Himmelsbach V, Pinter M, Scheiner B, Venerito M, Sinner F, Zimpel C, Marquardt JU, Trojan J, Waidmann O, Finkelmeier F. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. Cancers (Basel) 2022;14:1722. [PMID: 35406493 DOI: 10.3390/cancers14071722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 713 |
Chen M, Wang W, Hu S, Tong Y, Li Y, Wei Q, Yu L, Zhu L, Zhu Y, Liu L, Ju Z, Wang X, Jin H, Feng L. Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-022-00850-2] [Reference Citation Analysis]
|
| 714 |
Liu Z, Sun Y, Zhen H, Nie C. Network Pharmacology Integrated with Transcriptomics Deciphered the Potential Mechanism of Codonopsis pilosula against Hepatocellular Carcinoma. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-10. [DOI: 10.1155/2022/1340194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 715 |
Carlessi R, Denisenko E, Boslem E, Koehn-gaone J, Main N, Abu Bakar NDB, Shirolkar GD, Jones M, Poppe D, Dwyer BJ, Jackaman C, Tjiam MC, Lister R, Karin M, Fallowfield JA, Kendall TJ, Forbes SJ, Olynyk JK, Yeoh G, Forrest ARR, Ramm GA, Febbraio MA, Tirnitz-parker JEE. Single Nucleus RNA Sequencing of Pre-Malignant Liver Reveals Disease-Associated Hepatocyte State with HCC Prognostic Potential.. [DOI: 10.1101/2022.03.25.485695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 716 |
Tang H, You T, Sun Z, Bai C, Wang Y. Extracellular Matrix-Based Gene Expression Signature Defines Two Prognostic Subtypes of Hepatocellular Carcinoma With Different Immune Microenvironment Characteristics. Front Mol Biosci 2022;9:839806. [DOI: 10.3389/fmolb.2022.839806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 717 |
Choi NR, Kim JY, Hong JH, Hur MH, Cho H, Park MK, Kim J, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2022;22:135. [PMID: 35337274 DOI: 10.1186/s12876-022-02210-3] [Reference Citation Analysis]
|
| 718 |
Braghini MR, Lo Re O, Romito I, Fernandez-Barrena MG, Barbaro B, Pomella S, Rota R, Vinciguerra M, Avila MA, Alisi A. Epigenetic remodelling in human hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:107. [PMID: 35331312 DOI: 10.1186/s13046-022-02297-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 719 |
Malaguarnera G, Catania VE, Bertino G, Drago F, Madeddu R, Bonfiglio C, Malaguarnera M. Serum Folate deficiency in HCV related Hepatocellular Carcinoma. Sci Rep 2022;12:5025. [PMID: 35322130 DOI: 10.1038/s41598-022-09030-1] [Reference Citation Analysis]
|
| 720 |
Cai D, Zhao Z, Hu J, Dai X, Zhong G, Gong J, Qi F. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma. Front Surg 2022;9:836080. [DOI: 10.3389/fsurg.2022.836080] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 721 |
Li L, Xu L, Zhou S, Wang P, Zhang M, Li B. Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis. BMC Surg 2022;22:104. [PMID: 35313888 DOI: 10.1186/s12893-022-01564-5] [Reference Citation Analysis]
|
| 722 |
Lei D, Wang T, Zhong WL. circSYPL1 Promotes the Proliferation and Metastasis of Hepatocellular Carcinoma via the Upregulation of EZH2 Expression by Competing with hsa-miR-506-3p. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/2659563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 723 |
Zhou X, Zhang T, Sun Y, Li C, Ding X, Zhu Y, Li L, Fan Z. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma. Front Pharmacol 2022;13:764854. [PMID: 35300300 DOI: 10.3389/fphar.2022.764854] [Reference Citation Analysis]
|
| 724 |
Zhang Z, Zhang W, Wang Y, Wan T, Hu B, Li C, Ge X, Lu S. Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:792676. [PMID: 35295858 DOI: 10.3389/fcell.2022.792676] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 725 |
Zhang J, Shang L, Jiang W, Wu W. Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells. Bioengineered 2022;13:7904-18. [PMID: 35293266 DOI: 10.1080/21655979.2022.2052673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 726 |
Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, Ruan J, Chen J. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Front Oncol 2022;12:809709. [PMID: 35280760 DOI: 10.3389/fonc.2022.809709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 727 |
Chan HW, Lo YH, Chang DY, Li JJ, Chang WY, Chen CH, Chang CH, Chen CL, Wang HE, Liu RS, Wu CY. Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma. Gels 2022;8. [PMID: 35323293 DOI: 10.3390/gels8030180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 728 |
Ye J, Lin Y, Liao Z, Gao X, Lu C, Lu L, Huang J, Huang X, Bai T, Chen J, Wang X, Luo M, Xie M, Wu F, Wu G, Ma L, Xiang B, Li Y, Yu H, Luo X, Liang R. Deciphering the heterogeneous niche in the tumor progression of hepatocellular carcinoma: a Spatial single-cell landscape and multi-omics atlas analysis.. [DOI: 10.1101/2022.03.09.22272063] [Reference Citation Analysis]
|
| 729 |
Perng PS, Lai YH, Lee PH, Huang CC, Hsu HH, Lee JS. Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. J Clin Med 2022;11. [PMID: 35329863 DOI: 10.3390/jcm11061536] [Reference Citation Analysis]
|
| 730 |
Yang J, Wang J, Li H, Gao S, Fan Y, Wang K. IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Oncol 2022;12:746643. [DOI: 10.3389/fonc.2022.746643] [Reference Citation Analysis]
|
| 731 |
Nicolè L, Sanavia T, Cappellesso R, Maffeis V, Akiba J, Kawahara A, Naito Y, Radu CM, Simioni P, Serafin D, Cortese G, Guido M, Zanus G, Yano H, Fassina A. Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3+ and CD8+ T cell density and predict prognosis in hepatocellular carcinoma. J Immunother Cancer 2022;10:e004031. [PMID: 35264437 DOI: 10.1136/jitc-2021-004031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 732 |
Cheng N, Lou B, Wang H. An intelligent serological SERS test toward early-stage hepatocellular carcinoma diagnosis through ultrasensitive nanobiosensing. Nano Res . [DOI: 10.1007/s12274-022-4114-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 733 |
He Q, Fan B, Du P, Jin Y. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis. Front Cell Dev Biol 2022;10:806989. [DOI: 10.3389/fcell.2022.806989] [Reference Citation Analysis]
|
| 734 |
Zhu H, Zhou W, Wan Y, Lu J, Ge K, Jia C. Light-activatable multifunctional paclitaxel nanoprodrug for synergistic chemo-photodynamic therapy in liver cancer. Biofactors 2022. [PMID: 35254679 DOI: 10.1002/biof.1832] [Reference Citation Analysis]
|
| 735 |
Zhao X, Sun X, Huang W, Chen R, Chen K, Nie L, Fang C. A microenvironment-responsive FePt probes for imaging-guided Fenton-enhanced radiotherapy of hepatocellular carcinoma. J Nanobiotechnology 2022;20:100. [PMID: 35241082 DOI: 10.1186/s12951-022-01305-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 736 |
Zhang C, Bao T, Ke Y, Liu X, Wang X, Liao W, He Y, Wang L. Integrated analysis of ceRNA network reveals potential prognostic Hint1-related lncRNAs involved in hepatocellular carcinoma progression. World J Surg Oncol 2022;20:67. [PMID: 35241097 DOI: 10.1186/s12957-022-02535-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 737 |
Boulahtouf Z, Virzì A, Baumert TF, Verrier ER, Lupberger J. Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences. Int J Mol Sci 2022;23:2787. [PMID: 35269929 DOI: 10.3390/ijms23052787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 738 |
Li G, Qi L, Chen H, Tian G. Involvement of NF-κB/PI3K/AKT signaling pathway in the protective effect of prunetin against a diethylnitrosamine induced hepatocellular carcinogenesis in rats. J Biochem Mol Toxicol 2022;:e23016. [PMID: 35239232 DOI: 10.1002/jbt.23016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 739 |
Kanaya M, Miyamoto N, Fujii T, Kudo K, Kinota N, Kato H. Combination Therapy by Transarterial Injection of Miriplatin-Iodized Oil Suspension with Microwave Ablation for Medium-Sized Hepatocellular Carcinoma: the Preliminary Experience. Interventional Radiology 2022;7:1-8. [DOI: 10.22575/interventionalradiology.2021-0009] [Reference Citation Analysis]
|
| 740 |
Deng X, Xie Y, Lu Y, Li X, Guo X, Huang X, Lan X, Lin J, Tan W, Wang C. Jianpi Huayu Decoction enhances the effect of sorafenib and alleviates adverse events in hepatocellular carcinoma by remodeling the gut microbiota. Pharmacological Research - Modern Chinese Medicine 2022;2:100057. [DOI: 10.1016/j.prmcm.2022.100057] [Reference Citation Analysis]
|
| 741 |
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022;19:151-72. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Cited by in Crossref: 206] [Cited by in F6Publishing: 201] [Article Influence: 206.0] [Reference Citation Analysis]
|
| 742 |
Islami F, Guerra CE, Minihan A, Yabroff KR, Fedewa SA, Sloan K, Wiedt TL, Thomson B, Siegel RL, Nargis N, Winn RA, Lacasse L, Makaroff L, Daniels EC, Patel AV, Cance WG, Jemal A. American Cancer Society's report on the status of cancer disparities in the United States, 2021. CA Cancer J Clin 2022;72:112-43. [PMID: 34878180 DOI: 10.3322/caac.21703] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 31.0] [Reference Citation Analysis]
|
| 743 |
Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 744 |
Chiang JY, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Molecular and Cellular Endocrinology 2022. [DOI: 10.1016/j.mce.2022.111618] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 745 |
Guo Y, Shang A, Wang S, Wang M. Multidimensional Analysis of CHMP Family Members in Hepatocellular Carcinoma. IJGM 2022;Volume 15:2877-94. [DOI: 10.2147/ijgm.s350228] [Reference Citation Analysis]
|
| 746 |
Li X, Liu Z, Wei X, Lin J, Yang Q, Xie Y. Comprehensive Analysis of the Expression and Clinical Significance of THO Complex Members in Hepatocellular Carcinoma. IJGM 2022;Volume 15:2695-713. [DOI: 10.2147/ijgm.s349925] [Reference Citation Analysis]
|
| 747 |
Qiu X, Gao F, Wang K, Zhang Z, Shao C, Xu X. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment? iLIVER 2022;1:55-64. [DOI: 10.1016/j.iliver.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 748 |
Nguyen-Tran BS, Tran-Thi NP, Ngo QT, LE-Trong L, Nguyen-Thanh T, Dang-Cong T. Synchronous esophageal squamous cell carcinoma and hepatocellular carcinoma: A rare case report. Radiol Case Rep 2022;17:863-8. [PMID: 35059090 DOI: 10.1016/j.radcr.2021.12.035] [Reference Citation Analysis]
|
| 749 |
Wei J, Niu M, Yabo O, Zhou Y, Ma X, Yang X, Jiang H, Hui H, Cao H, Duan B, Li H, Ding D, Tian J. Advances in artificial intelligence techniques drive the application of radiomics in the clinical research of hepatocellular carcinoma. iLIVER 2022;1:49-54. [DOI: 10.1016/j.iliver.2022.02.005] [Reference Citation Analysis]
|
| 750 |
Yao F, Zhao Y, Ma L. LIF-ting ferroptosis to improve liver cancer therapy. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.02.013] [Reference Citation Analysis]
|
| 751 |
Gu Z, Du Y, Zhao X, Wang C. Diagnostic, Therapeutic, and Prognostic Value of the m6A Writer Complex in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:822011. [PMID: 35223847 DOI: 10.3389/fcell.2022.822011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 752 |
Poortahmasebi V, Nejati A, Abazari MF, Nasiri Toosi M, Ghaziasadi A, Mohammadzadeh N, Tavakoli A, Khamseh A, Momenifar N, Gholizadeh O, Norouzi M, Jazayeri SM. Identifying Potential New Gene Expression-Based Biomarkers in the Peripheral Blood Mononuclear Cells of Hepatitis B-Related Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2022;2022:9541600. [PMID: 35265561 DOI: 10.1155/2022/9541600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 753 |
Schrecker C, Waidmann O, El Youzouri H, Trojan J, Schnitzbauer AA, Bechstein WO, Zeuzem S, Koch C. Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma. Curr Oncol 2022;29:1475-87. [PMID: 35323324 DOI: 10.3390/curroncol29030124] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 754 |
Noh B, Park YM, Kwon Y, Choi CI, Choi BK, Seo KI, Park Y, Yang K, Lee S, Ha T, Hyon Y, Yoon M. Machine learning-based survival rate prediction of Korean hepatocellular carcinoma patients using multi-center data. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02182-4] [Reference Citation Analysis]
|
| 755 |
Yu Q, Chen W, Li Y, He J, Wang Y, Yang S, Zhou J. The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. Bioengineered 2022;13:4717-29. [PMID: 35212603 DOI: 10.1080/21655979.2022.2031398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 756 |
Liu S, He L, Bannister OB, Schnegelberger RD, Tao J, Althouse AD, Schopfer FJ, Wahlang B, Cave MC, Monga SP, Zhang X, Arteel GE, Beier JI. Western diet unmasks transient low-level vinyl chloride exposure-induced tumorigenesis; potential role of the (epi-)transcriptome.. [DOI: 10.1101/2022.02.24.481808] [Reference Citation Analysis]
|
| 757 |
Jia KF, Wang H, Yu CL, Yin WL, Zhang XD, Wang F, Sun C, Shen W. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00015-7. [PMID: 35260337 DOI: 10.1016/j.hbpd.2022.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 758 |
Shen R, Ke L, Li Q, Dang X, Shen S, Shen J, Li S, Liang L, Peng B, Kuang M, Ma Y, Yang Z, Hua Y. Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35211843 DOI: 10.1007/s12072-022-10299-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 759 |
Ribaldone DG, Caviglia GP, Gaia S, Rolle E, Risso A, Campion D, Brunocilla PR, Saracco GM, Carucci P. Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. Current Oncology 2022;29:1422-9. [DOI: 10.3390/curroncol29030119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 760 |
Ploeger C, Schreck J, Huth T, Fraas A, Albrecht T, Charbel A, Ji J, Singer S, Breuhahn K, Pusch S, Köhler BC, Springfeld C, Schirmacher P, Mehrabi A, Goeppert B, Roessler S. STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1154. [PMID: 35267462 DOI: 10.3390/cancers14051154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 761 |
Rizzo A. Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35193371 DOI: 10.2217/fon-2021-1623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 762 |
Lu L, Huang J, Mo J, Da X, Li Q, Fan M, Lu H. Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration, invasion, and glycolysis by regulating the miR-524-5p/SIX1 axis. Cell Mol Biol Lett 2022;27:17. [PMID: 35193488 DOI: 10.1186/s11658-022-00309-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 763 |
Mawatari S, Kumagai K, Oda K, Tabu K, Ijuin S, Fujisaki K, Tashima S, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Taniyama O, Toyodome A, Sakae H, Kure T, Sakurai K, Moriuchi A, Kanmura S, Ido A. Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus. PLoS One 2022;17:e0262267. [PMID: 35020772 DOI: 10.1371/journal.pone.0262267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 764 |
Bu X, Ma L, Liu S, Wen D, Kan A, Xu Y, Lin X, Shi M. A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2022;22:95. [PMID: 35193591 DOI: 10.1186/s12935-022-02507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 765 |
Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Tsai MC. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. Front Oncol 2022;12:816472. [PMID: 35186751 DOI: 10.3389/fonc.2022.816472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 766 |
Upata M, Siriwoharn T, Makkhun S, Yarnpakdee S, Regenstein JM, Wangtueai S. Tyrosinase Inhibitory and Antioxidant Activity of Enzymatic Protein Hydrolysate from Jellyfish (Lobonema smithii). Foods 2022;11:615. [PMID: 35206090 DOI: 10.3390/foods11040615] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 767 |
Tang H, You T, Sun Z, Bai C. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma. BMC Cancer 2022;22:197. [PMID: 35189839 DOI: 10.1186/s12885-022-09284-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 768 |
Chen Y, Zhang J, Liu J, Wang J, Shi C, Lu L, Cheng X, Niu G, Zhang S, Cui D. The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients. Journal of Immunology Research 2022;2022:1-7. [DOI: 10.1155/2022/1817694] [Reference Citation Analysis]
|
| 769 |
Gherman B, Hajjar NA, Tucan P, Radu C, Vaida C, Mois E, Burz A, Pisla D. Risk Assessment-Oriented Design of a Needle Insertion Robotic System for Non-Resectable Liver Tumors. Healthcare 2022;10:389. [DOI: 10.3390/healthcare10020389] [Reference Citation Analysis]
|
| 770 |
Yang M, Qiu Y, Yang Y, Wang W. An Integrated Analysis of the Identified PRPF19 as an Onco-immunological Biomarker Encompassing the Tumor Microenvironment, Disease Progression, and Prognoses in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:840010. [DOI: 10.3389/fcell.2022.840010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 771 |
Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 772 |
Zheng Y, Zhang W, Xu L, Zhou H, Yuan M, Xu H. Recent Progress in Understanding the Action of Natural Compounds at Novel Therapeutic Drug Targets for the Treatment of Liver Cancer. Front Oncol 2021;11:795548. [PMID: 35155196 DOI: 10.3389/fonc.2021.795548] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 773 |
Hassan M, Nasr SM, Elzallat M. Effect of CD133 Polymorphisms on the Risk of Developing Liver Cirrhosis and hepatocellular carcinoma Induced by Viral Hepatitis. Virus Res 2022;:198714. [PMID: 35181408 DOI: 10.1016/j.virusres.2022.198714] [Reference Citation Analysis]
|
| 774 |
Gungor MZ, Uysal M, Senturk S. The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. Cancers (Basel) 2022;14:940. [PMID: 35205692 DOI: 10.3390/cancers14040940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 775 |
Zhou J, Zheng Q, Chen Z. The Nrf2 Pathway in Liver Diseases. Front Cell Dev Biol 2022;10:826204. [DOI: 10.3389/fcell.2022.826204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 776 |
Wu L, Yin X, Jiang K, Yin J, Yu H, Yang L, Ma C, Yan S. Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma. Cancer Med 2022. [PMID: 35142083 DOI: 10.1002/cam4.4552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 777 |
Zhang X, Hu Y, Pan Y, Xiong Y, Zhang Y, Han M, Dong K, Song J, Liang H, Ding Z, Zhang X, Zhu H, Liu Q, Lu X, Feng Y, Chen X, Zhang Z, Zhang B. DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6. Oncogene 2022. [PMID: 35140331 DOI: 10.1038/s41388-022-02212-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 778 |
Chen Y, Huang K, Wang P, Chuang C, Yong C, Liu Y, Huang P, Yao C, Lin Y, Tsai M. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma. Medicina 2022;58:259. [DOI: 10.3390/medicina58020259] [Reference Citation Analysis]
|
| 779 |
Lee BC, Jeong YY, Heo SH, Kim HO, Park C, Shin SS, Cho SB, Koh YS. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization. Acad Radiol 2022:S1076-6332(21)00483-9. [PMID: 35151549 DOI: 10.1016/j.acra.2021.10.012] [Reference Citation Analysis]
|
| 780 |
Deng M, Sun S, Zhao R, Guan R, Zhang Z, Li S, Wei W, Guo R. The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. Mol Med 2022;28. [DOI: 10.1186/s10020-022-00445-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 781 |
Wan Z, Wang X. Role of SLC39A6 in the development and progression of liver cancer. Oncol Lett 2022;23:77. [PMID: 35111246 DOI: 10.3892/ol.2022.13197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 782 |
Zhang Y, Sun J, Song Y, Gao P, Wang X, Chen M, Li Y, Wu Z. Roles of fusion genes in digestive system cancers: dawn for cancer precision therapy. Crit Rev Oncol Hematol 2022;:103622. [PMID: 35124200 DOI: 10.1016/j.critrevonc.2022.103622] [Reference Citation Analysis]
|
| 783 |
Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Front Oncol 2022;12:822449. [DOI: 10.3389/fonc.2022.822449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 784 |
Zhang Z, Wu Y, Lin N, Yin S, Meng Z. Monitoring Clinical-Pathological Grading of Hepatocellular Carcinoma Using MicroRNA-Guided Semiconducting Polymer Dots. ACS Appl Mater Interfaces 2022. [PMID: 35112844 DOI: 10.1021/acsami.1c24191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 785 |
Wei H, Xu Z, Chen L, Wei Q, Huang Z, Liu G, Li W, Wang J, Tang Q, Pu J. Long non-coding RNA PAARH promotes hepatocellular carcinoma progression and angiogenesis via upregulating HOTTIP and activating HIF-1α/VEGF signaling. Cell Death Dis 2022;13:102. [PMID: 35110549 DOI: 10.1038/s41419-022-04505-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 786 |
Guo J, Ma C, Song X, Tang F, Guo L, Mao J, Li Y. Hepatocellular Carcinoma Complicated by Echinococcal Cyst: A Case Report. Front Surg 2022;8:816501. [DOI: 10.3389/fsurg.2021.816501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 787 |
Hu G, Yang J, Zhang H, Huang Z, Yang H. OTUB2 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells by PJA1 Deubiquitylation. Cell Mol Bioeng 2022;15:281-92. [PMID: 35611163 DOI: 10.1007/s12195-022-00720-4] [Reference Citation Analysis]
|
| 788 |
Karampa AD, Goussia AC, Glantzounis GK, Mastoridou EM, Anastasopoulos NT, Charchanti AV. The Role of Macroautophagy and Chaperone-Mediated Autophagy in the Pathogenesis and Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:760. [PMID: 35159028 DOI: 10.3390/cancers14030760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 789 |
Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2022;20:283-292.e10. [PMID: 33965578 DOI: 10.1016/j.cgh.2021.05.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 35.0] [Reference Citation Analysis]
|
| 790 |
Khan A, Sayles HR, Dhir M. Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality. HPB (Oxford) 2022;24:152-60. [PMID: 34607769 DOI: 10.1016/j.hpb.2021.08.948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 791 |
Desdouets C, Lujambio A. Decoding therapy resistance in liver tumours: a giant leap. Nat Rev Gastroenterol Hepatol 2022;19:83-4. [PMID: 34750549 DOI: 10.1038/s41575-021-00550-1] [Reference Citation Analysis]
|
| 792 |
Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 2022;47:596-607. [PMID: 34773467 DOI: 10.1007/s00261-021-03339-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 793 |
Huang H, Ruan SM, Xian MF, Li MD, Cheng MQ, Li W, Huang Y, Xie XY, Lu MD, Kuang M, Wang W, Hu HT, Chen LD. Contrast-enhanced ultrasound-based ultrasomics score: a potential biomarker for predicting early recurrence of hepatocellular carcinoma after resection or ablation. Br J Radiol 2022;95:20210748. [PMID: 34797687 DOI: 10.1259/bjr.20210748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 794 |
Canale M, Foschi FG, Andreone P, Ercolani G, Marisi G, Conti F, Vukotic R, Guarneri V, Burgio V, Ratti F, Aldrighetti L, De Cobelli F, Cascinu S, Ulivi P, Casadei-Gardini A. Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. HPB (Oxford) 2022;24:244-54. [PMID: 34366240 DOI: 10.1016/j.hpb.2021.06.421] [Reference Citation Analysis]
|
| 795 |
Xia A, Yuan W, Wang Q, Xu J, Gu Y, Zhang L, Chen C, Wang Z, Wu D, He Q, Yu W, Wang F, Xue C, Zhang Y, Bao G, Tao X, Liu S, Wang S, Hu Z, Sun B. The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. Nat Cancer 2022;3:203-18. [PMID: 35122073 DOI: 10.1038/s43018-021-00315-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 796 |
Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, Hao H, Xiong J. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B 2022;12:558-80. [PMID: 35256934 DOI: 10.1016/j.apsb.2021.09.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 797 |
Liu QP, Yang KL, Xu X, Liu XS, Qu JR, Zhang YD. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study. Abdom Radiol (NY) 2022;47:651-63. [PMID: 34918174 DOI: 10.1007/s00261-021-03375-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 798 |
Gigante E, Sutter O, Nahon P, Seror O, Nault J. Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria. Liver Cancer International 2022;3:37-46. [DOI: 10.1002/lci2.35] [Reference Citation Analysis]
|
| 799 |
Ma X, Zhuang H, Wang Q, Yang L, Xie Z, Zhang Z, Tan W, Tang C, Chen Y, Shang C. SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression. JHC 2022;Volume 9:83-98. [DOI: 10.2147/jhc.s349966] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 800 |
Lee TY, Choi HJ, Ahn J, Hong TH, You Y. Efficacy of Tumor Markers After Liver Transplantation In Patients With Hepatocellular Carcinoma. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.01.007] [Reference Citation Analysis]
|
| 801 |
Su H, Tang Y, Nie K, Wang Z, Wang H, Dong H, Chen G. Identification Prognostic Value and Correlation with Tumor-Infiltrating Immune Cells of Tripartite-Motif Family Genes in Hepatocellular Carcinoma. IJGM 2022;Volume 15:1349-63. [DOI: 10.2147/ijgm.s341018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 802 |
Li Y, Zhang R, Xu Z, Wang Z. Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer. IJN 2022;Volume 17:909-25. [DOI: 10.2147/ijn.s349426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 803 |
Wang L, Shi C, Yu J, Xu Y. FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-021-02372-2] [Reference Citation Analysis]
|
| 804 |
Tang Z, Yang Y, Chen W, Li E, Liang T. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. J Transl Med 2022;20:49. [PMID: 35093119 DOI: 10.1186/s12967-022-03249-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 805 |
Lu I, Lin S, Chu Y, Wen Y, Lin Y, Cheng W, Sheu J, Lin C. (−)-Agelasidine A Induces Endoplasmic Reticulum Stress-Dependent Apoptosis in Human Hepatocellular Carcinoma. Marine Drugs 2022;20:109. [DOI: 10.3390/md20020109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 806 |
Yan Y, Ren L, Liu Y, Liu L. Development and Validation of Genome Instability-Associated lncRNAs to Predict Prognosis and Immunotherapy of Patients With Hepatocellular Carcinoma. Front Genet 2022;12:763281. [DOI: 10.3389/fgene.2021.763281] [Reference Citation Analysis]
|
| 807 |
Liu D, Wu M, Zhang T, Wang C. Ferroptosis Regulator Modification Patterns and Tumor Microenvironment Immune Infiltration Characterization in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:807502. [DOI: 10.3389/fmolb.2022.807502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 808 |
van Hooff MC, Sonneveld MJ, Ijzermans JN, Doukas M, Sprengers D, Metselaar HJ, den Hoed CM, de Man RA. External Validation of the RETREAT Score for Prediction of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2022;14:630. [PMID: 35158898 DOI: 10.3390/cancers14030630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 809 |
Khaled NB, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken PA, Lange CM, Wege H, Kandulski A, Dechêne A, Venerito M, Berres ML, Luedde T, Kubisch I, Reiter FP, De Toni EN. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol 2022. [PMID: 35081747 DOI: 10.2217/fon-2021-1261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 810 |
Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 811 |
Yang T, Chen Y, Xu J, Li J, Liu H, Liu N. Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis. BMC Complement Med Ther 2022;22:21. [PMID: 35078445 DOI: 10.1186/s12906-021-03487-9] [Reference Citation Analysis]
|
| 812 |
Cheng HY, Lin HC, Lin HL, Uang YS, Keller JJ, Wang LH. Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation. Front Pharmacol 2021;12:805318. [PMID: 35069216 DOI: 10.3389/fphar.2021.805318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 813 |
Xu Y, Liao W, Luo Q, Yang D, Pan M. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol 2022;13:761046. [DOI: 10.3389/fimmu.2022.761046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 814 |
Lu J, Chen Y, Zhang X, Guo J, Xu K, Li L. A novel prognostic model based on single-cell RNA sequencing data for hepatocellular carcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02469-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 815 |
Wang X, Chen M, Liang X, Bai Y, Zeng J, Xu X, Li H, Wang J, Fan K, Zhao G. RNF135 Promoter Methylation Is Associated With Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Front Oncol 2022;11:752511. [DOI: 10.3389/fonc.2021.752511] [Reference Citation Analysis]
|
| 816 |
Yang T, Ma L, Hou H, Gao F, Tao W. FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors. Front Oncol 2021;11:797960. [PMID: 35059319 DOI: 10.3389/fonc.2021.797960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 817 |
Feng N, Yu F, Yu F, Feng Y, Zhu X, Xie Z, Zhai Y. Metabolomic biomarkers for hepatocellular carcinoma: A systematic review. Medicine (Baltimore) 2022;101:e28510. [PMID: 35060504 DOI: 10.1097/MD.0000000000028510] [Reference Citation Analysis]
|
| 818 |
Liao R, Wei X, Che P, Yin K, Liu L. Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection. Front Oncol 2022;11:755920. [DOI: 10.3389/fonc.2021.755920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 819 |
Li Y, Mo H, Wu S, Liu X, Tu K. A Novel Lactate Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironment in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:801959. [PMID: 35047511 DOI: 10.3389/fcell.2021.801959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 820 |
Zhang S, Xu J, Cao H, Jiang M, Xiong J. KB-68A7.1 Inhibits Hepatocellular Carcinoma Development Through Binding to NSD1 and Suppressing Wnt/β-Catenin Signalling. Front Oncol 2022;11:808291. [DOI: 10.3389/fonc.2021.808291] [Reference Citation Analysis]
|
| 821 |
Roddy H, Meyer T, Roddie C. Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:504. [PMID: 35158772 DOI: 10.3390/cancers14030504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 822 |
Kong H, Sun J, Zhang W, Zhang H, Li H. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered 2022;13:3108-21. [PMID: 35037556 DOI: 10.1080/21655979.2022.2025701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 823 |
Ni Z, Lu J, Huang W, Khan H, Wu X, Huang D, Shi G, Niu Y, Huang H. Transcriptomic identification of HBx-associated hub genes in hepatocellular carcinoma. PeerJ 2021;9:e12697. [PMID: 35036167 DOI: 10.7717/peerj.12697] [Reference Citation Analysis]
|
| 824 |
Chen G, Xie X, Wang M, Guo X, Zhang Z, Zhang L, Zhang B. Prognostic Significance of Tumor Growth Rate (TGR) in Patients with Huge Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization. Current Oncology 2022;29:423-32. [DOI: 10.3390/curroncol29020038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 825 |
Vogl TJ, Mader C, Michalik S, Hammerstingl R, Koch V. [Small hepatocellular carcinoma : Diagnostics according to guidelines and established in the clinical setting]. Radiologe 2022. [PMID: 35037980 DOI: 10.1007/s00117-021-00965-6] [Reference Citation Analysis]
|
| 826 |
Zheng Y, Xu M, Zeng D, Tong H, Shi Y, Feng Y, Zhang X. In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma. Diagn Pathol 2022;17:11. [PMID: 35034659 DOI: 10.1186/s13000-022-01194-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 827 |
Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q, Hook S, Schmitz J, Bräsen JH, Franke AC, Olarewaju O, Brandenberger C, Talbot SR, Fangmann J, Hacker UT, Odenthal M, Ott M, Piiper A, Büning H. Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. Cancers (Basel) 2022;14:427. [PMID: 35053588 DOI: 10.3390/cancers14020427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 828 |
Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [DOI: 10.4251/wjgo.v14.i1.19] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 829 |
Fan X, Wen J, Bao L, Gao F, Li Y, He D. Identification and Validation of DEPDC1B as an Independent Early Diagnostic and Prognostic Biomarker in Liver Hepatocellular Carcinoma. Front Genet 2022;12:681809. [DOI: 10.3389/fgene.2021.681809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 830 |
Lv W, Yao Q, Wang F. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients. Disease Markers 2022;2022:1-27. [DOI: 10.1155/2022/9428660] [Reference Citation Analysis]
|
| 831 |
Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 832 |
Cui H, Guo D, Zhang X, Zhu Y, Wang Z, Jin Y, Guo W, Zhang S. ENO3 Inhibits Growth and Metastasis of Hepatocellular Carcinoma via Wnt/β-Catenin Signaling Pathway. Front Cell Dev Biol 2021;9:797102. [PMID: 35004693 DOI: 10.3389/fcell.2021.797102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 833 |
Wang H, Lu Y, Liu R, Wang L, Liu Q, Han S. A Non-Invasive Nomogram for Preoperative Prediction of Microvascular Invasion Risk in Hepatocellular Carcinoma. Front Oncol 2021;11:745085. [PMID: 35004273 DOI: 10.3389/fonc.2021.745085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 834 |
Wang W, Wu J, Dai X, Cheng K. Inhibitory effect of CC chemokine ligand 23 (CCL23)/ transcription factor activating enhancer binding protein 4 (TFAP4) on cell proliferation, invasion and angiogenesis in hepatocellular carcinoma. Bioengineered 2022;13:1626-36. [PMID: 35001801 DOI: 10.1080/21655979.2021.2021125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 835 |
Choucair K, Kamran S, Saeed A. Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. Onco Targets Ther 2021;14:5521-32. [PMID: 35002257 DOI: 10.2147/OTT.S268309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 836 |
He DD, Shang XY, Wang N, Wang GX, He KY, Wang L, Han ZG. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. Oncogene 2022. [PMID: 35017665 DOI: 10.1038/s41388-022-02176-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 837 |
Lei P, Chen H, Feng C, Yuan X, Xiong Z, Liu Y, Liao W. Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy. ACS Nano 2022. [PMID: 35005889 DOI: 10.1021/acsnano.1c08477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 838 |
Wu C, Luo Y, Chen Y, Qu H, Zheng L, Yao J. Development of a prognostic gene signature for hepatocellular carcinoma. Cancer Treat Res Commun 2022;31:100511. [PMID: 35030478 DOI: 10.1016/j.ctarc.2022.100511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 839 |
Li X, Wang L, Wang L, Feng Z, Peng C. Single-Cell Sequencing of Hepatocellular Carcinoma Reveals Cell Interactions and Cell Heterogeneity in the Microenvironment. Int J Gen Med 2021;14:10141-53. [PMID: 34992435 DOI: 10.2147/IJGM.S338090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 840 |
Cao F, Yang Y, Si T, Luo J, Zeng H, Zhang Z, Feng D, Chen Y, Zheng J. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Front Oncol 2021;11:783480. [PMID: 34988019 DOI: 10.3389/fonc.2021.783480] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 841 |
Kim SY, Hwang S, Lee BR, Hong JA, Sung YH, Kim I. Inhibition of histone demethylase KDM4 by ML324 induces apoptosis through the unfolded protein response and Bim upregulation in hepatocellular carcinoma cells. Chem Biol Interact 2022;353:109806. [PMID: 34999051 DOI: 10.1016/j.cbi.2022.109806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 842 |
Lozanovski VJ, Ramouz A, Aminizadeh E, Al-Saegh SA, Khajeh E, Probst H, Picardi S, Rupp C, Chang DH, Probst P, Mehrabi A. Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis. BJS Open 2022;6:zrab130. [PMID: 35211739 DOI: 10.1093/bjsopen/zrab130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 843 |
Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med 2022;14:1. [PMID: 34986867 DOI: 10.1186/s13073-021-00995-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 844 |
Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 845 |
Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
|
| 846 |
Xu P, Luo A, Xiong C, Ren H, Yan L, Luo Q. SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway. Cancer Cell Int 2022;22:1. [PMID: 34980127 DOI: 10.1186/s12935-021-02402-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 847 |
Lu Y, Chan YT, Tan HY, Zhang C, Guo W, Xu Y, Sharma R, Chen ZS, Zheng YC, Wang N, Feng Y. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:3. [PMID: 34980204 DOI: 10.1186/s13046-021-02208-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 848 |
Gowda NGS, Shiragannavar VD, Santhekadur PK. Role of exosomes in hepatocellular carcinoma progression and metastasis. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 2022. [DOI: 10.1016/b978-0-323-98806-3.00010-6] [Reference Citation Analysis]
|
| 849 |
李 凡. The Research Progress in Bone Metastasis of Hepatocellular Carcinoma. ACM 2022;12:5434-5440. [DOI: 10.12677/acm.2022.126787] [Reference Citation Analysis]
|
| 850 |
Lu L, Zhan M, Li X, Zhang H, Dauphars DJ, Jiang J, Yin H, Li S, Luo S, Li Y, He Y. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology 2022;3:118-27. [DOI: 10.1016/j.crimmu.2022.05.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 851 |
Dasari K. Long non-coding RNA: Emerging role in Hepatocellular Carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 2022. [DOI: 10.1016/b978-0-323-98806-3.00012-x] [Reference Citation Analysis]
|
| 852 |
Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J Viral Hepat 2022;29:35-42. [PMID: 34661320 DOI: 10.1111/jvh.13625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 853 |
Gato MIR, dos Reis AN, dos Santos Silvério F, Ito FT, Lopes KF. Oncological Diseases. The Golden Guide to Oncologic Pharmacy 2022. [DOI: 10.1007/978-3-030-98596-7_2] [Reference Citation Analysis]
|
| 854 |
Nagasaka M, Al-share B, Shao YF, Sexton R, Al Hallak MN, Azmi AS, Sukari A. The Gut Microbiome and Cancer: A Comprehensive Review of Melanoma, Lung, Head and Neck and Gastrointestinal Tumors. Comprehensive Gut Microbiota 2022. [DOI: 10.1016/b978-0-12-819265-8.00047-4] [Reference Citation Analysis]
|
| 855 |
Jia W, Han Y, Mao X, Xu W, Zhang Y. Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Adv 2022;12:31068-31082. [DOI: 10.1039/d2ra05127c] [Reference Citation Analysis]
|
| 856 |
Rathi MA, Girisan EK, Gopalakrishnan VK, Meenakshi P, Guru Kumar D. Nanomaterials as Drug Carriers in Diagnosis and Treatment of Various Cancers. Materials Horizons: From Nature to Nanomaterials 2022. [DOI: 10.1007/978-981-19-2639-6_11] [Reference Citation Analysis]
|
| 857 |
Muñoz AE, Cartier M, Kisch AB. Statins in Liver Cirrhosis. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_12] [Reference Citation Analysis]
|
| 858 |
Richter KK. Tumorchirurgie. Therapie-Handbuch - Onkologie und Hämatologie 2022. [DOI: 10.1016/b978-3-437-23824-6.00003-1] [Reference Citation Analysis]
|
| 859 |
Daniell KM, Banson KM, Diamond BH, Sioshansi S. Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis. Curr Treat Options Oncol 2022;23:1761-74. [PMID: 36333623 DOI: 10.1007/s11864-022-01025-4] [Reference Citation Analysis]
|
| 860 |
Chen X. A novel nomogram based on the nutritional risk screening 2002 score to predict survival in hepatocellular carcinoma treated with transarterial chemoembolization. Nutr Hosp 2022. [DOI: 10.20960/nh.03983] [Reference Citation Analysis]
|
| 861 |
Tian Y, Lu J, Qiao Y. A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma. Front Mol Biosci 2022;9:988323. [PMID: 36250026 DOI: 10.3389/fmolb.2022.988323] [Reference Citation Analysis]
|
| 862 |
Zecca A, Barili V, Olivani A, Biasini E, Boni C, Fisicaro P, Montali I, Tiezzi C, Dalla Valle R, Ferrari C, Cariani E, Missale G. Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for Liver Cancer. Front Immunol 2022;13:875072. [PMID: 35677052 DOI: 10.3389/fimmu.2022.875072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 863 |
Liu L, Liu Z, Meng L, Li L, Gao J, Yu S, Hu B, Yang H, Guo W, Zhang S. An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma. Front Mol Biosci 2021;8:766609. [PMID: 34970594 DOI: 10.3389/fmolb.2021.766609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 864 |
Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, Zoulim F, de Ledinghen V, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Gastro Hep Advances 2022;1:604-17. [DOI: 10.1016/j.gastha.2022.02.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 865 |
Vogt N, Arya Z, Núñez L, Hobson K, Connell J, Brady SM, Aljabar P. A Deep-Learning Lesion Segmentation Model that Addresses Class Imbalance and Expected Low Probability Tissue Abnormalities in Pre and Postoperative Liver MRI. Medical Image Understanding and Analysis 2022. [DOI: 10.1007/978-3-031-12053-4_30] [Reference Citation Analysis]
|
| 866 |
Kone LB, Javadi C, Keilson JM, Maithel SK, Poultsides G, Maker AV. The Role of Surgery in Managing Primary and Metastatic Hepatopancreaticobiliary Cancers. Cancer Metastasis Through the Lymphovascular System 2022. [DOI: 10.1007/978-3-030-93084-4_40] [Reference Citation Analysis]
|
| 867 |
Ren Y, Guo Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma. Cancer Control 2022;29:10732748221076806. [PMID: 35343254 DOI: 10.1177/10732748221076806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 868 |
Kapacee ZA, de Liguori Carino N, Lamarca A, Hubner RA, Valle JW, Mcnamara MG. Hepatopancreaticobiliary Cancer in Older Adults with Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_24] [Reference Citation Analysis]
|
| 869 |
Guo L, Yi X, Chen L, Zhang T, Guo H, Chen Z, Cheng J, Cao Q, Liu H, Hou C, Qi L, Zhu Z, Liu Y, Kong R, Zhang C, Zhou X, Zhang Z, Song T, Xue R, Zhang N. Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma. Gastroenterology 2022;162:238-52. [PMID: 34481846 DOI: 10.1053/j.gastro.2021.08.052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 870 |
Mansouri V, Rezaei N. Interdisciplinary Approach in Hepatobiliary Cancers. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_70] [Reference Citation Analysis]
|
| 871 |
Vemula S, Shaik JB, Damu AG, Vadde R. Chemotherapy for hepatocellular carcinoma—an updated review. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00005-7] [Reference Citation Analysis]
|
| 872 |
Debbaut C, Bomberna T. Numerical modeling in support of locoregional drug delivery during transarterial therapies for liver cancer. Modeling of Mass Transport Processes in Biological Media 2022. [DOI: 10.1016/b978-0-323-85740-6.00012-1] [Reference Citation Analysis]
|
| 873 |
Orhan A. Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_147-1] [Reference Citation Analysis]
|
| 874 |
Cakil YD, Ozunal ZG, Kayali DG, Aktas RG, Saglam E. Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells. Braz J Pharm Sci 2022;58. [DOI: 10.1590/s2175-97902022e201148] [Reference Citation Analysis]
|
| 875 |
Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, Kudo M; JSUM A. I. investigators. Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. J Gastroenterol 2022;57:309-21. [PMID: 35220490 DOI: 10.1007/s00535-022-01849-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 876 |
Tealeb AI, Mohamed S. The role of heat shock protein 70 and glypican 3 expression in early diagnosis of hepatocellular carcinoma. Egypt J Pathol 2022;42:112. [DOI: 10.4103/egjp.egjp_21_22] [Reference Citation Analysis]
|
| 877 |
Sümbül Taner A, Beşen AA. Recent advances in medical treatment of hepatocellular cancer. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00004-5] [Reference Citation Analysis]
|
| 878 |
Wei Y, Yang C, Wei Z, Liao X, He Y, Zhou X, Huang H, Lan C, Han C, Peng T. High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma. IJGM 2022;Volume 15:609-21. [DOI: 10.2147/ijgm.s344858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 879 |
Suresh A, Dhanasekaran R. Implications of genetic heterogeneity in hepatocellular cancer. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.01.007] [Reference Citation Analysis]
|
| 880 |
Li L, Selaru FM. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.01.011] [Reference Citation Analysis]
|
| 881 |
贾 清. Study on the Expression of TOP2A in Hepatocellular Carcinoma and Its Relationship with Prognosis. ACM 2022;12:3668-3676. [DOI: 10.12677/acm.2022.124531] [Reference Citation Analysis]
|
| 882 |
Song L, Feng D, Tan J, Zhang H. Effects of TMEM206 on the malignant behavior of HepG2 human hepatocellular carcinoma cells. Eur J Inflamm 2022;20:1721727X2211227. [DOI: 10.1177/1721727x221122724] [Reference Citation Analysis]
|
| 883 |
Nagesh R, Patil RH, Naveen Kumar M, Kiran Kumar K, Biradar S, Lamani BR. Modulatory act of diverse transcriptional factors in liver carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2 2022. [DOI: 10.1016/b978-0-323-98807-0.00014-4] [Reference Citation Analysis]
|
| 884 |
Xu Z, Zhang F, Sun D, Zheng Q, Ji G, Wang K. Surgical Strategy for Resecting Hepatocellular Carcinoma in the Caudate Lobe: Isolated or Combined Lobectomy? A Single-Center Study and Meta-Analysis. JHC 2022;Volume 9:13-25. [DOI: 10.2147/jhc.s349335] [Reference Citation Analysis]
|
| 885 |
Celsa C, Stornello C, Giuffrida P, Giacchetto CM, Grova M, Rancatore G, Pitrone C, Di Marco V, Cammà C, Cabibbo G. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence. Ann Hepatol 2022;27 Suppl 1:100568. [PMID: 34699987 DOI: 10.1016/j.aohep.2021.100568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 886 |
Hare AE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_42] [Reference Citation Analysis]
|
| 887 |
Huang J, Zhang S, Yang Y, Zhang Z, Jiang N, Li W, Shen J, Zhong B, Zhu X. Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Clin Med Insights Oncol 2022;16:117955492211348. [DOI: 10.1177/11795549221134832] [Reference Citation Analysis]
|
| 888 |
Dos Santos ML, França A, Lima Filho ACM, Florentino RM, Diniz PH, Oliveira Lemos F, Gonçalves CAX, Coelho VL, Lima CX, Foureaux G, Nathanson MH, Vidigal PVT, Leite MF. Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma. Oncol Lett 2022;23:32. [PMID: 34966448 DOI: 10.3892/ol.2021.13150] [Reference Citation Analysis]
|
| 889 |
Lupberger J, Baumert TF. Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges. J Clin Med 2021;11:208. [PMID: 35011949 DOI: 10.3390/jcm11010208] [Reference Citation Analysis]
|
| 890 |
Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 891 |
Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 892 |
Rizzo A, Ricci AD, Brandi G. Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development 2022;7:1-3. [DOI: 10.1080/23808993.2022.2020091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 893 |
Yue R, Liu H, Huang Y, Wang J, Shi D, Su Y, Luo Y, Cai P, Jin G, Yu C. Sempervirine Inhibits Proliferation and Promotes Apoptosis by Regulating Wnt/β-Catenin Pathway in Human Hepatocellular Carcinoma. Front Pharmacol 2021;12:806091. [PMID: 34950042 DOI: 10.3389/fphar.2021.806091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 894 |
Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]
|
| 895 |
Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 896 |
He S, Li JF, Tian H, Sang Y, Yang XJ, Guo GX, Yang JE. A long non-coding RNA-based signature predicts early recurrence in hepatocellular carcinoma. Cancer Biomark 2021. [PMID: 34957996 DOI: 10.3233/CBM-210193] [Reference Citation Analysis]
|
| 897 |
Jie T, Guoying F, Gang T, Zhengrong S, Maoping L. Efficacy and Safety of Fusion Imaging in Radiofrequency Ablation of Hepatocellular Carcinoma Compared to Ultrasound: A Meta-Analysis. Front Surg 2021;8:728098. [PMID: 34938766 DOI: 10.3389/fsurg.2021.728098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 898 |
García-Pras E, Fernández-Iglesias A, Gracia-Sancho J, Pérez-Del-Pulgar S. Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities. Cancers (Basel) 2021;14:48. [PMID: 35008212 DOI: 10.3390/cancers14010048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 899 |
Fang ZS, Zhang Z, Liang ZJ, Long ZR, Xiao Y, Liang ZY, Sun X, Li HM, Huang H. Liquid-Liquid Phase Separation-Related Genes Associated with Tumor Grade and Prognosis in Hepatocellular Carcinoma: A Bioinformatic Study. Int J Gen Med 2021;14:9671-9. [PMID: 34934344 DOI: 10.2147/IJGM.S342602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 900 |
Hacioglu C. Capsaicin inhibits cell proliferation by enhancing oxidative stress and apoptosis through SIRT1/NOX4 signaling pathways in HepG2 and HL-7702 cells. J Biochem Mol Toxicol 2021;:e22974. [PMID: 34939720 DOI: 10.1002/jbt.22974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 901 |
Wang Y, Li N, Zheng Y, Wang A, Yu C, Song Z, Wang S, Sun Y, Zheng L, Wang G, Liu L, Yi J, Huang Y, Zhang M, Bao Y, Sun L. KIAA1217 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinoma Metastasis by Interacting with and Activating STAT3. IJMS 2021;23:104. [DOI: 10.3390/ijms23010104] [Reference Citation Analysis]
|
| 902 |
Barbosa BC, Santos LAR, Daher GHRM, Martins DL, Perales SR, Gallani SK, Costa LBED, Lago EAD, Boin IFSF, Caserta NMG, Ataíde EC. Clinical impact of the Model for End Liver Disease (MELD) score on the presence of microvascular invasion and on the postoperative outcome in patients undergoing liver transplantation. Rev Col Bras Cir 2021;48:e20212997. [PMID: 34932735 DOI: 10.1590/0100-6991e-20212997] [Reference Citation Analysis]
|
| 903 |
Yan J, Man Z, Gao L, Cai L, Lu Q, Dong J. The role of CpG island methylator phenotype in the clinical course of hepatocellular carcinoma. Bioinformatics 2021;38:9-15. [PMID: 34406374 DOI: 10.1093/bioinformatics/btab600] [Reference Citation Analysis]
|
| 904 |
Liu X, Wang C, Yang Q, Yuan Y, Sheng Y, Li D, Ojha SC, Sun C, Deng C. AC093797.1 as a Potential Biomarker to Indicate the Prognosis of Hepatocellular Carcinoma and Inhibits Cell Proliferation, Invasion, and Migration by Reprogramming Cell Metabolism and Extracellular Matrix Dynamics. Front Genet 2021;12:778742. [PMID: 34925460 DOI: 10.3389/fgene.2021.778742] [Reference Citation Analysis]
|
| 905 |
Zhang K, Li D, Zhou B, Liu J, Luo X, Wei R, Wang L, Hu X, Su Z, Lin H, Gao J, Shan H. Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC. Biomater Sci 2021;10:243-57. [PMID: 34846385 DOI: 10.1039/d1bm01374b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 906 |
Chen Z, He X. Application of third-generation sequencing in cancer research. Medical Review 2021;1:150-171. [DOI: 10.1515/mr-2021-0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 907 |
Deng M, Lin JB, Zhao RC, Li SH, Lin WP, Zou JW, Wei W, Guo RP. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma. BMC Cancer 2021;21:1347. [PMID: 34923955 DOI: 10.1186/s12885-021-09059-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 908 |
Mu W, Guo L, Liu Y, Yang H, Ning S, Lv G. Long Noncoding RNA SNHG1 Regulates LMNB2 Expression by Sponging miR-326 and Promotes Cancer Growth in Hepatocellular Carcinoma. Front Oncol 2021;11:784067. [PMID: 34917510 DOI: 10.3389/fonc.2021.784067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 909 |
Wei Y, Tang X, Ren Y, Yang Y, Song F, Fu J, Liu S, Yu M, Chen J, Wang S, Zhang K, Tan Y, Han Z, Wei L, Zhang B, Cheng Z, Li L, Wang H. An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. Signal Transduct Target Ther 2021;6:421. [PMID: 34916485 DOI: 10.1038/s41392-021-00801-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 910 |
Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu X, Martinez C, Su X, Rosato RR, Teng H, Hang Q, Yap S, Chen D, Wang Y, Chen MM, Zhang M, Liang H, Xie D, Chen X, Zhu H, Chang JC, You MJ, Sun Y, Gan B, Ma L. A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun 2021;12:7333. [PMID: 34921145 DOI: 10.1038/s41467-021-27452-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
|
| 911 |
Wang Q, Liu B, Qiao W, Li J, Yuan C, Long J, Hu C, Zang C, Zheng J, Zhang Y. The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study. Front Oncol 2021;11. [DOI: 10.3389/fonc.2021.756363] [Reference Citation Analysis]
|
| 912 |
Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article. Ann Hepatol 2021;22:100249. [PMID: 32896610 DOI: 10.1016/j.aohep.2020.08.067] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 913 |
Zhao LX, Zhang K, Shen BB, Li JN. Mesenchymal stem cell-derived exosomes for gastrointestinal cancer. World J Gastrointest Oncol 2021; 13(12): 1981-1996 [DOI: 10.4251/wjgo.v13.i12.1981] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 914 |
Low ES, Apostolov R, Wong D, Lin S, Kutaiba N, Grace JA, Sinclair M. Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. World J Gastrointest Oncol 2021; 13(12): 2149-2160 [DOI: 10.4251/wjgo.v13.i12.2149] [Reference Citation Analysis]
|
| 915 |
Chen Z, Zhu W, Zhu S, Sun K, Liao J, Liu H, Dai Z, Han H, Ren X, Yang Q, Zheng S, Peng B, Peng S, Kuang M, Lin S. METTL1 promotes hepatocarcinogenesis via m7 G tRNA modification-dependent translation control. Clin Transl Med 2021;11:e661. [PMID: 34898034 DOI: 10.1002/ctm2.661] [Cited by in Crossref: 25] [Cited by in F6Publishing: 37] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 916 |
Khashkhashi Moghadam S, Bakhshinejad B, Khalafizadeh A, Mahmud Hussen B, Babashah S. Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma. J Cell Mol Med 2021. [PMID: 34907642 DOI: 10.1111/jcmm.17126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 917 |
Mir IH, Jyothi KC, Thirunavukkarasu C. The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation. J Cell Biochem 2021. [PMID: 34897788 DOI: 10.1002/jcb.30190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 918 |
Cai C, Yang L, Zhou K. 8DEstablishment and validation of a hypoxia-related signature predicting prognosis in hepatocellular carcinoma. BMC Gastroenterol 2021;21:463. [PMID: 34895169 DOI: 10.1186/s12876-021-02057-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 919 |
Sun N, Zhang J, Li B, Li A, Lv M, Zhang C. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. Medicine (Baltimore) 2021;100:e27987. [PMID: 34889243 DOI: 10.1097/MD.0000000000027987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 920 |
Liu H, Wang M, Jin Z, Sun D, Zhu T, Liu X, Tan X, Shi G. FNDC5 induces M2 macrophage polarization and promotes hepatocellular carcinoma cell growth by affecting the PPARγ/NF-κB/NLRP3 pathway. Biochem Biophys Res Commun 2021;582:77-85. [PMID: 34695754 DOI: 10.1016/j.bbrc.2021.10.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 921 |
Liu Z, Ma C, Wang Q, Yang H, Lu Z, Bi T, Xu Z, Li T, Zhang L, Zhang Y, Liu J, Wei X, Li J. Targeting FAM134B-mediated reticulophagy activates sorafenib-induced ferroptosis in hepatocellular carcinoma. Biochem Biophys Res Commun 2021;589:247-53. [PMID: 34929448 DOI: 10.1016/j.bbrc.2021.12.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 922 |
Dong Z, Lin Y, Lin F, Luo X, Lin Z, Zhang Y, Li L, Li ZP, Feng ST, Cai H, Peng Z. Prediction of Early Treatment Response to Initial Conventional Transarterial Chemoembolization Therapy for Hepatocellular Carcinoma by Machine-Learning Model Based on Computed Tomography. J Hepatocell Carcinoma 2021;8:1473-84. [PMID: 34877267 DOI: 10.2147/JHC.S334674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 923 |
Icard P, Simula L, Wu Z, Berzan D, Sogni P, Dohan A, Dautry R, Coquerel A, Lincet H, Loi M, Fuks D. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? Drug Resist Updat 2021;:100790. [PMID: 34924279 DOI: 10.1016/j.drup.2021.100790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 924 |
Peng X, Lin G, Zeng Y, Lei Z, Liu G. Mesoporous Silica Nanoparticle-Based Imaging Agents for Hepatocellular Carcinoma Detection. Front Bioeng Biotechnol 2021;9:749381. [PMID: 34869261 DOI: 10.3389/fbioe.2021.749381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 925 |
Wu Q, Jiang S, Cheng T, Xu M, Lu B. A Novel Pyroptosis-related Prognostic Model for Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:770301. [PMID: 34869364 DOI: 10.3389/fcell.2021.770301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 926 |
Sun Z, Shi Z, Xin Y, Zhao S, Jiang H, Wang D, Zhang L, Wang Z, Dai Y, Jiang H. Artificial Intelligent Multi-Modal Point-of-Care System for Predicting Response of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Bioeng Biotechnol 2021;9:761548. [PMID: 34869272 DOI: 10.3389/fbioe.2021.761548] [Reference Citation Analysis]
|
| 927 |
Maulidina F, Rustam Z, Novita M, Setiawan QS, Sagiran. Feature Selection using Particle Swarm Optimization and Random Forest for Hepatocellular Carcinoma (HCC) Classification. 2021 International Conference on Decision Aid Sciences and Application (DASA) 2021. [DOI: 10.1109/dasa53625.2021.9682286] [Reference Citation Analysis]
|
| 928 |
Huang P, Xu M, Han H, Zhao X, Li MD, Yang Z. Integrative Analysis of Epigenome and Transcriptome Data Reveals Aberrantly Methylated Promoters and Enhancers in Hepatocellular Carcinoma. Front Oncol 2021;11:769390. [PMID: 34858848 DOI: 10.3389/fonc.2021.769390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 929 |
Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol 2021. [PMID: 34863035 DOI: 10.1002/1878-0261.13154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 930 |
Zhang Q, Wang Y, Zhang J, Zhang W, Gong J, Ma R. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study. Technol Cancer Res Treat 2021;20:15330338211060180. [PMID: 34855560 DOI: 10.1177/15330338211060180] [Reference Citation Analysis]
|
| 931 |
Han JW, Sung PS, Jang JW, Choi JY, Yoon SK. Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma. PLoS One 2021;16:e0260311. [PMID: 34855786 DOI: 10.1371/journal.pone.0260311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 932 |
Gao L, Yan H, Zhu S, Wang X, Tan Y, Du J, Feng D, Zhang H, Gu Z. Targeted delivery of Bi2Se3 Nanoflowers to orthotopic liver tumor via transarterial infusion for enhanced microwave ablation sensibilization. Nano Today 2021;41:101314. [DOI: 10.1016/j.nantod.2021.101314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 933 |
Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatol Res 2021;51:1229-41. [PMID: 34591334 DOI: 10.1111/hepr.13718] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 934 |
Wu T, Luo G, Lian Q, Sui C, Tang J, Zhu Y, Zheng B, Li Z, Zhang Y, Zhang Y, Bao J, Hu J, Shen S, Yang Z, Wu J, Wang K, Zhao Y, Yang S, Wang S, Qiu X, Wang W, Wu X, Wang H, Gu J, Chen L. Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis. Hepatology 2021;74:3249-68. [PMID: 34343359 DOI: 10.1002/hep.32088] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 935 |
Zhao L, Ma N, Liu G, Mao N, Chen F, Li J. Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis. Dig Dis Sci 2021;66:4384-97. [PMID: 33433806 DOI: 10.1007/s10620-020-06787-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 936 |
Beier JI, Arteel GE. Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns. Acta Pharm Sin B 2021;11:3768-78. [PMID: 35024305 DOI: 10.1016/j.apsb.2021.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 937 |
Sturm L, Muller L, Schultheiss M, Binder B, Huber JP, Thimme R, Bettinger D. Proton pump inhibitor therapy is associated with reduced survival following first-time transarterial chemoembolization in patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2021;33:e247-53. [PMID: 33323760 DOI: 10.1097/MEG.0000000000002018] [Reference Citation Analysis]
|
| 938 |
Liu G, Wang N, Zhang C, Li M, He X, Yin C, Tu Q, Shen X, Zhang L, Lv J, Wang Y, Jiang H, Chen S, Li N, Tao Y, Yin H. Fructose-1,6-Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis. Hepatology 2021;74:3037-55. [PMID: 34292642 DOI: 10.1002/hep.32064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 939 |
Wang F, Breslin S J P, Qiu W. Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma. Liver Res 2021;5:195-203. [PMID: 34900376 DOI: 10.1016/j.livres.2021.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 940 |
Mullangi S, Keesari PR, Zaher A, Pulakurthi YS, Adusei Poku F, Rajeev A, Vidiyala PL, Guntupalli AL, Desai M, Ohemeng-dapaah J, Asare Y, Patel AA, Lekkala M. Epidemiology and Outcomes of Hospitalizations Due to Hepatocellular Carcinoma. Cureus 2021. [DOI: 10.7759/cureus.20089] [Reference Citation Analysis]
|
| 941 |
Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 942 |
Chai B, Wang W, Wang F, Zhou G, Zheng C. Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma. Int J Hyperthermia 2021;38:1685-94. [PMID: 34843653 DOI: 10.1080/02656736.2021.1970825] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 943 |
Chen YS, Yang SY, Wang PM, Wang CC, Yong CC, Chen DW, Liu YW, Chuang CH, Huang PY, Yao CC, Lin YP, Tsai MC. Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study. J Pers Med 2021;11:1261. [PMID: 34945733 DOI: 10.3390/jpm11121261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 944 |
Xu M, Ma T, Shi S, Xing J, Xi Y. Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma. Life (Basel) 2021;11:1312. [PMID: 34947843 DOI: 10.3390/life11121312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 945 |
Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021;13:1568-83. [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 946 |
De Smet V, Eysackers N, Merens V, Kazemzadeh Dastjerd M, Halder G, Verhulst S, Mannaerts I, van Grunsven LA. Initiation of hepatic stellate cell activation extends into chronic liver disease. Cell Death Dis 2021;12:1110. [PMID: 34839349 DOI: 10.1038/s41419-021-04377-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 947 |
Su L, Li T, Ma Y, Geng C, Huang X, Zhang X, Gao Z, Chen J. Artematrovirenolides A—D and Artematrolides S—Z, Sesquiterpenoid Dimers with Cytotoxicity against Three Hepatoma Cell Lines from Artemisia atrovirens. Chin J Chem 2022;40:104-14. [DOI: 10.1002/cjoc.202100528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 948 |
Zhang H, Xia P, Liu J, Chen Z, Ma W, Yuan Y. ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival. Int J Biol Sci 2021;17:4442-58. [PMID: 34803509 DOI: 10.7150/ijbs.65669] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 949 |
Yi D, Wen-Ping W, Lee WJ, Meloni MF, Clevert DA, Cristina Chammas M, Tannapfel A, Forgione A, Dietrich CF. Hepatocellular carcinoma in the non-cirrhotic liver. Clin Hemorheol Microcirc 2021. [PMID: 34842182 DOI: 10.3233/CH-211309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 950 |
Zhang L, Chang S, Zhao Y, Cao G, Zhang D. MicroRNA-4317 suppresses the progression of hepatocellular carcinoma by targeting ZNF436-mediated PI3K/AKT signaling pathway. Tissue Cell 2021;74:101696. [PMID: 34861581 DOI: 10.1016/j.tice.2021.101696] [Reference Citation Analysis]
|
| 951 |
Xue J, Ni H, Wang F, Xu K, Niu M. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. J Interv Med 2021;4:105-13. [PMID: 34805958 DOI: 10.1016/j.jimed.2021.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 952 |
Luo X, Liu Y, Li H, Cheng T, Wu J, Chen L, Ju L, Cai W, Bian Z. Hsa_circ_001 |
